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1 Introduction  
1.1 Transition Metal-Catalyzed C–H Activation 
The past five decades have witnessed prosperous advances in the development of highly efficient 
transition metal-catalyzed C–C/C–Het bond forming processes that tremendously expanded the 
toolbox of modern organic synthesis. Thus far, predominantly transition metal-catalyzed cross 















 have found widespread applications in 
agrochemical and pharmaceutical industry and streamlined the total synthesis of complex natural 
products.
[8]
 Consequently, these significant innovations culminated in the Nobel Prize for Chemistry in 
2010 for Heck, Negishi and Suzuki. 
Despite this enormous progress, cross-coupling reactions are associated with a series of drawbacks 
like prefunctionalization to often sensitive starting materials and the generation of toxic by-products 
(Figure 1).
[9]
 However, climate change and severe environmental pollution due to chemicals have 








In striking contrast, C–H bond functionalizations
[13]
 have become an invaluable and powerful strategy 
to achieve synthetic versatility in excellent atom- and step-economies by obviating typical 
prefunctionalization steps and directly functionalizing C–H bonds.  
 
 
Figure 1. Comparison of general methods for C–C/C–Het bond formation. 
 
Nonetheless, environmentally benign and sustainable transition metal-catalyzed transformations 
should not only match substrate availability: the use of earth-abundant 3d base and particularly cost-
effective metals is also of prime importance. Thus, a boost in the development of inter alia 







 C–H functionalizations has revolutionized sustainable organic 
synthesis. 
The most important basis for the development of new efficient metal-catalyzed C–H functionalizations 
is a detailed mechanistic understanding. Consequently, considerable efforts have been made to 
elucidate several mechanistically distinct pathways for the crucial C–H activation step (Scheme 1).
[16]
  
In this respect, a) oxidative addition was observed for late metals in low oxidation states. Furthermore, 
for e.g. alkylidene-, amide-, imide-, or alkoxide complexes of early as well as late transition metals, b) 
1,2 addition to the C–H bond is favored via formal [2σ + 2π] reaction.
[17]
 In addition, c) an electrophilic 




 in polar media and involves the 
electrophilic attack of the metal to carbon.
[18]
 For inter alia actinides, lanthanides, and early transition 
metals which are not prone to oxidations state changes d) σ-bond metathesis is a commonly proposed 
pathway.
[16c]
 Closely related to σ-bond metathesis, Periana/Goddard
[19]
 coined the term internal 
electrophilic substitution (IES) for mechanisms involving electrophilic attack of the metal and  
deprotonation by e.g. alkoxy-ligands via a four-membered transition state. 
 
 
Scheme 1. Common mechanistic pathways for C–H activation. 
 
In contrast to the above mentioned mechanistic scenarios, numerous reports have highlighted base-




 have coined the term CMD 
(concerted metalation deprotonation), computational studies by MacGregor/Davies
[21]
 revealed an 
agostic metal-hydrogen interaction, being rationalized by the term ambiphilic metal-ligand activation 
(AMLA). In both mechanisms, the metalation and deprotonation steps proceed in a concerted fashion 
via a six-membered transition state (Scheme 2a). Additionally, typical experimental characteristics of 
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CMD-type C–H functionalizations are often high kinetic isotope effects (KIEs) and a clear preference 
for acidic C–H bonds.
[22]
  
Nevertheless, in recent years several reports have emphasized a significant rate acceleration of 
electrophilic substitution type C–H activations by bifunctional acetate or carboxylate additives, which 
are suggested to proceed via a six-membered transition state. Based on detailed mechanistic studies, 
this manifold was termed base-assisted internal electrophilic substitution (BIES) (Scheme 2b). Thus, 
intermolecular competition experiments have revealed a preference for more electron-rich substrates 
and typically low KIEs have been observed which clearly underline the unique mechanism of this 
pathway. Hence, in contrast to CMD-type C–H activation, the site-selectivity of BIES-type C–H 





Scheme 2. Base-assisted C–H activation mechanisms. 
 
Moreover, a major challenge in C–H functionalizations includes achieving regioselectivity in complex 
molecules which display C–H bonds with similar dissociation energies. Besides the preference for the 
activation of somewhat more acidic positions e.g. in azoles, a strategy involving Lewis basic 
functionalities, which direct the transition metal into close proximity, has been well established in the 
field of C–H activation (Scheme 3). 
 
 
Scheme 3. Regioselective C–H activation by directing groups. 
 
In recent years, numerous efforts have been made to explore weak,
[24]
 modifiable or even removable 
directing groups (Figure 2),
[25]
 which have overall strongly contributed to the versatility of C–H 
functionalizations and their impact on sustainable organic synthesis.  
 




Figure 2. Selected examples of important directing groups in C–H activation catalysis. 
 
1.2 Ruthenium-Catalyzed C–H Arylations 
The development of cost-effective methods for the preparation of biaryls has gained tremendous 
interest in the past decades since biaryls are common structural motifs in inter alia agrochemically and 
pharmaceutically relevant molecules. In addition, there is a lack of generally applicable classical 
methods for their synthesis.
[26]
 
Thus far, a number of synthetic methods have been developed for the synthesis of biaryls, with cross-
coupling reactions being particularly powerful.
[8]
 As mentioned above, a more sustainable strategy to 
accomplish C–C bond formations involves the direct C–H functionalization by cost-effective metals, 
such as ruthenium. Until now, ruthenium complexes have been employed for numerous C–H 
transformations, including C–C, but also a wealth of C–Het bond formations.
[26b, 27]
  
As early as 2001, the first ruthenium-catalyzed C–H arylation was reported by Oi/Inoue, who used the 
dimeric [RuCl2(benzene)]2 complex and triphenylphosphine as the crucial additive for the ortho-
selective C–H arylation of 2-phenylpyridine (1a) with aryl bromides 2 (Scheme 4). Remarkably, their 
studies already revealed that ruthenium(II) catalysts are able to undergo oxidative addition with 
challenging aryl chlorides 3 as well as aryl triflates 4.
[28]
 In this regard, the authors disclosed the 
following reactivity order for the mono-arylation of 2-phenylpyridine (1a): PhCl < PhOTf < PhI 
< PhBr.  
Interestingly, a series of additives, including phosphines, phosphites, and bidendate diphosphines 
rendered phosphines as the optimal choice. It is noteworthy that the di-arylated product 5aa' was 
obtained solely by drastically increasing the amount of the aryl bromide 2.  
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Scheme 4. Ruthenium(II)-catalyzed C–H arylation. 
 
Further studies by Oi/Inoue and coworkers
[29]
 have extended the applicability of these arylation 
methods to valuable directing groups, such as ketimines 6,
[30]
 oxazolines 7, and imidazolines 8.
[31]
 
Remarkably, the authors accomplished a highly Z-selective ruthenium(II)-catalyzed arylation of (E)-2-
styrylpyridines 9, which displayed a wide substrate scope of arylated (E)-2-styrylpyridines 10 
(Scheme 5).
[32]
 Nevertheless, the arylation of 2-vinylpyridines 11 was not achieved and there was no 
example for acyclic tetrasubstituted alkenes 11. However, the reaction system of Oi/Inoue was later 





Scheme 5. Ruthenium(II)-catalyzed arylation of alkenes (E)-styrylpyridines 9. 
 
At around the same time, Kakiuchi and coworkers accomplished a ruthenium(0)-catalyzed C–H 
arylations with arylboronates 12 as the arylating reagents, utilizing valuable ketones 13 as the 
directing group (Scheme 6a).
[34]
 The authors proposed that the ruthenium complex first undergoes 
oxidative addition with the C–H bond, then transmetalation, and finally reductive elimination occur. 
However, a major drawback of this reaction is the formation of one equivalent of the corresponding 
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benzylic alcohols by reduction of ketone 13. Subsequently, the efficiency of this reaction has been 
improved by the addition of acetone or pinacolone, which suppressed the reduction and thus avoided 
excess amounts of the ketone 13a (Scheme 6b).  
 
 
Scheme 6. Ruthenium(0)-catalyzed C–H arylation with arylboronate 12a. 
 
Interestingly, the authors presented compelling evidence for the coordination of the ketone 13 to the 
ruthenium-hydride complex, which they inferred from a difference between intra- and intermolecular 
kinetic isotope effects (KIEs). Under optimal reaction conditions, the authors showed a broad 
applicability towards electron-donating and electron-withdrawing substituents. Nonetheless, valuable 
functional groups such as esters, cyano-, chloro-, bromo-, and iodo-substituents not being within the 
reaction scope represented a major limitation.
[35]
  
Despite these undisputed advances, a general and efficient ruthenium-catalyzed arylation using 
inexpensive aryl chlorides 3 had not yet been disclosed at that time, and all protocols were limited to 
phosphine ligands.  
As early as 2005, Ackermann presented a significant breakthrough in ruthenium(II)-catalyzed 
arylations by employing structurally diverse (heteroatom-substituted) secondary phosphine oxides
[36]
 
((HA)SPOs) as powerful preligands (Scheme 7).  
 
Introduction  7 
 
 
Scheme 7. Ruthenium(II)-catalyzed C–H arylations using SPOs as additives. 
 
Hence, a large variety of different air-stable SPOs and HASPOs was tested, somewhat 
counterintuitively rendering the sterically most hindered di-adamantyl-substituted SPO as the optimal 
additive. Under the optimized reaction conditions a series of valuable functional groups, such as 
esters, ketones, and nitriles, was well tolerated and, moreover, it was demonstrated that modifiable 
ketimines 6 as the directing group delivered the corresponding mono-arylated products 5 in overall 
higher efficiency than Oi/Inoue had previously achieved by using phosphine additives (vide supra).
[30]
 
Thereafter, the mechanistic working mode of the SPO preligands was proposed to be a ruthenium(II)-




Subsequently, Ackermann and coworkers reported on a (HA)SPO-preligand enabled ruthenium-






Inspired by the successful strategy of applying bifunctional ligands like SPOs, Ackermann and 
coworkers introduced ‒for the first time in ruthenium-catalyzed C–H functionalizations‒ carboxylates 
as additives (Scheme 8).
[36a]
 The mechanistic pathway of the C–H activation by carboxylate-assistance 
was suggested to proceed via a six-membered CMD-type transition state 16 that had first been 
proposed by Reutov and coworkers
[38]
 and was thereafter computationally studied by Fagnou/Gorelsky 
for the palladium-catalyzed C–H activation.
[20c, 39]
 
Hence, a significant rate acceleration by carboxylates as compared to phosphines and phosphates was 
also observed for the ruthenium(II)-catalyzed C–H arylation of triazoles 17. Notably, triazoles 17 are 
valuable directing groups due to their considerable impact on bioorganic chemistry and material 
sciences.
[40]
 In contrast to previous reports, less polar toluene was successfully employed as the 
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Scheme 8. Ruthenium(II)-catalyzed C–H arylation through carboxylate-assistance. [a] 10 mol %. 
 
Thereafter, the idea of using carboxylate additives was picked up by Dixneuf and coworkers, as they 
utilized the well-defined ruthenium(II)-acetate complex [Ru(OAc)2(p-cymene)] as a competent 
catalyst for the construction of poly-heterocyclic molecules by C–H arylation.
[41]
  
The first detailed mechanistic insights for carboxylate-assisted ruthenium-catalyzed C–H activations 
were reported by Ackermann and coworkers in 2010.
[42]
 The authors achieved the synthesis of a well-
defined ruthenium(II)biscarboxylate complex [Ru(O2CMes)2(p-cymene)] (20), which displayed an 
excellent reactivity for the C–H arylation of inter alia pyrazoles 18, triazoles 17, oxazolines 7, 
imidazoles 19, as well as 2-styrylpyridines 9.  
Besides these synthetically useful contributions, a set of important mechanistic findings shed light on 
the reaction mechanism. First, H/D-exchange experiments indicated the C–H activation to be 
reversible (Scheme 9a). Second, the 2-phenylpyridine derivative 1b was shown to form the ruthenium 
cyclometalated complex 21 through a stoichiometric reaction with [Ru(O2CMes)2(p-cymene)] (20). 
Third, the complex 21 was demonstrated to be catalytically active and thus delivered the arylated 
product 5bb (Scheme 9b) in high yield. Finally, various intermolecular competition experiments 
revealed a clear preference for electron-deficient aryl bromides 2, which suggested that the oxidative 
addition is the turnover-limiting elementary step in this transformation.
[42]
 
Introduction  9 
 
 
Scheme 9. Key mechanistic findings for the carboxylate-assisted C–H arylation. 
 
To summarize all these mechanistic results, the authors proposed a general catalytic cycle (Scheme 
10), which is initiated by a reversible carboxylate-assisted C–H ruthenation via a CMD-type six-
membered transition state 16 to deliver ruthenacycle 23. Subsequently, a turnover-limiting oxidative 
addition of the aryl halide 24 to the ruthenium(II) complex 23 occurs and generates a ruthenium(IV) 
intermediate 25. Ultimately, a reductive elimination produces the desired arylated product 26 and 
regenerates the active ruthenium complex 27.  




Scheme 10. Proposed catalytic cycle for the carboxylate-assisted ruthenium(II)-catalyzed C–H 








Furthermore, the excellent performance and broad applicability of ruthenium(II)-carboxylate 
complexes was highlighted by regioselective arylations of diversely substituted heterocycles, such as 
pyrroles 28, thiophenes 29 and indoles 30, which bear a removable pyrimidyl directing group.
[43]
 
Based on seminal observations by Ackermann (vide supra) using water as additive in ruthenium-
catalyzed C–H arylations,
[36c]
 Dixneuf and coworkers demonstrated the robustness of ruthenium-
catalyzed C–H arylations by establishing water as an economically attractive and environmentally 
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Scheme 11. Water-tolerant ruthenium(II)-catalyzed C–H arylation. 
 
Notably, Ackermann and coworkers presented a ruthenium(II) biscarboxylate-catalyzed arylation in 
PhMe as the solvent and tetrazoles 31 as the directing group. Thereby, the authors highlighted a step-
economical access to the angiotensin(II)-receptor blocker Valsartan (Scheme 12). Seki reported on a 





Scheme 12. Step-economical access to a Valsartan building block. 
 
Furthermore, Pratap and coworkers disclosed  a ruthenium(II)-catalyzed C–H arylation on a purine 
derivative by using triphenylphosphine as an additive and aryl iodides 3 as arylating reagent.
[46]
  
In striking contrast, ruthenium-catalyzed C–H arylations were not only accomplished by the 
corresponding dimer [RuCl2(arene)]2/RCO2H or well-defined ruthenium(II)biscarboxylate complexes, 
but also by the simple [RuCl3∙xH2O] salt (Scheme 13). In this regard, Ackermann and coworkers 




Moreover, Yu and coworkers presented a similar system comprising the same ruthenium-catalyst and 
NMP as the solvent to accomplish C–H arylations with aryl chlorides 3. However, PPh3 as the additive 
and Na2CO3 as the base were shown to be crucial for achieving high efficiencies.
[48]
 However, in these 
systems the exact structure of the active catalyst has so far remained unknown. Preliminary studies 
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Scheme 13. [RuCl3∙xH2O]-catalyzed C–H arylations. 
 
1.3 Cobalt-Catalyzed C–H Activation 
In 1938, Otto Roelen made a groundbreaking advance in homogenous catalysis by reporting on the 
first metal-catalyzed hydroformylation reaction.
[49]
 Remarkably, after testing a variety of catalytic 
systems, he suggested that the simple and inexpensive cobalt complex [CoH(CO)4] is the optimal 
catalyst.
[50]
 After these pioneering studies, the following decades have witnessed enormous progress in 
cobalt catalysis, e.g. the development of the Pauson-Khand-reaction.
[51]
 Nowadays, the great 
importance of cobalt catalysts is reflected by numerous industrial processes using economically 
attractive cobalt complexes, such as the Fischer-Tropsch-process
[52]




Due to the earth abundance and thus inexpensiveness
[54]
 of cobalt as well as the beneficial step- and 
atom-economical features of C–H activation catalysis, it appeared particularly attractive to investigate 
the performance of cobalt catalysts in C–H functionalizations. Thus, Murahashi and coworkers 
accomplished one of the first examples of C–H functionalizations in 1955, as they reported on a 
cobalt-catalyzed carbonylative cyclization of azobenzenes 35. However, extremely harsh conditions 
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Scheme 14. Cobalt-catalyzed carbonylative cyclization. 
 
Almost 40 years later, one of the first examples for a stoichiometric C–H activation by a cobalt 
complex was reported by Klein and coworkers in 1993 by again using azobenzene (35a) as the 
substrate and [CoMe(PMe3)4] as the cobalt source (Scheme 15).
[56]
 The authors suggested that the 
reaction is initiated by a dissociation of one PMe3 ligand. Subsequently, oxidative addition of the 
ortho-C–H bond to the cobalt complex occurs, and finally a reductive elimination of methane provides 
the cyclometalated species 37. 
 
 
Scheme 15. Stoichiometric formation of a cobaltacycle through C–H activation. 
 
Based on these findings, Klein and coworkers reported on the synthesis of several cobaltacycles by 




These fundamental studies paved the way for a blossom of cobalt-catalyzed C–H functionalizations by 
initially low-valent cobalt catalytic systems, with numerous contributions by inter alia Ackermann and 
Yoshikai.
[15]
 Despite the broad synthetic applicability of low-valent cobalt-catalyzed C–H 
functionalizations, one of the major drawbacks of some low-valent cobalt catalytic systems is often the 
need for stoichiometric amounts of Grignard reagents, which limit the overall atom-efficiency and the 
substrate scope with respect to base-labile functional groups.  
 
1.3.1 Cobalt(III)-Catalyzed C–H Functionalization 





which obviate the use of Grignard reagents and usually follow the reactivity features of the well-
established rhodium(III) C–H activation catalysis.
[13o, 59]
 As an early example in 2013, they 
investigated the catalytic performance of several cobalt complexes in addition reactions of 2-
phenylpyridine (1a) to highly electrophilic sulfonylimines 38 as well as α,β-unsaturated ketones, esters 
and amides 39 (Scheme 16).
[60]
 During their optimization studies, the authors emphasized that only 





Cp*]- complexes were powerful catalysts for these transformations, whereas CoCl2 did not 
furnish the desired products. 
 
 
Scheme 16. Cobalt(III)-catalyzed C–H functionalization and addition to electrophiles. 
 
Under comparably mild reaction conditions, various functional groups, such as enolizable ketones, 
hydroxyls as well as ester-groups, were tolerated, contrasting the often limited substrate scope of low-
valent cobalt-catalyzed reactions.  




 was shown to be inefficient in 
addition reactions to less electrophilic α,β-unsaturated esters and amides, indicating the unique 
reactivity profile of [Co
III
Cp*]-catalysts. Presumably, the higher nucleophilicity of the cobalt-carbon 
bond enables the addition reaction to even less electrophilic functionalities. In this regard, the Pauling 
electronegativity of cobalt is χF ≈ 1.9 and of rhodium it is χF ≈ 2.3.
[62]
 




a plethora of new synthetic 
methods were developed, with partly new reactivities and selectivities as compared to the analogous 
[Rh
III
Cp*]-catalysis. Shortly afterwards, the same group reported on a similar reaction with indoles 30, 
but using KOAc as the crucial additive to accomplish a significant rate acceleration.
[63]
 The authors 
proposed that the C–H activation elementary step proceeds either via an electrophilic or acetate-
assisted CMD-type mechanism.  
Encouraged by these seminal reports of Matsunaga/Kanai, Ellman and coworkers probed the 
reactivity of cobalt(III) complexes to aldehyde 43 functionalities in addition reactions.
[64]
 The reported 
reaction comprised a sequence of an addition and successive cylization reaction to furnish indazoles 
44 with azobenzenes 35 or furanes 45 employing α,β-unsaturated oximes 46 (Scheme 17). 
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Scheme 17. Cobalt(III)-catalyzed synthesis of a) furanes 45 and b) indazoles 44. 
 
In addition, the isohypsic synthesis of heterocyles, such as isoquinolines
[65]
 49 (Scheme 18a) and 
indoles 50 (Scheme 18b),
[23c]
 by cobalt(III)-catalyzed C–H/N–O functionalizations was accomplished 
by Ackermann and coworkers, employing oximes 46 and nitrones 47 as the directing groups. These 
reactions exhibited a broad scope with respect to both substrates. Intriguingly, the overall high 
efficiency of cobalt(III) catalysis was highlighted by a reaction time of only 15 min (Scheme 18a). 











Scheme 18. Cobalt(III)-catalyzed C–H/N–O functionalizations for the synthesis of heterocycles. 
 
The syntheses presented above already indicated the great importance of nitrogen-containing 
heterocycles.
[70]
 Along this line, Matsunaga/Kanai published an amidation of 2-pyrimidylindoles 50 
with sulfonyl azides 51
[71]
 (Scheme 19) with ample scope and excellent yields. Thereafter, the same 
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Scheme 19. Cobalt(III)-catalyzed amidation with sulfonyl azides 51. 
 







 independently reported on cobalt(III)-catalyzed 
cyanations. The reaction system of Ackermann and coworkers is characterized by a low catalyst 
loading of only 2.5 mol % and functionalizations of valuable heteroarenes to inter alia cyanated 2-
pyrimidylindoles 58/60 and 2-pyrimidylpyrroles 59 (Scheme 20). The corresponding products were 




Scheme 20. Cobalt(III)-catalyzed C–H cyanation of heteroarenes. 
 
Moreover, the authors proposed a catalytic cycle of the cobalt(III)-catalyzed C–H cyanation (Scheme 
21), which is initiated by reversible C–H cobaltation involving an acetate-assisted deprotonation 
pathway to deliver cobaltacycle 62a. After coordination of the cyanation reagent 56, a β-nitrogen 
elimination takes place. Subsequently, proto-demetalation with the in situ generated acetic acid 
delivers the cyanated product 66 and regenerates the catalytically active cobalt(III)-acetate species 
62a.  








Generally, the β-nitrogen elimination described above was found to be an energetically preferred step 
due to the formation of strong metal-nitrogen bonds. Likewise, the same pathway should be favored 
for oxygen, which is in β-position to a metal center. Consequently, a process involving C–H 
functionalization and subsequent β-oxygen elimination is a step-economical approach for installing 
functionalities, such as synthetically versatile allyl-groups, which have found widespread applications 
in organic synthesis.
[76]







coworkers have independently devised several methods merging cobalt(III)-catalyzed C–H activation 
with C–O bond cleavage by β-oxygen elimination to accomplish C–H allylations with a variety of 
directing groups and allylating reagents (Scheme 22). Accompanied by a report on cobalt(III)-
catalyzed cyanations, brominations, and iodinations, Glorius and coworkers showed that allyl 
carbonates 67 are competent reagents for the allylation of 2-pyrimidylindoles 50. In a follow-up work, 
the same group demonstrated that benzamides 68 (Scheme 22a) and acrylamides 69 could also be 
efficiently allylated.
[79]
 The reaction system of Ackermann and coworkers highlighted the use of 
simple allyl acetates 71 to accomplish C−H allylations of inter alia 2-pyrimidylindoles 50 as well as 
less eletron-rich pyridyl- and pyrimidylarenes. Surprisingly, the crucial β-oxygen elimination step 
turned out to be such a strong driving force that even weak leaving groups like hydroxyls could be 
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eliminated by using allyl alcohols 74 directly, as Kanai/Matsunaga and coworkers demonstrated. In 
addition, the authors emphasized that the reactivity of the cobalt(III) complex was much higher as 




Scheme 22. Cobalt(III)-catalyzed C–H allylations. 
 
Furthermore, a catalytic cycle for the general leaving group OR can be postulated (Scheme 23). 
Interestingly, all reported catalytic systems featured a significant rate acceleration by carboxylates or 
carboxylic acid additives, which leads to the assumption that the cationic cobalt-carboxylate 62 (cf. 
Scheme 21) might be catalytically active species.  
Initially, a base-assisted C–H cobaltation takes place, which was shown to be reversible and not 
turnover-limiting, at least in the case of indole substrates.
[77]
 After reversible coordination of the allyl 
substrate 76 to form complex 77, a migratory insertion furnishes intermediate 78, which undergoes a 
β-oxygen elimination step to release the allylated product 79 and a cobalt(III)-alkoxy species. 
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Additionally, Kanai/Matsunaga showed by DFT-studies that a competing SN2' pathway is 
unfavorable.
[78]
 Finally, a reaction of the cobalt(III)-alkoxy species with carboxylic acid regenerates 
the active cobalt(III)-carboxylate catalyst 62.  
 
 




1.3.2 Cobalt-Catalyzed Hydroarylations 
The first example of a cobalt-catalyzed C–H hydroarylation reaction was reported by Kisch and 
coworkers in 1994, using azobenzenes 35 and tolane 48a as substrates.
[80]
 The corresponding di-
functionalized products 80 were obtained in good isolated yields of around 70–80% (Scheme 24). 
 
 
Scheme 24. Cobalt(I)-catalyzed C–H hydroarylation. 
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These fundamental findings inspired Yoshikai and coworkers to develop a cobalt-catalyzed C–H 
hydroarylation of internal alkynes 48 (Scheme 25). The catalytic system comprised comparably low 
amounts of a simple cobalt salt as the catalytic precursor, a phosphine ligand, and stoichiometric 
amounts of a Grignard reagent as the reductant. In this context, the authors first succeeded in 
functionalizing 2-phenylpyridines 1.
[81]
 Afterwards they extended the substrate scope to ketimines 6
[82]
 
and indoles 30 as well.
[83]
 Under the optimal reaction conditions, the desired alkenylated products 81 
were delivered in very good yields and an excellent regiocontrol was achieved in the case of 
unsymmetrical alkynes 48. Most of the reactions proceeded at ambient temperature so that even 
sensitive functional groups such as nitriles were well tolerated. 
 
 
Scheme 25. Low-valent cobalt-catalyzed C–H hydroarylation with ketimines 6. 
 
Thereafter, the excellent performance of low valent cobalt catalysis in hydroarylation reactions was 




 Yoshikai and 
coworkers developed a cobalt-catalyzed C–H hydroarylation with styrenes 82 and 2-phenylpyridines 1 
(Scheme 26). Remarkably, the authors accomplished a complete switch in Markovnikov/anti-
Markovnikov selectivity by the judicious choice of the ligand. While bulky NHC ligands afforded 
linear products 83, phosphine ligands completely reversed the selectivity and delivered the branched 
products 84 in overall good to excellent regioselectivities. 
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Scheme 26. Low-valent cobalt-catalyzed regioselective C–H hydroarylations. 
 
Moreover, the authors conducted deuterium labeling experiments with deuterated 2-phenylpyridine-d5 
([D]5-1a). In the case of the branched product 84aa a higher content of deuterium was observed in the 
α-position of the styrene moiety. In contrast, for the linear product 83aa a larger deuterium 
incorporation could be detected in β-position.
[84]
 These findings led to the mechanistic hypothesis that 
the C–H activation via oxidative addition as well as the migratory insertion steps are reversible for 
both reactions, while the reductive elimination is turnover-limiting as well as regioselectivity-
determining (Scheme 27). The bulky NHC ligand forces the styrene 82 to insert linearly into the 
carbon-cobalt bond to avoid steric interactions, whereas the linear-selective reaction is controlled by 
the electronically favored formation of a benzylic cobalt species,
[86]




Scheme 27. Proposed mechanism for the regioselective cobalt-catalyzed C–H hydroarylation. 
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Thereafter, Nakamura and coworkers disclosed a low-valent cobalt-catalyzed C–H hydroarylation of 
benzamides 68 with mostly electronically unactivated alkenes 88. However, the authors also presented 
a few examples comprising styrenes 82 (Scheme 28).
[85]
 The catalytic system was characterized by an 
inexpensive Co(acac)3 catalyst, stoichiometric amounts of a Grignard reagent, and a reaction 
temperature as low as 25 °C. The authors proposed DMPU to be an essential ligand, which they had 
previously shown for a related reaction.
[87]
 Importantly, under very mild reaction conditions, even 
base-labile functional groups like esters were well tolerated. Interestingly, electronically unactivated 
alkenes 88 delivered solely the linear-selective product 89 in excellent yields and regioselectivities. In 
contrast, the use of styrene (82a) afforded the linear product 89ca in only moderate regioselectivity. 
Nevertheless, the authors did not propose a mechanistic reason for this interesting change in 
selectivity, which is obviously related to Yoshikai’s observation (vide supra). 
 
 
Scheme 28. Low-valent cobalt-catalyzed C–H hydroarylation of benzamides 68 with alkenes 88. 
 
Intriguingly, Yoshikai and coworkers accomplished an enantioselective low-valent cobalt-catalyzed 
hydroarylation with styrenes 82 in the C2-position of indole 90, which bear a ketimine directing group 
in C3-position (Scheme 29).
[88]
 The key to success in achieving moderate to good enantioselectivity 
was the use of phosphoramidite ligands,
[89]
 featuring a BINOL-derived backbone.
[88]
 Overall, good 
yields and enantioselectivities were obtained, albeit sterically demanding indoles 90 led to a clear 
decrease in yield and enantioselectivity, as it was demonstrated for the 7-ethyl substituted indole 90b.  
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Scheme 29. Low-valent cobalt catalyzed enantioselective C–H hydroarylation. 
 
Based on a previous report by Fagnou and coworkers on a rhodium(III)-catalyzed C–H 
hydroarylation
[90]
 with alkynes 48 and low-valent cobalt-catalyzed reaction of Yoshikai,
[83]
 




Remarkably, the authors achieved a full control of chemoselectivity depending on the directing group 
(Scheme 30). While carbamoyl-substituted indoles 92 furnished the expected hydroarylation products 
93 with excellent regioisomeric ratios and a broad scope (Scheme 30a), a morpholine unit on the 
carbamoyl residue in substrate 94 almost exclusively afforded the corresponding pyrroloindolones 95 
(Scheme 30b) via a hydroarylation/annulation sequence.  
The authors emphasized the unique selectivity features of cobalt(III) catalysis by comparison with the 
chemoselectivity of the corresponding rhodium(III)-catalyzed hydroarylation. Notably, rhodium(III) 
catalysis exclusively yielded the hydroarylated product 93, regardless of the carbamoyl-moiety.  
 




Scheme 30. Cobalt(III)-catalyzed chemoselective C–H hydroarylations with alkynes 48. 
 
Finally, the authors proposed a catalytic cycle (Scheme 31), which is initiated by the formation of the 
catalytically active cobalt(III)-monoacetate species 62a. Subsequently, a reversible cobaltation 
delivers the cobaltacycle 96 via an acetate-assisted C–H activation mechanism. The exact pathway of 
this C–H activation step is presumably not fully concerted, as it was shown by DFT calculations. 
Rather, a stepwise mechanism was proposed, which is initiated by a weak interaction between cobalt 
and the C2-position of indole, followed by deprotonation through acetate-assistance.
[20]
 After 
reversible coordination of the alkyne 48 and migratory insertion, the crucial cobalt-alkenyl-
intermediate 98 is produced. Depending on the leaving group ability of the dialkylamine unit, either a 
proto-demetalation follows, delivering the product 93, or an annulation reaction by nucleophilic attack 
of the cobalt-carbon bond with following β-nitrogen elimination affords the pyrroloindolone 95. In 
addition, DFT calculations and charge estimation by a natural population analysis led to the 
assumption that a crucial cobalt(III)-alkenyl intermediate 98 is more nucleophilic than the analogous 
rhodium(III)-intermediate due the diminished electrophilicity of cobalt (vide supra). In this respect, a 
simple change to a better leaving group, such as the morpholino-unit, energetically favoured the 
successive annulation reaction. 
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1.4 Manganese-Catalyzed C–H Activation 
The achievement of sustainable chemical processes ideally involves the use of earth-abundant reagents 
and catalysts. In this regard, manganese represents an ideal candidate for C–H activation catalysis, 
since it is the twelfth most abundant element in the earth crust, and the third most abundant transition 
metal after iron and titanium.
[54]
 However, manganese could be an appealing metal for new catalysts 
not only from an economical viewpoint, but also due to its usually low toxicity,
[54, 92]
 which matches 
the principles of green chemistry.
[12]
 In addition, there are several manganese co-factors in enzymes 
that are involved in the human metabolism of inter alia carbohydrates and amino acids, rendering 
manganese essential for human life.
[93]
  
Thus, by strong analogy with the stoichiometric cobalt-mediated C–H activation by Klein and 
coworkers (cf. chapter 1.3), Stone/Bruce and coworkers presented a manganese-mediated C(sp
2
)–H 












Thereafter, a number of reactivities with these well-defined manganacycles were disclosed by inter 
alia Liebeskind for the synthesis of indenoles,
[95]





accomplishments have already predicted the great potential of manganese in C–H activation catalysis.  
However, almost 40 years had passed since the report of Stone/Bruce until the first example of 
manganese-catalyzed C–H activation was reported by Kuninobu/Takai in 2007 (Scheme 33).
[98]
 Here, 
the authors presented a manganese(I)-catalyzed C–H activation of imidazoles 19 and a subsequent 
addition reaction of the manganacycle to electrophilic aldehydes 43. Notably, triethylsilane turned out 
to be a crucial reagent for catalytic turnover, delivering the silyl-protected benzylic alcohols 100 in 
overall moderate to good yields. The authors emphasized that only a manganese-catalyst was efficient, 
whereas other representative metal-catalysts based on inter alia rhenium, ruthenium, and iridium-
complexes were not active. Within a comprehensive scope it was demonstrated that even sterically 
demanding substrates like ortho-substituted phenyl-groups led to only a slight decrease in yield.  
 
 
Scheme 33. Manganese(I)-catalyzed C–H addition to aldehydes 43.  
 
Moreover, a plausible mechanistic scenario was proposed (Scheme 34). The yet undefined structure of 
the catalytically active manganese(I) species 101 undergoes C–H activation by oxidative addition, 
furnishing the manganese(III)-hydride species 102. Afterwards, migratory insertion of the polar 
carbonyl bond into the nucleophilic carbon-manganese bond takes place. Finally, triethylsilane 
promotes a reductive elimination to release the silyl-protected product 100, the active catalyst, and 
molecular hydrogen. 
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Scheme 34. Proposed catalytic cycle for the manganese(I)-catalyzed C–H addition to aldehydes 43. 
 
Even though this reaction represented a significant breakthrough in manganese C–H activation 
catalysis, a serious limitation was represented by the need for triethylsilane to achieve catalytic 
turnover. In contrast, Wang and coworkers succeeded in the development of a more general 
manganese(I)-catalyzed C–H addition to aldehydes 43 by using ZnBr2 and Me2Zn (Scheme 35).
[99]
 
The optimal reaction conditions allowed for aromatic as well as olefinic C–H activation and various 
functional groups like halogens, ester-, and methoxy- groups were tolerated. Likewise, detailed 
mechanistic studies led to the hypothesis that Me2Zn was crucial for the in situ formation of the active 




Scheme 35. Manganese(I)-catalyzed C–H addition to aldehydes 43. 
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Additionally, Ackermann and coworkers reported on a manganese(I)-catalyzed aminocarbonylation of 
heteroarenes through C–H addition to furnish isocyanates.
[100]
 The authors presented an ample scope 
of differently substituted 2-pyridylindoles 105 and a large variety of isocyanates 106 to afford the 
corresponding aminocarbonylated products 107 in very good yields. Notably, sensitive functional 
groups, such as ketones and esters, were well tolerated under the optimal reaction conditions.  
 
 
Scheme 36. Manganese(I)-catalyzed aminocarbonylation. 
 
Recently, Ackermann and coworkers disclosed a manganese(I)-catalyzed cyanation reaction on several 
heterocycles (Scheme 37).
[101]
 Overall, a variety of functional groups was tolerated, including esters, 
ketones, and tryptophans. The authors introduced the new and more electrophilic cyanation reagent N-
cyano-N-(4-fluorophenyl)-4-methylbenzenesulfonamide (NCFS) (108) and compared its reactivity 
with Beller’s well-established N-cyano-N-phenyl-p-toluenesulfonamide (NCTS) (56).
[102]
 Thus, with 
respect to the cyanation of very challenging tryptophan 110, NCFS was shown to be a more powerful 
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Intermolecular competition experiments with electron-donating and electron-withdrawing substituents 
indicated a clear preference for electron-rich substrates. Moreover, H/D-exchange experiments and a 
KIE study revealed a fully reversible C–H activation step to be at work. In addition, detailed DFT 
studies were supportive of ZnCl2 to act as a Lewis acid and to facilitate the turnover-limiting migratory 
insertion step in a hetero-bimetallic fashion.  
However, the reactivity of manganacycles was not only limited to addition reactions with strong 
electrophiles. Indeed, the insertion of inherently less polar carbon-carbon multiple bonds proved to be 
viable as well. Thus, Wang and coworkers accomplished the first manganese(I)-catalyzed alkenylation 






Scheme 38. Manganese(I)-catalyzed C–H alkenylation. 
 
In this reaction, a variety of aryl- as well as alkyl-substituted terminal alkynes 111 reacted smoothly to 
provide the (E)-configurated alkenes 112 with perfect anti-Markovnikov selectivity. Finally, the 
authors performed DFT calculations to shed light on the reaction mechanism. Based on these studies, 
it was proposed that Cy2NH facilitates the C–H activation step via a base-assisted deprotonative 
pathway. 
Thereafter, the same group extended the manganese(I)-catalyzed hydroarylation protocol to 
electronically activated α,β-unsaturated carbonyls 113 (Scheme 39).
[104]
 The reaction proceeded with 
excellent mono-selectivities, delivering the corresponding products 114 in satisfactory yields. 
 




Scheme 39. Manganese(I)-catalyzed hydroarylation of α,β-unsaturated carbonyls 113. 
 
Furthermore, Wang and coworkers demonstrated that the C–H hydroarylation strategy turned out to be 
applicable in C–H/N–H annulation reactions with imines 115 and terminal 111 as well as internal 
alkynes 48 to deliver isoquinolines 116 (Scheme 40).
[105]
 In addition to a broad substrate scope with 
good yields and regioselectivities, the authors unraveled large parts of the reaction mechanism.  
 
 
Scheme 40. Manganese(I)-catalyzed C–H/N–H annulation. 
 
Thus, the authors proposed a catalytic cycle (Scheme 41), which is commenced by a presumably 
turnover-limiting C–H activation step to form manganacycle 117. After ligand exchange of CO by 
alkyne-coordination, a migratory insertion leads to intermediate 119, which is prone to undergo 
reductive elimination to release the desired product 116 and generates a manganese-hydride species 
120. The latter reacts with a new imine 115 to again deliver manganacycle 117 through C–H 
manganation under evolution of hydrogen. 
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Scheme 41. Postulated catalytic cycle for the manganese(I)-catalyzed C–H/N–H annulation. 
 
Ackermann and coworkers reported on an manganese-catalyzed C–H annulation with acrylates
[106]
 to 
afford highly valuable β-amino esters
[107]
 122 (Scheme 42) in good yields and overall intriguing levels 
of diastereoselectivities.  
 
 
Scheme 42. Manganese-catalyzed synthesis of β-amino esters via a C–H annulation process. [a] 
[Mn2(CO)10] (10 mol %) in PhMe. 
 
In addition to the previously described substitutive cobalt(III)-catalyzed C–H allylation with allyl 
carbonates 67 (cf. Scheme 22), manganese catalysis was shown to be a competent alternative to enable 
C–H allylations.  
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In this regard, the Ackermann group reported on a C–H allylation of ketimines 6 with allyl carbonates 
67, delivering the corresponding allylated ketones 123 in excellent yields and good 





Scheme 43. Manganese-catalyzed C–H allylation with allyl carbonates 67. [a]
 
At 120 °C. [b]
 
[Mn2(CO)10] (10 mol %).  
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2 Objectives 
The development of novel strategies for highly stereoselective transition metal-catalyzed C–C bond 
forming processes is of prime importance for expanding the toolbox of modern organic synthesis. In 
recent years, C–H bond functionalizations
[13]
 have emerged as a powerful reaction class due to their 




Thus, the focus of this thesis is 
directed towards exploring novel cost-effective and environmentally benign C–H 
functionalizations.
[12b]
 In this context, particularly the efficiency of catalysts should be studied that are 





In the past decade, invaluable advances in ruthenium-catalyzed C–H arylations were inter alia 
achieved by Ackermann and coworkers, highlighting powerful carboxylates as the additives of 
choice.
[20a, 109] 
Nevertheless, also the use of secondary phosphine oxides (SPOs) as preligands has been 
revealed to be highly beneficial.
[36] 
Within this thesis, the performance of well-defined and easily 
modifiable ruthenium(II)-phosphinous acid (PA) complexes 124 in the C–H arylation of (E)-
styrylpyridines 9 as challenging acyclic alkene substrates should be explored (Scheme 44). Moreover, 




Scheme 44. Ruthenium(II)-PA-catalyzed C−H arylation. 
 
Despite of undisputed progress in the field of cobalt(III)-catalyzed C–H bond activations,
[15]
 there is 
still a lack of methods that merge C–H with C–C
[110]
 functionalizations in a tandem process. In this 
regard, vinylcyclopropanes 125
[111] 
are due to their ring strain ideal synthons for achieving the first 
cobalt-catalyzed C–H/C–C functionalization, along with detailed mechanistic studies (Scheme 45). 
 
 
Scheme 45. Cobalt(III)-catalyzed C–H/C–C functionalization. 
 
So far, there have been numerous reports on transition metal-catalyzed C–H hydroarylations,
[112]
 with 
a plethora of metals and broad synthetic applicability. Thus far, the control of Markovnikov/anti-
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Markovnikov regioselectivity has relied on the use of expensive ligands
[113]
 and was mostly restricted 
to electronically activated styrenes 82.
[114]
 Within this thesis, a new concept for regiocontrol in C–H 
hydroarylations of unactivated alkenes should be developed (Scheme 46). This approach should 
encompass the design of reaction conditions to easily switch between branched and linear selectivity.  
 
 
Scheme 46. Control of branched/linear selectivity in cobalt(III)-catalyzed C–H hydroarylations. 
 
There is a strong demand for novel synthetic methods to install fluorine in organic molecules,
[115]
 
because fluorine is known to improve several physicochemical properties of e.g. pharmaceuticals, 
such as metabolic stability, lipophilicity and membrane permeability.
[116]
 So far, several methods for 
C–H/C–X functionalizations are known
 







 eliminations. Thus, a cobalt(III)-catalyzed C–H activation was intended to be 
combined with C–F functionalizations
[118]
 through β-fluoride elimination
[119]
 using 
perfluoroalkylalkenes 127 and 1,1-difluoroalkenes 128 (Scheme 47). 
 
 
Scheme 47. Cobalt(III)-catalyzed allylative and alkenylative C–H/C–F functionalization. 
 
In recent years, a tremendous progress has been achieved in utilizing manganese(I) catalysts for C–H 
functionalizations
[14]
 with partly unique levels of selectivity control.
[117d, 120]
 Thus, the development of 
a novel manganese(I)-catalyzed C–H/C–F functionalization was intended (Scheme 48). Particularly, a 
comparison with the analogous cobalt(III)-catalyzed reaction in terms of reactivities and selectivities  
should be of prime importance for revealing unique features of metals in C–H activation catalysis. 
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Scheme 48. Manganese(I)-catalyzed allylative and alkenylative C–H/C–F functionalization. 
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3 Results and Discussion 
3.1 C−H Arylations by Ruthenium(II)-Phosphinous Acid Catalysts 
The last years have witnessed significant progress in the development of ruthenium catalyzed C–H 
arylations. In this context, especially well-defined ruthenium(II)-carboxylate catalysts have proven to 
be powerful catalysts with a broad applicability and excellent functional group tolerance.
[20a, 109a]
  
However, there is still a strong demand for the synthesis of novel and efficient ruthenium catalysts, 
which could be used for applications in inter alia polymer chemistry and material sciences.
[121]
  
For this purpose, highly reactive and bench-stable catalysts are needed which bear an easily 
modifiable ligand such as phosphinous acid. Thus, the exploration of versatile single-component 
ruthenium(II)-PA complexes 124, their use in C–H arylations, and new mechanistic insights represent 
a great opportunity to raise the potential of ruthenium-catalyzed C–H arylation methods. 
3.1.1 Optimization Studies  
We initiated our optimization studies by probing the effect of different ruthenium(II) catalysts on the 
desired C−H arylation of (E)-2-styrylpyridine (9a) (Table 1). In this context, conventionally used 
catalytic precursors like [RuCl3∙xH2O]
[47-48]
 and [RuCl2(p-cymene)]2 (entries 1 and 2) were clearly 
outcompeted by well-defined single component phosphinous acid (PA) ruthenium(II) catalysts 124,
[122]
 
that have been synthesized following an optimized protocol by S. Warratz.
[123]
 It is noteworthy that in 
the absence of any ruthenium precursor the desired product 10ab was not formed (entry 3). To 
elucidate the role of the substitution pattern on the phosphorous atom of the phosphinous acid ligand, 
the reactivity of different ruthenium(II)-PA complexes 124 with aliphatic as well as aromatic 
substituents has been studied (entries 4–10). Aromatic substituents only led to moderate yields, with a 
decrease in reactivity for electron-poor substituents (entry 5). In contrast, a clearly higher reactivity 
was achieved by employing alkyl-substituted PA-ligands (entries 7 and 8). However, a sterically more 
congested substitution pattern led to only unsatisfactory results (entries 9 and 10), which reveals that a 
balanced situation between the repulsive steric interactions and electronic parameters of the PA-ligand 
is necessary for an efficient transformation.  
Generally, it can be speculated that electron-donating substituents on the phosphorous atom increase 
the basicity of the deprotonated phosphinous acid ligand, which acts as internal base during the metal-
ligand cooperated C–H activation.
[36a, 123]
 Consequently, a faster C–H activation elementary step would 
occur. In addition, the contribution of attractive London dispersion interactions
[124]
 to the stabilization 
of the C–H activation transition state should be considered as well, since a significant rate acceleration 
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Table 1. Optimization for the C–H arylation of (E)-2-styrylpyridine (9a) with aryl bromides 2.  
 
 





2 [RuCl2(p-cymene)]2 9 
3 ---     ---
[b,c] 
4 [RuCl2(p-cymene)(Ph2POH)] (124a) 77 
5 [RuCl2(p-cymene){(p-FC6H4)2POH}] (124b) 60 
6 [RuCl2(p-cymene)(t-BuPhPOH)] (124c) 51 
7 [RuCl2(p-cymene)(i-Pr2POH)] (124d) 92 
8 [RuCl2(p-cymene)(n-Bu2POH)] (124e) 96 





[a] Reaction conditions: 9a (0.50 mmol), 2b (0.75 mmol), [Ru] (5.0 mol %), K2CO3 (1.00 mmol), PhMe 
(0.25 M), 120 °C, 18 h, isolated yield. [b] Determined by GC with n-dodecane as the internal standard. [c] n-
Bu2P(O)H (20 mol %) as additive.  
 
Encouraged by these preliminary optimization results, the catalytic performance of the optimal 
ruthenium(II)-PA complex 124e was furthermore tested by reducing the catalyst loading (Table 2), 
employing slightly higher concentrations and reaction temperatures. Surprisingly, catalyst loadings as 
low as 0.90 mol % still provided an excellent conversion to the desired product 10ab (entry 4), while 
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Table 2. Reduction of the catalyst loading. 
 





2 2.50 99 
3 1.00 98
 
4 0.90 98 
5 0.75 82 
[a] Reaction conditions: 9a (0.50 mmol), 2b (0.75 mmol), [Ru] (5.0 mol %), K2CO3 (1.00 mmol), PhMe 
(1.00 M), 140 °C, 18 h. Conversions determined by means of GC with n-dodecane as the internal standard. 
 
3.1.2 Scope of the C–H Arylation with Aryl Bromides  
With the optimized catalytic system in hand, the substrate scope for the C–H arylation of (E)-2-
styrylpyridine (9a) with aryl bromides 2 was explored. To start with, different substitution patterns as 
well as valuable functional groups on the aryl bromide 2 were extensively tested (Table 3). 
Furthermore, a variation of substituents in para-position of the aryl bromide 2 led to overall good to 
excellent yields. However, no clear reactivity trend with respect to the electronic nature of the aryl 
bromide 2 (entries 1–8) could be disclosed. Notably, even challenging functional groups, such as 
esters, amines, as well as enolizable ketones, were well tolerated under the optimal reaction 
conditions. Furthermore, substituents in meta- and ortho-positions (entries 9 and 10) were well 
accepted and afforded the desired arylated products 10 in good yields under slightly altered reaction 
conditions for the ortho-substituted aryl bromide 2j. Nevertheless, a significant limitation was 
observed by using the sterically very congested aryl bromide 2k (entry 11).
[125]
 The electron-rich 
heteroarene 3-bromothiophene (2l) afforded the corresponding product 10l in very good yield 
(entry 12), together with detectable amounts of the diastereomer (Z/E = 96:4), which might be 
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Table 3. Scope of the ruthenium(II)-PA-catalyzed C–H arylation with aryl bromides 2. 
 
 






































































[a] Reaction conditions: 9a (0.50 mmol), 2 (0.75 mmol), [Ru] (5.0 mol %), K2CO3 (1.00 mmol), PhMe (2.0 mL, 
0.25 M), 120 °C, 18 h, isolated yields. [b] At 140 °C, PhMe (1.00 M). [c] Z/E = 96:4, determined by means of 
1
H-
NMR spectroscopy.  
 
Having revealed the broad applicability of the reaction with respect to electronic and steric parameters 
of the aryl bromide 2, the substitution pattern of (E)-2-styrylpyridine (9a) was tested next (Table 4). 
Herein, a slight preference for electron-rich substrates with methyl- (9b) and methoxy-substituents 
(9c) (entries 1–5) as compared to the electron-poor trifluoromethyl-substituted (E)-2-styrylpyridine 
(9d) (entries 6–8) was observed, albeit the overall high reactivity of the catalytic system might have 
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product  10 yield / %
[a]
 
1 Me OMe 
 
10bb 90 
2 Me CF3 
 
10bf 85 
3 Me CO2Et 
 
10bg 87 





5 OMe CF3 
 
10cf 84 
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6 CF3 OMe 
 
10db 90 
7 CF3 CF3 
 
10df 77 
8 CF3 C(O)Me 
 
10dh 78 
[a] Reaction conditions: 9 (0.50 mmol), 2 (0.75 mmol), [Ru] (5.0 mol %), K2CO3 (1.00 mmol), PhMe (0.25 M), 
120 °C, 18 h, isolated yield. 
 
It is noteworthy that the sterically encumbered trisubstituted alkene 9e was successfully converted to 
the fully substituted acyclic alkene 10eb, displaying the first synthesis of tetrasubstituted acyclic 
alkenes by ruthenium-catalyzed C–H arylation (Scheme 49). Tetrasubstituted alkenes are important 
key motifs in inter alia pharmaceuticals and thus far considerable efforts have been made to devise 





Scheme 49. Ruthenium(II)-PA-catalyzed synthesis of the tetrasubstitued acyclic alkene 10eb. 
 
Given the overall excellent performance of the catalytic system, more challenging aryl chlorides 3 
with an inherently higher C–Cl dissociation energy
[37b]
 were probed as arylating reagents under 
otherwise identical reaction conditions (Table 5). In summary, all the tested aryl chlorides 3 were 
efficiently converted into the desired products 10 in good to excellent yields, demonstrating that 
ruthenium(II)-PA complexes are very competent arylating catalysts, disregarding the C–X bond 
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strength. In this context, it should be emphasized that S. Warratz succeeded in using aryl tosylates as 




Table 5. Scope of the ruthenium(II)-PA-catalyzed C–H arylation with aryl chlorides 3. 
 
 























[a] Reaction conditions: 9a (0.50 mmol), 3 (0.75 mmol), [Ru] (5.0 mol %), K2CO3 (1.00 mmol), PhMe (0.25 M), 
120 °C, 18 h, isolated yield. 
 
The overall reactivity of the optimized catalytic system seemed to be only moderately affected by the 
electronic nature of both reagents. In summary, the substitution pattern of the (E)-2-styrylpyridines 9 
had a slight impact on the reactivity, whereas the electronics of the organic electrophile exerted only a 
minor influence. Only the steric effects of the aryl bromide 2 had a major influence on the reactivity, 
with a significant drop in reactivity for di-ortho-substituted aryl bromides 2 (cf. Table 3, entry 11). 
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3.1.3 Mechanistic Studies 
3.1.3.1 Experiments with Radical Scavengers 
A key step in the mechanism of C–H arylation reactions involves the activation and cleavage of C–Hal 
bonds. So far, the mechanism of this process has remained elusive and underexplored, as it has been 
unclear whether a single electron transfer (SET)-type process is operative. In this context, there are a 







 proceeding via SET-type activation of the C–Hal bond. 
To delineate the C–Hal bond activation pathway, a set of well-established radical scavengers in 
stoichiometric amounts was added to the catalytic system (Table 6). In all cases, the catalytic reaction 
was significantly inhibited, which might suggest that a SET-type C–Br cleavage process occurred. 
Interestingly, a similar observation for ruthenium(II)-catalyzed C–H arylations was recently reported 
by Ackermann and coworkers
[131]
 Nevertheless, no radical adduct of the scavenger and any reaction 
intermediate could be detected by means of GC- and 
1
H-NMR- analysis. To shed light on this 
interesting mechanistic pathway, further studies should include for instance spin trapping experiments, 








Entry radical scavenger conversion 
1 TEMPO 2 % 
2 Ph2C=CH2 --- 
3 BHT --- 
4 Galvinoxyl --- 
5 DPPH --- 
[a] Reaction conditions: 9a (0.50 mmol), 2b (0.75 mmol), [Ru] (5.0 mol %), K2CO3 (1.00 mmol), scavenger 
(0.50 mmol), PhMe (2.0 mL, 0.25 M), 120 °C, 18 h. Conversions were determined by GC with n-dodecane as the 
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3.1.3.2 Hammett Plot Analysis 
Besides the exact working mode of the C–Hal bond activation, a particularly interesting question in 
ruthenium(II)-catalyzed C–H arylations encompasses the nature of the turnover-limiting step in the 
catalytic cycle. So far, there has been limited evidence for the oxidative addition to be turnover-
limiting, albeit detailed kinetic studies have not been presented.
[42]
 In this regard, a Hammett plot 
analysis
[133]
 is a suitable analysis tool, which relies on a logarithmic relationship between the reaction 
rate k and a specific substitution parameter 𝜎 of the reacting substrate as well as a reaction parameter 𝜌 
(Equation 1).  
 
                                                                           log 𝑘 =  𝜎 × 𝜌                               (Equation 1) 
Notably, a Hammett plot analysis is particularly interesting for C–H arylations with para-substituents 
on aryl halides because of the overall minor steric effects and the availability of known values for 
commonly used arylating substrates.
[134]
 Based on the initial reaction rates kX, employing differently 
para-substituted aryl bromides 2 and the known σp-values, the resulting Hammett plots could indicate 
whether electronic effects of the aryl halide have a considerable impact on the overall reaction rate. 
Depending on the sign of the slope, it can furthermore elucidate whether oxidative addition or 
reductive elimination are turnover-limiting.
[135]
 
Thus, a Hammett plot analysis of the C–H arylation on (E)-2-styrylpyridines 9 with differently para-
substituted aryl bromides 2 was performed by comparing initial rates and correlating them with 
literature known σp-values (Scheme 50, Figure 3 and Figure 4). 
 
Scheme 50. Hammett plot analysis of differently para-substituted aryl bromides 2. 
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0,0  = –0.18  0.01



















Figure 3. Hammett plot of the ruthenium(II)-PA-catalyzed arylation of (E)-2-styrylpyridine (9a). 
 
 
Figure 4. Initial rates using different aryl bromides 2. 
 
Remarkably, the obtained Hammett plot exhibited an unusual V-shape with slopes of ρ = 0.42 ± 0.06 
and ρ = −0.18 ± 0.01. Likewise, a similar behaviour has been disclosed by Chatani and coworkers for 
a ruthenium(II)-catalyzed arylation with a bidentate directing group.
[135b]
  
This unusual finding can be interpreted by a change in the turnover-limiting step from oxidative 
addition in the regime of electron-donating substituents to reductive elimination with electron-
deficient aryl bromides 2. Nevertheless, the observed ρ-value within the electron-deficient substitution 
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regime is not significantly high enough for drawing a reliable conclusion and the absolute reaction 
rates for electron-deficient aryl bromides 2 were still found to be comparably high. Overall, it can be 
concluded that rather oxidative addition is the turnover-limiting step, while for highly electron-
deficient aryl bromides 2 the reductive elimination becomes energetically less feasible. 
 
3.1.3.3 KIE Studies 
Based on the results of the Hammett plot analysis, further mechanistic evidence for a turnover-limiting 
oxidative addition were indeed necessary. For this purpose, a study of the kinetic isotope effect (KIE) 




Scheme 51. KIE of the ruthenium(II)-PA-catalyzed arylation. 
 
In this regard, a comparison of the independent reaction rates
[136]
 with 9a and the isotopically labeled 
[D]1-9a was conducted by an in situ ReactIR
 
analysis (Scheme 51, Figure 5 and Figure 6). For this 
purpose, the initial rates were followed by integration of a characteristic IR-band of the products 10ab 
and [D]n-10ab at 1520 cm
−1 




Figure 5. Kinetic profile of the C–H arylation followed by in situ-IR analysis.  
 
This observation reveals that the C–H cleavage is a kinetically relevant elementary step, either being 
the turnover-limiting step itself or happening before turnover-limiting step as an equilibrium reaction. 
The latter assumption is in agreement with studies of S. Warratz who detected a significant H/D-
exchange in the ortho-positions of 2-phenyloxazoline 7a in a ruthenium(II)-PA catalyzed C–H 
arylation, which indicates a reversible C−H activation to be operative.
[123]
 Therefore, the observed KIE 
               1520 cm
–1 
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value can be interpreted in terms of a reversible, but kinetically relevant C–H activation before the 
turnover-limiting formal oxidative addition.  
 
Figure 6. KIE of the ruthenium(II)-PA-catalyzed C–H arylation of 9a by ReactIR analysis.  
 
3.1.3.4 Kinetic Reaction Order 
3.1.3.4.1 Reaction Order with respect to the concentration of (E)-2-styrylpyridine (9a) 
Generally, an analysis of the kinetic reaction order in dependence on the concentration of each reactant 




Thus, the overall reaction rate showed a first order dependence (n = 0.87 ± 0.02) on the concentration 
of (E)-2-styrylpyridine (9a), which is a hint for the C–H activation elementary step to be kinetically 
relevant (Figure 7).  
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Figure 7. Reaction order n in [(E)-2-styrylpyridine] (9a). 
 
3.1.3.4.2 Reaction Order with respect to the concentration of 4-bromoanisole (2b) 
The kinetic order with respect to the concentration of the arylating reagent 4-bromoanisole (2b) 
exhibited saturation kinetics (Figure 8). 





































Figure 8. Reaction order n in [4-bromoanisole] (2b). 
 
This observation is indicative of the oxidative addition to be the turnover-limiting step of the catalytic 
cycle. For the studied reaction, a simplified reaction is depicted in Scheme 52. Assuming that the 
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concentration of ruthenacycle 127 follows steady-state kinetics (Equation 2) and the subsequent steps 
after oxidative addition are fast and neglectable for the reaction rate, the overall rate law for the 




                                                    𝑑[𝟏𝟐𝟕]
𝑑𝑡
=  𝑘1[𝟗𝐚][𝟏𝟐𝟔] − 𝑘−1[𝟏𝟐𝟕] − 𝑘2[𝟏𝟐𝟕][𝟐𝐛] = 0     (Equation 2) 
                                                 
𝑑[𝟏𝟎𝐚𝐛]
𝑑𝑡
=  𝑘1[𝟐𝐛][𝟏𝟐𝟕]           (Equation 3) 






      (Equation 4) 
If there is a very high concentration of 4-bromoanisole (2b), the term k2[2b] could become larger than 
k−1 and consequently the overall reaction rate becomes independent on the concentration of the 4-
bromoanisole (2b). That could be reasonable explanation for the observed saturation kinetics. 
 
 
Scheme 52. Simplified kinetic scheme of the ruthenium(II)-PA-catalyzed C–H arylation. 
 
3.1.3.4.3 Reaction Order with respect to the concentration of complex 124e 
Further kinetic investigations established a first order dependence on the concentration of the single-
component ruthenium(II)-PA complex 124e (Figure 9), which reveals the presence of a mononuclear 
ruthenium-complex within the turnover-limiting step of the catalytic cycle. 
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log (n (124e) / mol %)
 
Figure 9. Reaction order in [124e]. 
 
3.1.4 Proposed Catalytic Cycle 
In summary, it can be concluded that the C–H activation is a reversible, but kinetically relevant 
elementary step (Scheme 53). Presumably, the C–H activation proceeds by metal-ligand-cooperation, 
in which the in situ formed phosphinite acts as an internal base for the deprotonation step. Likewise, a 
Hammett plot analysis, KIE studies as well as kinetic order experiments supported the oxidative 
addition to be the turnover-limiting step. However, for electron-deficient aryl bromides 2 a slight trend 
to a slower reductive elimination step was observed. Additionally, computational studies involving 
DFT-calculations, performed by S. J. Garden, confirmed that the PA-ligand assisted the deprotonation 
during a metal-ligand-cooperative C–H activation step (transition state 127).
[123]
  
Thereafter, a SET-type oxidative addition of the aryl bromide 2 to the cyclometalated complex 128 
occurs and furnishes the ruthenium(IV) complex 129. After reductive elimination, the product 10a is 
released and the active ruthenium(II)-PA catalyst 126 is regenerated.  
However, the exact structures of some assumed intermediates have thus far remained unclear and 
some efforts should be made to investigate possible hapticity changes or even a decoordination of the 
p-cymene ligand in the course of the reaction. In this regard, a possible dissociation of the p-cymene 
ligand has already been proposed in related reactions.
[138]
 Additionally, Ackermann and coworkers 









Scheme 53. Proposed catalytic cycle of the ruthenium(II)-PA-catalyzed C–H arylation. 
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3.2 Cobalt(III)-Catalyzed C−H/C−C Functionalization  




 for C–H 
functionalization reaction has been intensively studied in the last few years. In this regard, not only the 
cost-efficiency of these metals is of prime importance, but also a systematic study of their unique 
reactivity profile is essential for making considerable advances in transition metal-catalysis.  
There are indeed aspects in C–H functionalizations like reactivity and stereoselectivity that can be 
controlled not only by the judicious choice of ligands, but also by the distinctive features of any metal. 









 on higher reactivities and distinct chemoselectivities for cobalt(III) complexes as 
compared to the corresponding rhodium(III) C–H activation catalysis.  
Despite these intriguing advances, there is still demand for the exploration of distinct selectivity 
features in cobalt(III) catalysis. Therefore, the control of diastereoselectivity in C–H/C–C 
activations
[117a, 117c, 117d]
 with vinylcyclopropanes 125 represents a promising objective. 
 
3.2.1 Optimization Studies 
The optimization studies were commenced by probing the effect of various acetate- and pivalate bases 
with different alkali metal counter cations (Table 7). Lithium, sodium and potassium acetate as 
additives delivered the desired product 130aa in satisfactory yields, whereas cesium acetate was by far 
the least effective additive (entries 1–4). The same trend was observed for pivalate bases, with sodium 
pivalate being the optimal base for this transformation (entry 6). In contrast, potassium- and cesium 
pivalate led to a significant drop in reactivity (entries 7 and 8).  
Furthermore, no reaction was observed by omitting the cobalt(III) catalyst, which is a clear hint for 
cobalt catalysis to be operative in this reaction (entry 9). In addition, the silver additive AgSbF6 was 
found to be essential for catalytic activity (entry 10). Based on previous results in C–H activation by 
cobalt(III) catalysis, no further optimization of the silver additive was performed.
[15a]
 A reaction 
without base additive led to only moderate yield and 10% of a double bond regioisomer was detected, 
in which the double bond was shifted into conjugation with the indole nucleus (entry 11). In contrast, 
efficient conversion can only be accomplished in the presence of a base additive, which is a hint for a 
BIES-type C–H activation pathway. 
Notably, all tested reaction conditions exclusively furnished the thermodynamically less favored Z-





 Furthermore, Q. Bu tested different cobalt(III) sources, indicating that 
silver is not necessary for the reaction (entry 15) and other ligands are inferior to the electron-rich Cp* 
(entries 16 and 17). In this context, she detected a slight decrease in E/Z-ratio to 8:1, which could be 
interesting for future developments of ligand-controlled diastereoselective C–H/C–C 
functionalizations. 
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Remarkably, the catalytic performance was only moderately affected by decreasing the reaction 
temperature to 25 °C (entry 18). 




[a] Reaction conditions: 105a (0.50 mmol), 125a (0.60 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), additive 
(20 mol %), DCE (1.0 mL), 20 h, isolated yield. py = pyridyl, E = CO2Me; all E/Z = 1:11. [b] Additive (10 mol %). [c] 
Without [Co]. [d] Without AgSbF6. [e] Double bond regioisomer (10%) observed. [f] [Cp*Co(CH3CN)3](SbF6)2 (10 mol %). 





Entry additive yield / %
[a] 
1 LiOAc 74 
2 NaOAc 88 
3 KOAc 76 
4 CsOAc 11 
5 LiOPiv 61 
6 NaOPiv 93 
7 KOPiv 51 











12 NaO2C(3-CF3)C6H4 68 
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3.2.2 Scope of the Cobalt(III)-Catalyzed C–H/C–C Functionalization 
Under the optimized reaction conditions for the cobalt(III)-catalyzed C–H/C–C functionalization, an 
extensive substrate scope was probed (Table 8). At first, various substituents in C5-position of the 
indole were tested, such as methoxy, bromo, iodo, and nitro groups (entries 2–5). Notably, all 
functional groups were fully tolerated, delivering the desired Z-configurated product in very good 
yields ranging from 88% to 92% and good diastereoselectivities.  
Furthermore, sterically demanding substituents in C3-position were employed, furnishing the desired 
products 100fa and 100ga still in good to excellent yield (entries 6 and 7), with a minor drop in 
diastereoselectivity for product 100fa, probably due to steric effects. The substituent in C3-position of 
105g can flexibly rotate and is sterically less demanding than the methyl-substituted analogue. 
Substituents in C4- and C6-position (entries 8 and 9) were well tolerated, affording the corresponding 
products 105ha and 105ia in excellent yields. For the C7-substituted product 105ja (entry 10) the 
diastereoselectivities were somewhat reduced, presumably due to steric interactions, which is in good 
agreement with the observation for the C3-methyl-substituted product 130fa (entry 6). The pyridyl-
directing group of the products 130 was shown to be removable (cf. chapter 5.3.2). However, a 
chemoselective method, that tolerated the alkene functionality, has not been disclosed so far. 
Finally, a sterically more congested substitution pattern on the pyridyl-directing group did not 
influence the reactivity, with overall very good yields of 130ka and 130la (entries 11 and 12). Only 
the diastereoselectivity profited somewhat from the changed substitution on the pyridyl-ring, affording 
the product in excellent selectivities of Z/E = 14:1. A reasonable explanation for this unexpected 
finding could be the involvement of stabilizing London dispersion interactions,
[124, 142]
 partly exhibited 
by the pyridyl-ring, which was highlighted by DFT-calculations of M. Feldt.
[143]
  



















130ba 13:1 92 











































130ja 8:1 68 










130la 14:1 92 
[a] Reaction conditions: 105 (0.50 mmol), 125a (0.60 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), NaOPiv 
(20 mol %), DCE (1.0 mL), 50 °C, 20 h, isolated yield. 
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Furthermore, the scope was extended to vinylcyclopropane 125b derived from meldrums acid
[144]
 
(Table 9). Herein, a remarkable switch in diastereoselectivity to the E-configurated products was 
found. In all cases, the main isomer was the E-configurated product, but the selectivities were overall 
poor. By comparison with the analogous rhodium(III)-catalyzed reaction, the same reactivity and 
similar selectivity were obtained, with an even higher E/Z-ratio (entry 1).  
The reason for this unexpected switch in diastereocontrol is not yet fully elucidated and there is need 
for detailed computational studies dealing with this kind of substrate-controlled stereoselectivity. In 
this respect, a detailed understanding of this observation would possibly give rise to the development 
of a switchable control in diastereoselectivity of C–H/C–C bond activations by the substitution pattern 
on the vinylcyclopropane 125. 
 



























[a] Reaction conditions: 105 (0.50 mmol), 125b (0.60 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), NaOPiv       
(20 mol %), DCE (1.0 mL), 50 °C, 20 h, isolated yield. [b] With [Cp*Rh(CH3CN)3](SbF6)2 (10 mol %) product 130ab (83%, 
Z/E = 1:5.9) was obtained. 
 
Besides the applicability of this reaction to the functionalization of 2-pyridylindoles 105, also the 
inherently less electron-rich heterocycles were tested (Table 10). Thus, also 2-phenylpyridines 1 were 
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successfully converted with comparable efficiency, but somewhat decreased diastereoselectivities 
(entries 1 and 2). In contrast, rhodium(III) catalysis furnished the E-configurated product 132ba' in 
lower yield, poor selectivity of E/Z = 2:1 and a significant amount of the di-functionalized product 
132ba'' was observed (entry 3). These findings emphasize the unique diastereo- and site-selectivities 
of the cobalt(III)-catalyzed C–H/C–C activation.  
In this respect, a reasonable explanation for the mono-selectivity could be the overall shorter cobalt-
carbon bond lengths,
[117b]
 which presumably increase steric interactions in catalytic intermediates 
towards the mono-functionalized product 132ba. Furthermore, 1-(thiophen-2-yl)-1H-pyrazole (131) 
reacted with moderate yield, but excellent diastereoselectivity (entry 4). In this regard, Q. Bu could 
extend the heteroarene-scope to valuable examples of functionalized phenylpyrazoles 18 with 


































133 12:1 40 
[a] Reaction conditions: 1 or 131 (0.50 mmol), 125a (0.60 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), NaOPiv 
(20 mol %), DCE (1.0 mL), 20 h, isolated yields. [b] With [Cp*Rh(CH3CN)3](SbF6)2 (10 mol %) di-substituted 132ba''  
(12%, Z/E = 1:3) was obtained. 
 
Additionally, some limititations in the scope were disclosed (Scheme 54). Benzamides 68, oximes 48 
as well as oxazolines 7 unfortunately delivered no or only traces of the desired products under 
otherwise identical reaction condition. Moreover, the use of weaker directing groups like tetrazoles 31 
and the functionalization via a six-membered cobaltacycle with substrate 136a turned out to be 
unfavorable. However, it cannot be excluded that extensive optimization studies on a certain substrate 
might lead to the desired transformation. 
 
 
Scheme 54. Limitations of the cobalt(III)-catalyzed C–H/C–C functionalization. 
 
Subsequently, it was explored whether the developed catalytic reaction could proceed under even 
milder conditions, at an ambient temperature of 25 °C (Table 11). In this manner, a minor decrease in 
reactivity was observed, with yields being around 10% less than under the optimized reaction 
conditions, except for the unsubstituted substrate 105a (entry 1). Overall, the observed 
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130ha 10:1 75 
[a] Reaction conditions: 105 (0.50 mmol), 125a (0.60 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), NaOPiv 
(20 mol %), DCE (1.0 mL), 25 °C, 20 h, isolated yield. 
 
3.2.3 Mechanistic Studies 
3.2.3.1 H/D-Exchange Experiment 
To rationalize the C–H activation mechanism, a catalytic reaction in the presence of deuterated co-
solvent CD3OD was carried out under otherwise unchanged reaction conditions. In the reisolated 
starting material 105a as well as in the product 130aa a significant H/D-scrambling was observed 
(Scheme 55). In the case of the reisolated starting material 105a, a deuterium incorporation of 41% in 
C2-position is indicative of a reversible C–H activation step.  
Furthermore, in the starting material 105a and the product 130aa significant amounts of H/D-
exchange in C7- as well as in C3-position of the indole were detected. Deuterium incorporation in C7-
position can be explained by the formation of a six-membered cobaltacycle, which has been reported 
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functionalizations. Nevertheless, the corresponding C7-substituted product could not be detected, 
which might be due to the unfavored formation of an expected eight-membered intermediate after 
migratory insertion of the alkene. The H/D-scrambling in C3-position can be explained by a reversible 
electrophilic activation and following deutero-demetalation. 
 
Scheme 55. H/D-exchange study of the cobalt(III)-catalyzed C–H/C–C functionalization. E = CO2Me. 
 
3.2.3.1.1 H/D-exchange in the Absence of Cobalt(III) Catalyst 
Based on the observed deuterium incorporation in C3-position of the indole nucleus, a reaction in the 
presence of deuterated co-solvent CD3OD without the cobalt(III) catalyst and vinylcyclopropane 125a 
was performed. Herein, no detectable H/D-scrambling in any position of the recovered indole 105a 
(Scheme 56) was observed. These findings emphasize that the C–H activation occurs solely via an 
organometallic cobalt(III) catalysis, and the previously described H/D-scrambling C7-position (vide 
supra) is a result of cobalt(III)-catalyzed C–H activation via a six-membered cobaltacycle. 
 
Scheme 56. H/D-exchange study in the absence of the cobalt(III) catalyst. 
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3.2.3.2 Kinetic Isotope Effect 
To gain a deeper mechanistic understanding of the C–H activation elementary step, a KIE-experiment 
by comparison of independent reaction rates of 2-pyridylindole (105a) and [D]1-105a was performed 
(Scheme 57). In this reaction, a KIE of kH/kD = 1.3 was obtained, which suggests a facile and not 
turnover-limiting C−H activation to be operative.  
 
 
Scheme 57. KIE experiment for the cobalt(III)-catalyzed C–H/C–C functionalization. 
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Figure 10. KIE-experiment for the cobalt(III)-catalyzed C–H/C–C functionalization. 
 
3.2.4 Proposed Catalytic Cycle 
Based on these mechanistic findings, a catalytic cycle was proposed (Scheme 58). The active catalytic 
species 138 might be a cationic cobalt(III)-pivalate complex formed by reaction between the 
cobalt(III) precursor and silver hexafluoroantimonate.
[91]
 In this respect, hexafluoroantimonate is a 
non-nucleophilic and weakly-coordinating anion
[148]
 and it is proposed to energetically stabilize the 
catalytically active species as well as the following cationic reaction intermediates.
 
The first step 
comprises a facile and reversible C–H cobaltation that is assisted by the pivalate additive and 
presumably proceeds via a BIES-type mechanistic pathway to furnish the cobaltacycle 139 (cf. Table 
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7). For the following steps, extensive computational studies by DFT calculations were performed by 
M. Feldt.
[117b] 
Accordingly, a coordination of the vinylcyclopropane 125a leads to intermediate 140, in 
which a migratory insertion of the coordinated vinylcyclopropane 125a into the carbon-cobalt bond 
occurs. An oxygen-coordination of the ester group to the cobalt center is suggested to energetically 
stabilize the following intermediate 141. Thereafter, a diastereoselectivity-determining C–C cleavage 
process leads to the favored Z-configurated intermediate 142.  
By applying the energetic span model
[149]
 to the  energetic profile, the activation barrier difference for 
this selectivity-determining C–C cleavage process amounts to 6.5 kcal/mol in favor of the Z-
configurated transition state. The origin of this diastereocontrol presumably lies in attractive London 
dispersion interactions that are more pronounced for the compact Z-configurated transition state.
[143]
 
Along the same line, the diastereodivergence between cobalt(III) and rhodium(III) catalysis is 
proposed to be an effect of dispersion interactions due to the smaller carbon-cobalt bonds. The reduced 
bond lengths in cobalt(III) intermediates of this reaction lead to larger dispersion contributions, which 
are strongly dependent on the interaction distance r by proportionality to r
–6
. Finally, a proto-
demetalation step by the in situ formed pivalic acid regenerates the active catalyst and releases the 
product 130aa. Notably, Q. Bu did not observe any post catalytic-isomerization of the double bond, 
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3.3 Regioselective Cobalt(III)-Catalyzed C−H Alkylations 
Transition metal-catalyzed C–H alkylations by alkene hydroarylation reactions represent a versatile 
and powerful strategy to achieve highly atom-economical alkylations.
[110c, 150]
 However, in these 
reactions there is an inherent requirement for Markovnikov/anti-Markovnikov selectivity control, 
which has so far been mainly restricted to electronically activated alkenes and the use of complex 
ligands.
[113-114, 151]
 Yoshikai and coworkers have indeed demonstrated a switchable regiocontrol in low 
valent cobalt-catalyzed C–H hydroarylations, but stoichiometric amounts of Grignard reagents were 
required, which translated into a considerable limitation regarding the substrate scope.
[114]
  
Consequently, a new and sustainable concept to achieve regiocontrol in cobalt(III) catalysis is 
indispensable. The new catalytic system must obviate the use of Grignard reagents, laborious ligand 
design and should ideally be applicable to hydroarylations with unactivated alkenes. In this regard, a 
full control of linear/branched selectivity is of prime importance.  
 
3.3.1 Optimization Studies for the Linear-Selective C–H Alkylation 
The optimization studies for the cobalt(III)-catalyzed anti-Markovnikov-selective C–H alkylation were 
commenced by testing the effect of a few selected acetate and pivalate additives (Table 12, 
entries 1−5). Among a series of alkali metal cations, especially lithium and sodium performed well, 
while the cesium analogue delivered the desired linear product 144aa in only unsatisfactory yield or 
trace amount (entries 3 and 5). Remarkably, acetate bases displayed a slightly higher selectivity up to 
an excellent ratio of AM:M = 99:1. Thereafter, the effect of different reaction temperatures on the 
regioselectivity was studied by using pivalic acid as the additive. Interestingly, the selectivity dropped 
with decreasing temperature in favor of the Markovnikov-product 145aa (entries 6–8). Moreover, the 
use of sterically much more congested 1-adamantanecarboxylic acid as additive (entries 9–11) led to a 
further drop in linear selectivity. Notably, by increasing the acid loading up to one equivalent, an 
intriguing inversion of selectivity (entry 11) towards the branched product 145aa was observed.  
In summary, lower temperatures and carboxylic acids as additives tend to favor the formation of the 
branched product, although the temperature-dependence is much less pronounced.  
To achieve an excellent linear selectivity of AM:M > 99:1, the temperature was kept at 120 °C and no 
additive was utilized (entry 14). Noteworthily, no reactivity was observed by omitting the essential 
AgSbF6 or the catalyst (entries 12 and 13). Silver was found to play no role in the catalytic reaction, 
because silver-free conditions with [Cp*Co(CH3CN)3](SbF6)2 as the catalyst still furnished the desired 
product 144aa in satisfactory yield (entry 15). Additionally, cobalt(III) complexes with differently 
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1 LiOAc 120 99:1 82 
2 NaOAc 120 98:2 77 
3 CsOAc 120 98:2 15 
4 NaOPiv 120 88:12 46 
5 CsOPiv 120 --- traces 
6 PivOH 120 93:7 80 
7 PivOH 100 85:15 67 
8 PivOH 60 52:48 56 
9 1-AdCO2H 120 88:12 82 
10 1-AdCO2H (40 mol %) 120 46:54 74 
11 1-AdCO2H (100 mol %) 120 37:63 81 
12
 





--- 120 --- ---
[c]
 
14 --- 120 >99:1 82 
15 --- 100 >99:1 75 
16
 














Reaction conditions: 105a (0.50 mmol), 143a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), 















3.3.2 Optimization Studies for the Branched-Selective C–H Alkylation 
With the results from the previous optimization study in hand (vide supra), it was initially tested 
whether the formation of the Markovnikov-selective product 145aa is mainly controlled by reaction 
temperature. However, still the linear product 144aa (Table 13, entry 1) was formed in the absence of 
additives although the reaction temperature was decreased to as low as 50 °C. Furthermore, the steric 
effect of the additives was investigated by comparing a set of carboxylates (entries 2–6). Therein, it 
could be pointed out that the sterically encumbered 1-adamantylcarboxylate delivered the branched 
product 145aa in moderate yield, but very good regioselectivity (entries 3 and 6). Moreover, a series 
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of carboxylic acids (entries 7–12) was studied, similarly leading to very good selectivities and 
moderate yields. The use of bulky pivalic and 1-adamantanecarboxylic acid (entries 8 and 12) 
furnished the Markovnikov-selective product 145aa in good yields. Notably, an increase of the 1-
adamantanecarboxylic acids concentration furthermore improved the selectivity up to an excellent 
ratio of M:AM = 95:5 (entries 14–16). Interestingly, carboxylic acids delivered the branched product 
145aa with comparable selectivities, whereas a clear trend in steric effects along a series of 
carboxylates was observed (vide supra). These observations might indicate that the branched-selective 
mechanistic pathway is generally preferred by using acid additives. As it had previously been 
observed (vide supra), no product was formed in the absence of AgSbF6 or the catalyst (entries 17 and 
18). Noteworthily, under silver-free conditions and [Cp*Co(CH3CN)3](SbF6)2 as the catalyst 
(entry 19), the product 145aa was still afforded in good yields, but the selectivity decreased slightly to 
M:AM = 75:25. In this regard, it can be assumed that the acetonitrile ligands of 
[Cp*Co(CH3CN)3](SbF6)2 reduce the selectivity by hampering the reaction between the catalyst or a 
catalytic intermediate and the acid additive. As observed before (Table 12), cobalt(III) complexes with 
differently substituted Cp-ligands performed poorly (entries 20 and 21).  
 




Entry additive T / °C 144aa:145aa
[a]
 yield / %
[a] 
1 --- 50 >99:1 9 
2 LiOAc 50 27:73 6 
3 LiO2C-(1-Ad) 50 8:92 48 
4 NaOAc 50 35:65 11 
5 NaOPiv 50 22:78 44 
6
 
NaO2C-(1-Ad) 50 12:88 50 
7
 
AcOH 50 14:86 43 
8 PivOH 50 17:83 68 
9 CyCO2H 50 14:86 58 
10 C6H5CO2H 50 14:86 57 
11
 
CF3CO2H 50 --- --- 
12 1-AdCO2H  50 13:87 68 
13 1-AdCO2H 60 20:80 71 
14 1-AdCO2H (40 mol %) 50 10:90 79 
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15 1-AdCO2H (100 mol %) 50 5:95 80
 
16 1-AdCO2H (100 mol %) 40 >1:99 48 
17
[b] 
--- 50 --- --- 
18
[c]
 1-AdCO2H 50 --- --- 
19
[d] 
1-AdCO2H 50 25:75 65 
20
[e] 
1-AdCO2H 50 --- traces 
21
[f] 
1-AdCO2H 50 --- traces 
[a] 
Reaction conditions: 105a (0.50 mmol), 143a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), 















3.3.3 Scope of the Linear-Selective C–H Alkylation  
Under the optimized conditions for the linear-selective C–H alkylation, the effect of various 2-
pyridylindoles 105 was probed (Table 14). Among a series of substituents in C5-position of the indole 
nucleus, halogens were well tolerated and delivered the corresponding products in good yields 
(entries 3–5). Even in the presence of a very challenging and redox-active nitro-substituent, a 
moderate yield of 144ea was achieved (entry 6), although substrate 105e displayed a low solubility in 
DCE. It is noteworthy that methyl- and ester-substituents in C3-position performed with similar 
reactivities (entries 7 and 8). Substitution in the C4-position (entries 9 and 10) furnished the desired 
products 144ha and 144oa in good yields. Nonetheless, a slight drop in yield was observed for indole 
105j bearing an ethyl-substituent in the C7-position, which is possibly due to steric effects (entry 11). 
Remarkably, the pyridyl-directing group was shown to be removable and the corresponding free 
indoles were obtained in excellent yields (cf. chapter 5.4.2). 
With respect to limitations of the substrate scope, 1-(thiophen-2-yl)-1H-pyrazole (131) was not 
converted under otherwise unchanged reaction conditions (entry 12). In this regard, V. Müller showed 
that substrate 131 only reacted by addition of pivalic acid at 140 °C, delivering the corresponding 
product in good yield and selectivity of AM:M = 55:45.
[152]
 
In addition, 2-pyridyl-1H-pyrrole (146) delivered the desired product 147 with an excellent selectivity 
of AM:M > 99:1, but only unsatisfactory yields were obtained and significant amounts of di-
functionalized product 147' were formed (entry 13). In summary, all products were afforded with an 
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[a] Reaction conditions: 105 (0.50 mmol), 143a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), 




45% of di-substituted product 147' (AM:M > 99:1) was isolated.   
 
Furthermore, alkenes 143 with selected functional groups were examined under the linear-selective 
reaction regime (Table 15). Initially, allyl benzene (143b) reacted with excellent regioselectivities and 
no by-products from isomerization of the double bond were observed. Likewise, alkenes with different 
chain lengths performed well (entries 2–4), with somewhat higher yields for longer alkyl chains, 
which might be attributed to lower boiling points. The boiling point of 1-hexene (143e) at ambient 
pressure is 63 °C,
[153]
 presumably leading to evaporation under elevated reaction temperatures. 
Notably, ester- (143f) and challenging hydroxyl-groups (143g) on the alkene were well tolerated 
(entries 5 and 6). The good performance of 1,7-octadiene (143h) demonstrated that double bonds did 
not isomerize during the reaction. In addition, only selective monofunctionalization occurred (entry 7), 
albeit the overall yield was somewhat diminished. In this regard, the polymerization of 1,7-octadiene 
(143h) as a potential side reaction should be considered. Furthermore, internal alkenes, such as 
cis/trans-2-octene (143i), did not react under otherwise unchanged reaction conditions (entry 8).  
 




Entry alkene  143 product  144 yield / %
[a]
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2  143c 
 
144ac 79 





















8  143i 
---  --- 
[a] Reaction conditions: 105a (0.50 mmol), 143 (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), 
DCE (1.0 mL, 0.5 M), 120 °C, 20 h, isolated yield; all AM:M > 99:1, determined by 
1
H-NMR spectroscopy.  
 
3.3.4 Scope of the Branched-Selective C–H Alkylation  
The substrate scope under the Markovnikov-selective reaction regime was initially explored by 
probing various substituents in C5-position, such as methoxy and halogens (Table 16, entries 2–5). 
Fortunately, all reactions performed with good yields and selectivities in the range of M:AM = 95:5.  
However, a methyl-substituent in C3-position of the indole nucleus obviously disfavored the 
formation of the branched product 145fa likely due to repulsive steric effects. Thus, the undesired 
anti-Markovnikov product 144fa was afforded (entry 7). In contrast, substituents in C4- or C7-position 
again resulted in overall satisfactory yields and very good selectivities (entries 8 and 9). Remarkably, 
1-(thiophen-2-yl)-1H-pyrazole (131) was successfully C–H alkylated in acceptable selectivity and 
very good yield at 80 °C (entry 10). Unfortunately, 2-pyridyl-1H-pyrrole (146) delivered mainly the 
linear-selective product 149 in lower yield (entry 11). 
In summary, only substitution in C3-position affected the branched/linear-selectivity, while different 
functional groups had no observable impact on the selectivity. The overall reactivity was obviously 
not controlled by electronic parameters of the indole substrate. Interestingly, the pyridyl-directing 
group was shown to be removable in an excellent yield (cf. chapter 5.4.2). 
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[a] Reaction conditions: 105 (0.50 mmol), 143a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %) 
and 1-AdCO2H (0.50 mmol), DCE (0.5 mL, 1.0 M), 50 °C, 20 h, isolated yield; all AM:M ratios determined by 
1
H-NMR spectroscopy. [b] At 80 °C. 
 
Subsequently, a comprehensive study as to the scope of the alkene 143 was analogously performed 
under the branched-selective reaction conditions (Table 17). Herein, allylbenzene (143b) delivered the 
corresponding product 145ab with an outstanding selectivity of M:AM = 99:1 and a good yield of 
82% (entry 1). Thereafter, a variation of the alkyl chain showed no effect on the selectivity, and only a 
moderate decrease in yield with shorter chain lenght was found (entries 2–4). Remarkably, an ester-
group on the alkene 143f was well tolerated and the corresponding product 143af was afforded with an 
excellent selectivity of M:AM = 99:1 (entry 5). A challenging hydroxyl-group performed moderately 
(entry 6) with slightly lower yield of the corresponding product 145ag. As observed before, a selective 
mono-functionalization of 1,7-octadiene 143h was observed with a higher yield of 78% of the 
corresponding branched product 145ah than under linear-selective conditions (cf. Table 15, entry 7). 
This finding could be either explained by a reduced evaporation of 1,7-octadiene (143h) or the 
diminished polymerization tendency at the lower reaction temperatures. Furthermore, it was shown 
that internal alkenes, such as cis/trans-2-octene 143i, were not converted under otherwise unchanged 
reaction conditions (entry 8).  
 





entry alkene  143 product  145 M:AM yield / %
[a]
 




2  143c 
 
145ac 95:5 76 
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4  143e 
 














145ah 94:6 78 
8  143i ---  --- --- 
[a] Reaction conditions: 105a (0.50 mmol), 143 (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), 
1-AdCO2H (0.50 mmol), DCE (0.5 mL, 1.0 M), 50 °C, 20 h, isolated yield; all AM:M ratios determined by 
means of 
1
H-NMR spectroscopy.  
 
3.3.5 Enantioselective Cobalt(III)-Catalyzed C–H Hydroarylations 
Given the inherent possibility to induce enantioselectivity within the presented branched-selective 
cobalt(III)-catalyzed C–H hydroarylation, extensive optimization studies were performed by 
employing chiral carboxylic acids (Table 18). In this respect, the use of natural amino acids as chiral 
additives is particularly attractive because of their synthetic versatility
[154]
 and natural availability.
 





 have been reported, in which mono-protected amino acids have 
been utilized as beneficial additives. However, their role in these transformations has been mainly 
limited to the in situ formation of the corresponding bases for a CMD-type C–H activation pathway.  
In stark contrast, the utilization of their chirality to enable asymmetric C–H functionalizations is 
restricted to only a few examples.
[157]







 to synthesize costly, but efficient chiral Cp-ligands for asymmetric 
C–H functionalizations.  
In the herein described branched-selective C–H hydroarylation reaction, the acid additive is 
presumably not only involved in the BIES-type C–H activation, but also serves as a proton source for 
the product releasing proto-demetalation (vide infra: Scheme 70). If the step before the turnover-
limiting proto-demetalation, namely the migratory insertion of the alkene 143, is a reversible step, then 
potentially enantioselectivity might be induced by the amino acid (cf. Scheme 70). 
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To start with, the N-pthalimide protected L-isoleucine was tested (Table 18) at different concentrations 
and reaction temperatures, and indeed an intriguing ee of 23% (entries 1–3) was observed in product 
145aa. Subsequently, different N-pthalimide-protected amino acids were probed, with an optimal ee of 
25% for mono-protected L-leucine (entries 4–7).
[161]
 In summary, no clear trend in steric effects of the 
amino acid backbone was observed. It is noteworthy that different N-pivaloyl and -1-adamantoyl 
protected amino acids delivered the product as racemic mixture (entries 8–11). Additionally, N-acetyl, 
-ester and -t-butyloxycarbonyl (Boc) protecting groups furnished the products in only unsatisfactory 
enantioselectivities and partly very low branched/linear selectivities (entries 12–16). Moreover, two 
selected dipeptides were tested, with overall low enantioselectivities and conversions (entries 17 
and 18). Interestingly, the stronger Brønsted acid (R)-BINOL-phosphoric acid failed to provide the 
desired product.  
In summary, phthalimide was found to be the optimal protecting group. However, the exact reason for 
that observation has remained unclear. Notably, extensive optimization studies by V. Müller and F. 
Pesciaioli concerning different protecting groups, including a structural diversification of the 
phthalimide-protecting group as well as different amino acids, led thus far to a slight increase in 















1 Phth-Ile-OH 92:8 33 (67) 23 
2 Phth-Ile-OH 93:7 37 (69)
[b] 
23 
3 Phth-Ile-OH 98:2 (45)
[c] 
23 
4 Phth-Leu-OH 90:10 25 (41) 25 
5 Phth-Ala-OH 89:11 18 (35) 19 
6 Phth-Trp-OH 93:7 27 (48) 21 
7 Phth-Phe-OH 93:7 (67) 21 
8 1-Ad-Val-OH --- (5) --- 
9 1-Ad-t-Leu-OH 85:15 25
[b]
 1 
10 Piv-Ile-OH 80:20 (37) --- 
11 Piv-Asp-OH 45:55 18
[b]
 --- 
12 Ac-Ile-OH 80:20 (33)
[b]
 18 
76  Results and Discussion 
 
 
13 CO2Me-Ile-OH 96:4 (81) 7 
14 Boc-Ile-OH 95:5 (35) 10 
15 Boc-Tyr-OH --- ---
[b]
 --- 
16 Boc2-Val-OH 90:10 31
[b]
 12 
17 Boc-Val-Gly-OH 80:20 (25)
[b]
 3 
18 Boc-Trp-Gly-OH 99:1 (4)
[b]
 2 
19 (R)-BINOL-phosphoric acid --- --- --- 
[a] 
Reaction conditions: 105a (0.50 mmol), 143a (1.50 mmol), [Cp*Co(CO)I2] (10 mol %), AgSbF6 (20 mol %), 
additive (20 mol %), DCE (0.5 mL, 1.0 M), 50 °C, 20 h, isolated yield. For all entries, L-amino acids were used. 
Branched/linear selectivities and conversions were determined by GC-analysis with n-dodecane as the internal 
standard. Enantioselectivities were determined by means of analytical HPLC. [b] Additive (1.00 equiv), DCE 
(1.0 M). [c] At 40 °C. 
 
3.3.6 Mechanistic Studies 
3.3.6.1 H/D-Exchange Experiments 
3.3.6.1.1 H/D-Exchange for the linear-selective reaction 
 
 
Scheme 59. H/D-exchange under the linear-selective reaction conditions. 
 
To study the mechanism of the C–H activation elementary step, an H/D-exchange experiment under 
the linear-selective reaction regime with CD3OD as the co-solvent was conducted. As a result, a 
significant deuterium incorporation was observed in C3- and C7-positions of the product 144ab and 
the starting material 105a (Scheme 59), as it had previously been shown for the cobalt(III)-catalyzed 
C–H/C–C activation (cf. chapter 3.2.3.1). Importantly, a significant H/D-exchange in C2-position of 
the reisolated starting material 105a suggested a facile and reversible cobalt(III)-catalyzed C–H 
activation event to be operative.  
Notably, a considerable amount of deuterium incorporation could be exclusively detected in α-position 
of the alkyl chain in product 144ab. Based on this result, a H/D-exchange reaction with product 144ab 
under otherwise unchanged reaction conditions resulted again in a significant H/D-scrambling in α-
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position of the alkyl chain (Scheme 60), rendering a post-catalytic H/D-exchange likely. A reasonable 







Scheme 60. H/D-exchange with product 144ab under the linear-selective reaction conditions. 
 
3.3.6.1.2 H/D-Exchange for the branched-selective reaction 
Under the Markovnikov-selective reaction conditions a significant H/D scrambling was detected in C3- 
as well in C7-position (Scheme 61). Additionally, the reisolated starting material 105a displayed a 
moderate H/D-exchange in C2-position, however, in slightly less amount than under the linear-
selective conditions (cf. Scheme 59). Overall, the C–H activation under the branched-selective 
reaction regime seems to be reversible, but proceeds less readily than under linear-selective 
conditions. Furthermore, a minor deuterium incorporation in the methyl group of the alkyl chain was 
observed, which might be in agreement with the proposed mechanism to involve a proto-demetalation 
step (vide infra). 
 
Scheme 61. H/D-exchange under the branched-selective reaction conditions. 
 
 
3.3.6.1.3 H/D-exchange with alkenes 143 
The previously shown experiments revealed that H/D-exchange can occur after the catalytic reaction 
(cf. Scheme 60) in product 144ab. In addition to this observation, also H/D-exchange with solely the 
alkene 143c was studied under the otherwise unchanged reaction conditions.  
First, 1-pentadecene (143c) could be reisolated in almost quantitative yield under linear-selective 
conditions, which showed that no detectable side reactions like dimerization or isomerization of the 
double bond occurred (Scheme 62a). However, significant H/D-scramblings in both alkene positions 
were detected. Even under the milder branched-selective reaction conditions, H/D-scrambling was 
observed (Scheme 62b). Based on these observations, H/D-exchange studies of the cobalt(III)-
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catalyzed C–H alkylation should be cautiously interpreted with respect to the prediction of possible 
mechanistic pathways. However, these preliminary results bear potential for the development of 






Scheme 62. H/D-exchange with alkene 143c under a) linear- and b) branched-selective conditions. 
 
3.3.6.1.4 H/D-exchange with [D]1-105a during the reaction progress  
Under otherwise unchanged linear-selective reaction conditions, but in the absence of any external 
deuterium-/proton-source, a H/D-exchange experiment was performed with isotopically labeled [D]1-
105a (Scheme 63). Besides the previously observed H/D-scrambling in C2, C3- and C7-positions of 
the reisolated starting material 105a as well as the product 144aa (cf. Scheme 59) a significant 
deuteration in α-position of the alkyl sidechain was detected. 
 
 
Scheme 63. H/D-exchange with [D]1-105a under linear-selective reaction conditions. 
 
With respect to the previously observed H/D-exchange study of the product 144ab (cf. Scheme 60), 
this finding can be most likely explained by post-catalytic deuterium exchange with product 144aa. 
Remarkably, minor deuteration was detected in β-position, which might proceed by deutero-
demetalation of a catalytically relevant intermediate (vide infra Scheme 69). 
Results and Discussion  79 
 
 
3.3.6.1.5 H/D-exchange with [D]1-105a 
Moreover, a H/D-exchange reaction with substrate [D]1-105a was conducted under linear-selective 
reaction conditions, but in the absence of any alkene (Scheme 64). The substrate [D]1-105a could be 
almost quantitatively reisolated in 93%, with significant H/D-scramblings in C2-, C3- and C7-
position. A reasonable explanation for this observation is a reversible C–H activation in C2-position 
and proto-demetalation, likely by traces of water in the solvent DCE.  
 
 
Scheme 64. H/D-exchange experiment with deuterated substrate [D]1-105a. 
 
3.3.6.1.6 Intermolecular competition experiment 
In addition, an intermolecular competition experiment under the branched-selective reaction 
conditions was carried out by comparing the reaction rates of the electronically distinct 2-
pyridylindoles 105b and 105m (Scheme 65). As a result, the electron-rich 5-methoxypyridylindole 
(105b) reacted preferentially, which possibly supports a BIES-type C–H activation.  
 
 
Scheme 65. Intermolecular competition experiment for the branched-selective C–H alkylation. 
 
Notably, V. Müller showed a significant preference for the electron-rich 1-(p-tolyl)-1H-pyrazole (18a) 
as compared to [1-(4-(trifluoromethyl)phenyl]-1H-pyrazole (18b), which is in agreement with the 
above mentioned findings. Here, the electron-rich pyrazole 18a reacted almost nine times faster than 
substrate 18b. 
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3.3.6.2 KIE Studies 
3.3.6.2.1 KIE of the linear-selective reaction 
 
 
Scheme 66. KIE of the linear-selective reaction. 
 
The kinetic isotope effect (KIE) of the anti-Markovnikov-selective reaction was measured by 
comparison of independent reaction rates for substrate 105a and its isotopically labeled analogue [D]1-
105a, resulting in a minor value of kH/kD ≈ 1.2 (Scheme 66). The observed KIE is in good agreement 
with the results obtained from the H/D-exchange experiments, suggesting the reversible C–H 
activation not to be the turnover-limiting step of the catalytic cycle.  


























m = 0.584  0.04
R
2
 = 0.98 
 
Figure 11. KIE under the linear-selective reaction conditions. 
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3.3.6.2.2 KIE of the branched-selective reaction 
 
 
Scheme 67. KIE of the branched-selective reaction. 
 
The kinetic isotope effect (KIE) of the Markovnikov-selective reaction was analogously determined to 
be kH/kD ≈ 1.7 (Scheme 67 and Figure 12). The comparatively lower H/D-exchange in C2-position of 
the starting material 105a for the branched-selective reaction (vide supra) and the higher KIE value 
show that the C–H activation step under the Markovnikov-selective reaction regime presumably does 
not follow an electrophilic activation pathway. Along this line, a rate acceleration by acids as well as 
carboxylate additives has been observed (cf. Table 13). Overall, these findings might support a BIES-
type C–H activation mechanism by assistance of the in situ formed 1-adamantylcarboxylate to be 
operative for the branched-selective reaction regime. 
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3.3.6.3 Kinetic reaction orders 
3.3.6.3.1 Kinetic reaction order for the linear-selective reaction 
3.3.6.3.1.1 Reaction order with respect to the concentration of 2-pyridylindole (105a) 
 
The kinetic order of the reaction with respect to the concentration of 2-pyridylindole (105a) equals 
n = 1.24 ± 0.11, which might correspond to a reaction order of one (Figure 13). This result can be 
interpreted as a clear hint for the participation of 2-pyridylindole (105a) in the turnover-limiting step 
of the reaction.  







































Figure 13. Kinetic order in [2-pyridylindole] (105a) under linear-selective conditions. 
 
3.3.6.3.1.2 Reaction order with respect to the concentration of 1-octene (143a) 
Interestingly, a non-integer reaction order
[165]
 of n = 0.30 ± 0.02 with respect to the alkene-
concentration 143a was observed (Figure 14), suggesting a complex rate law for this reaction. One 
possible explanation could be that the step after alkene-insertion is turnover-limiting and both the 
coordination and the following migratory insertion of the alkene 143a are two interdepending 
equilibrium reactions, which are kinetically relevant for the following turnover-limiting step. 
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Figure 14. Kinetic order in [1-octene] (143a) under linear-selective conditions. 
 
3.3.6.3.1.3 Reaction order with respect to the concentration of [Cp*Co(CO)I2]  
The reaction order with respect to the catalyst concentration is roughly one, with n = 1.08 ± 0.12 
(Figure 15), showing that the catalyst is part of the turnover-limiting step of the catalytic cycle. 
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Figure 15. Kinetic order in [[Cp*Co(CO)I2]] under the linear-selective reaction regime. 
 
3.3.6.3.2 Kinetic reaction order for the branched-selective reaction 
3.3.6.3.2.1 Reaction order with respect to the concentration of 2-pyridylindole (105a) 
In stark contrast to the observed first-order-dependence for the linear-selective reaction regime, a zero-
order-dependence with respect to the concentration of 2-pyridylindole (105a) with n = 0.00 ± 0.09 was 
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observed (Figure 16). Notably, a similar result was obtained by V. Müller, who performed 
19
F-NMR 
studies of the same reaction system utilizing 5-fluoro-1-(pyridin-2-yl)-1H-indole (105m).
[162b]
 Based 
on these results, it can be proposed that the concentration of 2-pyridylindole (105a) is not kinetically 
relevant and it is neither part of an equilibrium reaction before nor of the turnover-limiting step itself.  
































log ([105a] / mol L
–1 
)  
Figure 16. Kinetic order in [2-pyridylindole] (105a) under branched-selective conditions. 
 
3.3.6.3.2.2 Reaction order with respect to the concentration of 1-octene (143a) 
In contrast to the non-integer reaction order for the linear-selective regime (cf. Figure 14), the 
Markovnikov-selective reaction displayed a first order dependence with respect to [1-octene] (143a), 
which reveals the participation of 1-octene (143a) within or before the turnover-limiting step (Figure 
17).   
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Figure 17. Kinetic order in [1-octene] (143a) under branched-selective conditions. 
 
3.3.6.3.2.3 Reaction order with respect to the concentration of [Cp*Co(CO)I2]  
As for the linear-selective reaction (cf. Figure 15), a first-order dependence was observed with respect 
to the concentration of the cobalt(III) catalyst (Figure 18). 
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Figure 18. Kinetic order in [[Cp*Co(CO)I2]] under branched-selective conditions. 
 
3.3.6.4 Arrhenius Activation Energies 
A common approximation for the measurement of activation barriers EA of inter alia catalytic 
reactions is the Arrhenius plot, in which the natural logarithm of the reaction rate k is plotted against 
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the inverse reaction temperature T (Equation 5).
[166]
 The slope of the thus obtained graph corresponds 
to the activation energy EA divided by the ideal gas constant R and the y-axis intercept represents the 
natural logarithm of the preexponential factor A.  






                                              (Equation 5)  
Thus, the activation energy of the linear-selective reaction was determined to be EA = 
22.3 ± 1.7 kcal/mol (Figure 20) and the branched-selective reaction displayed a barrier of EA = 
14.4 ± 1.6 kcal/mol (Figure 22), which were obtained by comparison of the initial rates at different 
reaction temperatures for both reactions (Figure 19 and Figure 21). The difference in activation energy 
for both reactions amounts to roughly 8.0 kcal/mol, which is in good agreement with the difference in 
each optimized reaction temperature of 120 °C and 50 °C, respectively.  
 
Figure 19. Initial rates at different reaction temperatures for the linear-selective reaction. 
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Figure 20. Arrhenius plot for the linear-selective reaction regime. 
 
Figure 21. Initial rates at different temperatures for the branched-selective reaction. 
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Figure 22. Arrhenius plot for the branched-selective reaction regime. 
 
3.3.6.5 Attempted Post-Synthetic Isomerization Studies 
Furthermore, it was studied whether a post-catalytic isomerization through cobalt(III)-catalyzed C–C 
bond cleavage could occur for the linear product 144aa under branched-selective conditions (Scheme 
68a) and vice versa (Scheme 68b). Overall, there was no change in connectivity, which indicates that 
both products are thermodynamically stable under the catalytic reaction conditions.  
 
 
Scheme 68. Attempted isomerization of a) the linear 144aa and b) the branched product 145aa. 
 
3.3.7 Proposed Catalytic Cycles 
In summary, there are several mechanistically distinct characteristics of the presented regiodivergent 
catalytic reactions. The linear-selective reaction seems to involve a feasible C–H activation step which 
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is indicated by the significant H/D-scrambling in C2-position and the minor KIE of 1.2, overall 
rendering the C–H activation to be facile and reversible. For the branched-selective reaction (i) a clear 
rate acceleration was accomplished using carboxylic acids (cf. Table 13), (ii) a reversible H/D-
exchange was detected, (iii) a higher KIE of 1.7 was measured and (iv) a clear preference for electron-
rich substrates was observed. Altogether, these results indicate that the C–H activation for the 
Markovnikov-selective reaction follows a BIES-type mechanistic pathway, which is clearly different 
from the linear-selective reaction.  
The kinetic order studies reveal a first-order-dependence on [2-pyridylindole] (105a) for the linear-
selective regime, whereas a zero-order-dependence was found for the branched one. With respect to 
[1-octene] (143a), a non-integer order of roughly 0.3 was observed in the case of the linear-selective 
reaction, and a first-order-dependence could be shown for the branched-selective one. The kinetic 
order of the reaction with respect to the catalysts concentration equaled one for both reactions. In 
summary, these differences clearly reveal that the regiodivergence of the studied reactions is possibly 
rooted in two mechanisms with distinct rate-determining steps.  
To gain a deeper mechanistic insight, DFT-studies were performed in collaboration with S. Grimme 
and M. Bursch.
[161] 
The computational results showed the selectivity control to be a consequence of 
two mechanistically different pathways for the proto-demetalation elementary step.  
On the one hand, linear selectivity is clearly preferred by a ligand-to-ligand hydrogen transfer (LLHT), 
which enabled the proto-demetalation by delivering the proton from a second substrate 105a to 
intermediate 153 (Scheme 69, TS1). The energetic difference of both regioisomers amounts to 
7.9 kcal/mol. These theoretical results match the experimentally observed regioselectivities as well as 
the first-order-dependence on substrate 105a because the recoordination with the second 2-
pyridylindole (105a) seems to be the overall highest calculated activation barrier.  
 




Scheme 69. Proposed catalytic cycle for the linear-selective reaction with only the preferred linear 




In the case of the branched-selective reaction, the turnover-limiting proto-demetalation step proceeds 
via TS2 (Scheme 70) with 1-adamanantanecarboxylic acid as the proton source and results in the 
formation of the favored branched product 145aa. The energy difference of the overall activation 
barriers equals 6.5 kcal/mol, which reflects the excellent experimental regioselectivities. A minor 
amount of linear product 144aa under the branched-selective reaction conditions might possibly be 
caused by the anti-Markovnikov-selective LLHT mechanism being in parallel operative, but it is 
clearly the less favored mechanistic pathway under these conditions (cf. Table 13, entry 1).  
The regiocontrol in the Markovnikov-selective reaction is presumably caused by steric interactions in 
the unfavored linear transition state TS2l (Figure 23), which was disclosed by DFT-calculations of M. 
Bursch. The linear product formation is considerably less favored because the alkyl-chain R = n-Hex 
hinders the approach of the sterically congested 1-adamantanecarboxylic acid, which is needed as 
proton source for the proto-demetalation step. In this context, it could be shown that attractive London 
dispersion interactions
[124, 142]
 significantly contribute to a stabilization of all catalytically relevant 
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intermediates as well as transition states, but they do not compensate for the energetic destabilization 
by steric interactions and overall do not influence Markovnikov/anti-Markovnikov selectivity.
[161]  
Generally, the proto-demetalation step is kinetically favored by the presence of carboxylic acids as 
compared to their carboxylate analogues, which can only form the corresponding acid in situ during 
the BIES-type C–H activation. This hypothesis is in good agreement with the previously described 
observation that acids, even in high concentrations and regardless of their steric demand, favor the 
branched product formation, whereas only sterically demanding carboxylates lead to comparably good 
selectivities (cf. Table 13, entries 2–12).   
 
 
Scheme 70. Proposed catalytic cycle for the branched-selective reaction with only the preferred 








Figure 23. Calculated transition states of the proto-demetalation for the branched-selective reaction 
with a) the unfavored linear arrangement and b) the energetically favored branched transition state 
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3.4 Cobalt(III)-Catalyzed Allylative and Alkenylative C–H/C–F 
Functionalizations  
The selective synthetis of fluorinated molecules is a major challenge in organic synthesis, since about 
20–30% of all agrochemicals and pharmaceuticals contain fluorine for the improvement of inter alia 
their metabolic stability and lipophilicity (Figure 24).
[118h, 118k, 167]
 Consequently, there is a continued 
demand for selective and mild conditions to install fluorinated motifs in late-stage modifications of 
complex molecules.
[13k, 118]
 A particularly sustainable and step-economical access to highly 
functionalized fluorine-containing molecules can be achieved by merging C–H with C–F 





Figure 24. Selected examples of fluorine-containing pharmaceuticals. 
 
3.4.1 Optimization Studies for the Allylative C–H/C–F Functionalizations  
The optimization studies for the cobalt(III)-catalyzed C–H/C–F functionalization were started by 
probing the effect of representative solvents for cobalt(III)-catalyzed C–H activation (Table 19). 
Interestingly, fluorinated solvents
[169]
 such as HFIP and TFE by far outcompeted DCE and MeOH 
(entries 1–4), with TFE delivering the desired product 158aa in an almost quantitative yield of 97% 
with a good diastereoselectivity of Z/E = 86:14. According to a report of Berkessel and coworkers on 
the beneficial effects of fluorinated solvents,
[170]
 it can be assumed that TFE and HFIP form higher 
order solvent aggregates that significantly stabilize cationic intermediates in catalysis by enhanced H-
bond donor abilities. In the absence of any cobalt(III) catalyst, no reactivity was observed (entry 5). 
Furthermore, a catalyst loading of 0.25 mol % still provided the product 158aa in excellent yield, 
albeit reduced catalyst loadings as low as 0.10 mol % seemed to be less efficient (entries 6 and 7). 
Notably, the reaction still proceeded at 0 °C and furnished the product in overall moderate yield, but 
with an improved diastereoselectivity of Z/E = 93:7 (entry 8).  
Thereafter, various bases were tested, especially mild bases like carbonates. Within a series of alkali 
metal carbonates, an increased reactivity from lithium to potassium carbonate was found, but with 
cesium carbonate a significant drop in yield to only 8% was noticed (entries 4 and 9–12). The 
preference for potassium as countercation in this reaction was furthermore revealed by obtaining 
excellent yields with potassium hydrogen carbonate and potassium acetate as the bases (entries 13 
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and 14). Among significantly more basic hydroxides, potassium hydroxide was found to be the most 
efficient base (entries 15 and 16). Based on these findings, it can be assumed that potassium-
containing bases are generally favored regardless of their pKB-values.  
Importantly, qualitative solubility experiments in TFE as solvent showed an increasing solubility in a 
row from lithium to cesium fluoride, which is agreement with quantitative experiments of Wynn and 
coworkers.
[171]
 Thus, by only taking the solubility of fluorides into account, lithium carbonate as base 
would create the strongest driving force for the reaction. However, the solubility of the corresponding 
carbonate bases should be considered as well. In this regard, qualitative solubility experiments 
indicated an increasing solubility from lithium to cesium carbonate, which would lead to the highest 
reactivity for cesium carbonate. Based on these results, only well-balanced solubilities of the 
carbonate bases as well as the precipitating alkali metal fluorides can account for this reactivity trend, 
resulting in the overall highest efficiency for potassium carbonate. 
 
 








1 K2CO3 DCE 3 
2 K2CO3 MeOH 12 
3 K2CO3 HFIP 91 











7 K2CO3 TFE 44
[d] 
8 K2CO3 TFE 46
[e] 
9 Li2CO3 TFE 18 
10 Na2CO3 TFE 81 
11 Rb2CO3 TFE 49 
12 Cs2CO3 TFE 8 
13 KHCO3 TFE 94 
14 KOAc TFE 87 
15 KOH TFE 93 
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16 Ca(OH)2 TFE 45 
[a]
 
Reaction conditions: 105a (0.50 mmol), 127a (0.60 mmol), [Co] (2.5 mol %), base (1.00 equiv), solvent 
(0.5 mL, 1.0 M), 25 °C, 20 h, isolated yield; all Z/E = 86:14. [b] Without [Co]. [c]
 
0.25 mol % [Co]. [d]
 
0.10 mol % [Co]. [e] At 0 °C, Z/E = 93:7. 
 
To explore this reaction with respect to even more cost-efficient cobalt sources, a comprehensive 




 was performed (Table 20). Catalysts with Cp 
or substituted (t-Bu)2-Cp-ligands delivered only traces of the desired product 158aa (entries 2 and 3). 
In striking contrast, the beneficial influence on stereoselectivities by substituents on the Cp-ligand had 
previously been disclosed by Rovis and coworkers in rhodium(III)-catalyzed C–H activation 
catalysis.
[172]
 Unfortunately, also simple cobalt salts, such as cobalt(III) fluoride (entry 4) and 
cobalt(II) bromide (entry 8), failed to furnish any desired product as well as other salts, such as cobalt 
acetylacetonate and cobalt acetate (entries 5–7). In summary, these findings show the great importance 
of the Cp*-ligand for efficient catalysis, probably due to its very good donor abilities and rigid 
structure. 
 




Entry [Co] yield / %
[a] 
1 [Cp*Co(CO)I2] 97 
2 [CpCo(CO)I2] traces 
3 [1,3-(t-Bu)2C5H3Co(CO)I2] traces 
4 CoF3 --- 
5 Co(acac)3 --- 
6 Co(acac)2 --- 
7 Co(ac)2 --- 
8 CoBr2 --- 
[a]
 
Reaction conditions: 105a (0.50 mmol), 127a (0.60 mmol), [Co] (2.5 mol %), K2CO3 (1.00 equiv), solvent 
(0.5 mL, 1.0 M), 25 °C, 20 h. Conversions were determined by GC with n-dodecane as the internal standard. 
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3.4.2 Optimization Studies for the Alkenylative C–H/C–F Functionalization  
Based on the optimization studies for the allylative C–H/C–F functionalization, it was studied whether 
1,1-difluorostyrenes 128 can be efficiently converted by cobalt(III) catalysis (Table 21). 1,1-
difluorostyrenes 128 are synthetically easily accessible and biologically relevant substrates.
[173]
 For 
this purpose, it was initially observed that the reaction performed poorly in the absence of base 
(entry 1), whereas AgSbF6 had a beneficial influence on the reactivity (entry 2). Thereafter, a 
significant increase in product yield was achieved by utilizing potassium carbonate as the base 
(entry 3), while no improvement by additional AgSbF6 (entry 4) was observed. Moreover, the optimal 
base loading was found to be 1.50 equivalents (entries 5–7). Noteworthily, after screening different 
metal carbonates the corresponding potassium salt turned out to be optimal (entries 5–11), showing 
same reactivity trend as it was previously observed for the C–H/C–F allylative functionalization (cf. 
Table 19, entries 8–12).  
Importantly, a slight increase of the 1,1-difluorostyrenes (128a) concentration furnished the desired 
alkenylated product 159aa in almost quantitative yield and excellent Z-diastereoselectivity (entry 12). 
Moreover, a control reaction revealed that this reaction is indeed cobalt(III)-catalyzed (entry 13). 
Subsequently, selected solvents were tested, with an unsatisfactory result for the more expensive 
perfluorinated HFIP (entry 14). Unfortunately, more economic solvents, such as MeOH and H2O, 
showed no reactivity (entries 16 and 17). It is noteworthy that in all cases excellent 
diastereoselectivities of Z/E > 99:1 were achieved. 






yield  / %
[a]
 
1 --- TFE ---
 
2 --- TFE 37
[b]
 
3 K2CO3 TFE 77 
4 K2CO3 TFE 73
[b] 
5 K2CO3 (0.50 equiv) TFE 33 
6 K2CO3 (1.50 equiv) TFE 86 
7 K2CO3 (2.00 equiv) TFE 67 
8 Li2CO3 TFE --- 
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9 Na2CO3 TFE 18 
10 Rb2CO3 TFE 60 







13 K2CO3 TFE ---
[d] 
14 K2CO3 HFIP 46 
15 K2CO3 DCE 
--- 
16 K2CO3 MeOH 
--- 




Reaction conditions: 105a (0.50 mmol), 128a (0.60 mmol), [Co] (2.5 mol %), base (1.00 equiv), solvent 
(0.5 mL, 1.0 M), 25 °C, 20 h, isolated yield; all Z/E-ratios > 99:1, determined by 
1
H-NMR spectroscopy. [b] With 
AgSbF6 (5.0 mol %). [c]
 




3.4.3 Scope of the Allylative Cobalt(III)-Catalyzed C–H/C–F Functionalization 
Under the optimized reaction conditions several heterocycles, including indoles 105, pyrroles 146 and 
phenylpyrazoles 18 were probed (Table 22). Initially, 1H,1H,2H-perfluorohexene (127b) furnished the 
corresponding product 158ab in excellent yield and good Z/E-ratio (entry 2), displaying a considerable 
variability with respect to the perfluoroalkyl chain length. Subsequently, various substituents in the 
C5-position of 2-pyridylindole (105a) were tested, with overall very good yields and good 
diastereoselectivities (entries 3–7). It is noteworthy that even sterically demanding substrates like 
105p were successfully converted although an elevated reaction temperature and higher catalyst 
loading were necessary (entry 8). Notably, due to the higher reaction temperature the 
diastereoselectivity dropped to moderate Z/E = 80:20. Moreover, it was demonstrated that also 1-
(pyridin-2-yl)-1H-pyrrole (146) and phenylpyrazoles 18 could deliver the desired products (entries 
9−11). In the latter case, an optimal reactivity was achieved by using AgSbF6 (20 mol %) as the 
additive, which is presumably due to an unfavored BIES-type C–H activation step, as the arene is less 
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Reaction conditions: 105a (0.50 mmol), 127a (0.60 mmol), [Co] (2.5 mol %), K2CO3 (1.00 equiv), TFE 
(0.5 mL, 1.0 M), 25 °C, 20 h, isolated yield; Z/E-ratio determined by 
1
H-NMR spectroscopy. [b] 1H,1H,2H-
perfluorohex-1-ene (127b) (0.60 mmol) was used. [c] At 70 °C and [Co] (10 mol %). [d] 8% of di-substituted 
160' (Z/E = 84:16)was detected. [e] With AgSbF6 (20 mol %). 
 
3.4.4 Scope of the Alkenylative Cobalt(III)-Catalyzed C–H/C–F Functionalization 
With the optimized catalytic reaction conditions in hand, the substrate scope with respect to various 
indoles 105 and 1,1-difluorostyrenes 128 was performed (Table 23). Electron-rich as well as electron-
poor indoles reacted in very good yields and excellent diastereoselectivities (entries 1–4). Notably, V. 
Müller and R. R. Presa extended the scope to more examples of ortho- and meta-substituted 1,1-
difluorostyrenes 128. 
[174]
 Furthermore, it was demonstrated that the thiophene-derived substrates 
(entries 5 and 6) performed well, delivering the desired products 159ab and 159ac in almost 
quantitative yield. However, a slightly decreased diastereoselectivity for the 3-substituted thiophene 
128c was observed. Elevated temperatures were necessary to convert the naphthalene-derived 
substrate 128d (entry 7). In this manner, the sterically even more biased fluorescent anthracene-
derivative 128e failed to yield the corresponding product, revealing a limitation for this reaction with 
respect to bulky 1,1-difluoroalkenes 128.  




Entry indole 105 alkene 128 product 159 











 105a 128a 159aa  









































 105a 128c 159ac  
7 









 105a 128e 159ae  
[a]
 
Reaction conditions: 105a (0.50 mmol), 128a (0.75 mmol), [Co] (2.5 mol %), K2CO3 (1.00 equiv), TFE 
(0.5 mL, 1.0 M), 25 °C, 20 h, isolated yield; Z/E-ratios in parentheses, determined by 
1
H-NMR spetroscopy. [b] 
At 50 °C. [c] At 70 °C.  
 
Remarkably, under the same reaction conditions as well as the reported one by Loh and 
coworkers,
[168d]  
rhodium(III) catalysis was clearly shown to be less efficient. Indeed, the desired 
product 159aa was delivered with the same excellent diastereoselectivity of Z/E > 99:1, but with a 
considerably reduced efficacy (Scheme 71). The exact reason for this significant difference has yet not 
been fully elucidated. It can be speculated that the increased nucleophilicity of the cobalt-carbon bond 
(Pauling-electronegativity of cobalt is χF ≈ 1.9 and for rhodium it is χF ≈ 2.3)
[62]
 presumably enables an 
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Scheme 71. Performance of a rhodium(III) catalyst in C–H/C–F functionalizations at 25 °C. 
 
3.4.5 Mechanistic Studies 
3.4.5.1 H/D-Exchange Experiments 
Initially, a H/D-exchange study was conducted with deuterated 2-pyridylindole [D]1-105a in the 
presence of TFE as solvent and proton source (Scheme 72). In the reisolated starting material 105a 
and the product 158aa minor amounts of deuterium incorporation in C3-positions were detected, 
which was previously observed for the cobalt(III)-catalyzed C–H/C–C functionalization as well (cf. 
Scheme 55). This finding might be explained by an electrophilic activation at the C3-position with 
cobalt(III) and subsequent deutero-demetalation. In contrast to previous observations, no deuteration 
was detected in the C7-position, which is possibly due to the kinetically unfavored formation of a six-
membered cobaltacycle at the lower reaction temperature. It is noteworthy that almost full protonation 
in C2-position of the reisolated starting material was observed, which indicated that the C–H 
activation step is fully reversible and not turnover-limiting. Furthermore, it should be mentioned that 
no H/D-scrambling in any position of the perfluoroalkyl chain could be detected. These results might 
suggest that the migratory insertion is irreversible. 
 
Scheme 72. H/D-exchange study for the cobalt(III)-catalyzed allylative C–H/C–F functionalization. 
 
3.4.5.2 KIE Studies 
The KIE of the allylative cobalt(III)-catalyzed C–H/C–F functionalization was determined by 
comparison of independent reaction rates for substrate 105a and its isotopically labeled analogue [D]1-
105a, resulting in a value of kH/kD ≈ 1.5 (Scheme 73 and Figure 25). The KIE value is in good 
agreement with the H/D-exchange experiment, which altogether indicate that the C–H activation is 
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facile and reversible. Nevertheless, the slightly larger KIE as compared to previously studied reactions 
(cf. Figure 11) leads to the mechanistic hypothesis that the C–H activation could be a kinetically 
relevant equilibrium step before the turnover-limiting migratory insertion. 
 
 
Scheme 73. KIE study of the allylative cobalt(III)-catalyzed C–H/C–F functionalization. 
 


































Figure 25. KIE study of the allylative cobalt(III)-catalyzed C–H/C–F functionalization. 
 
3.4.5.3 Intermolecular Competition Experiments 
To gain further insight regarding the C–H activation mechanism, an intermolecular competition 
experiment between the electron-rich substrate 18a and electron-poor trifluoromethyl-substituted 18b 
was conducted (Scheme 74).  
Importantly, a strong preference for the electron-rich substrate 18a was found which reacted almost 
four times faster than the corresponding electron-poor substrate 18b. Along with the slightly higher 
KIE of 1.5, this finding reveals that the C–H activation possibly follows a BIES-type pathway, which 
is clearly favored for electron-rich substrates. Furthermore, a kinetically relevant migratory insertion, 
which benefits from a more nucleophilic carbon-cobalt bond in electron-rich substrates, could be a 
reasonable explanation for this reactivity trend. 
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Scheme 74. Intermolecular competition experiment. 
 
3.4.6 Proposed Catalytic Cycle 
In summary, the C–H activation presumably occurs via a reversible and facile BIES-type pathway, in 
which the C–H cleavage likely is assisted by the carbonate, which in situ forms the active 
cobalt(III)carbonate catalyst 162. Afterwards, the generated cobaltacycle 163 first undergoes a 
reversible coordination of the perfluoroalkylalkene 127a to furnish intermediate 164. Thereafter, a 
migratory insertion into the cobalt-carbon bond proceeds to form intermediate 165. The migratory 
insertion step is proposed to be irreversible because the H/D-exchange study revealed no H/D-
scrambling in the perfluoroalkylalkene side-chain (Scheme 72). Afterwards, a process involving the β-
fluoride elimination
[119f]
 and reaction with the initially formed bicarbonate regenerates the active 
catalytic species 162 and releases the product 158aa. In principle, the same sequence of elementary 
steps can be proposed for the alkenylative C–H/C–F functionalization. 
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3.5 Manganese(I)-Catalyzed Allylative C–H/C–F Funtionalizations 
The use of very inexpensive and less toxic
[54, 92]
 manganese complexes in catalysis has been 
intensively studied in recent years.
[14]
 In this regard, it has been reported that manganese catalysts 
allowed for C–H/C–Het functionalizations by β-oxygen, -nitrogen or -carbon elimination.
[108, 117a, 117d]
 
As it was previously reported, β-fluoride elimination is a feasible process
[119]
 that allows for the metal-
catalyzed installation of fluorine into organic molecules. Thus, it appears to be very attractive to 
explore the efficiency of manganese catalysts for allylative and alkenylative C–H/C–F 
functionalizations
[168]
 on a variety of valuable substrates. Additionally, detailed mechanistic studies 
should eventually lead to the development of related C–H/C–Het transformations.   
3.5.1 Optimization Studies for Indoles as Substrates 
The optimization study for the desired transformation was commenced by screening various solvents, 
initially with unsatisfactory yields of the desired product 158aa (Table 24, entries 1–6). In stark 
contrast, 1,4-dioxane turned out to be the optimal solvent for this reaction (entry 7) and by far 
outcompeted other prevalent solvents for manganese(I)-catalyzed C–H activations, such as DCE and 
n-Bu2O. Subsequently, the effect of bases was probed which were shown to be essential for an 
efficient conversion (entry 8). Stronger bases like calcium and potassium hydroxide only performed 
poorly to moderately, with the same observation for potassium phosphate (entries 9–11). These 
findings are comparable with a related cobalt(III)-catalyzed reaction (cf. chapter 3.4.1) and clearly 
demonstrate that no direct correlation between reactivity and base strength was observed for this 
transformation. In this manner, also considerably weaker bases like potassium hydrogen carbonate and 
sodium acetate, which is a common base in manganese(I)-catalyzed C–H activation catalysis,
[14]
 
displayed a moderate to good reactivity (entries 12 and 13). As it has been previously observed (cf. 
Table 7 and Table 24), a comparison between several alkali metal carbonates showed that the 
reactivity increased from lithium to potassium carbonate, but significantly dropped, when heavier 
analogues like rubidium and cesium carbonate were employed (entries 15–18). Notably, qualitative 
solubility experiments in 1,4-dioxane revealed an increasing solubility of alkali metal fluorides as well 
as carbonates from lithium to cesium salts. This observation is in good agreement with the previously 
observed trend for the cobalt(III)-catalyzed C–H/C–F functionalization in TFE (cf. chapter 3.4.1). 
Finally, a reaction in the absence of the manganese(I) catalyst afforded no detectable amounts of the 
desired product 158aa (entry 19). It is noteworthy that the diastereoselectivity of Z/E = 90:10 was 
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1 K2CO3 DCE 23 
2
 
K2CO3 TFE 8 
3 K2CO3 PhMe 6 
4 K2CO3 acetone 23 
5 K2CO3 H2O 14 
6 K2CO3 n-Bu2O 14 
7 K2CO3 1,4-dioxane 97 
8 --- 1,4-dioxane 7
 
9 Ca(OH)2 1,4-dioxane 37 
10 KOH 1,4-dioxane 78 
11
 
K3PO4 1,4-dioxane 19 
12
 
KHCO3 1,4-dioxane 70 
13 NaOAc 1,4-dioxane 52 
14 K2CO3 1,4-dioxane 45
[b]
 
15 Li2CO3 1,4-dioxane 8 
16 Na2CO3 1,4-dioxane 92 
17 Rb2CO3 1,4-dioxane 25 
18
 






[a] Reaction conditions: 105a (0.50 mmol), 127a (0.60 mmol), [MnBr(CO)5] (10 mol %), base (0.50 mmol), 
solvent (0.5 mL, 1.0 M), 20 h, isolated yield; all Z/E = 90:10, determined by 
1
H-NMR spectroscopy. [b] At 
50 °C. [c] Without [Mn].  
 
3.5.2 Optimization Studies for Ketimines as Substrates 
Ketimines 6 are a powerful and transformable class of directing groups
[14a, 175]
 which could give access 
to the corresponding ketones 166 after hydrolysis. Thus, a comprehensive optimization study with 
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mainly para-methoxyphenyl- (PMP)-substituted ketimines 6 was attempted (Table 25). Indeed, the 
desired ketone 166aa was furnished even in the absence of any base additive (entry 1). To increase the 
reactivity, acetate bases were utilized (entries 2 and 3), revealing the sodium salt to be optimal, as it 
was reported before for manganese-catalyzed C–H activations.
[14] 
Furthermore, the influence of the 
reaction temperature was probed, giving optimal yields at 105 °C (entry 5). In contrast, higher reaction 
temperatures, such as 120 °C, led to a slight decrease in yield. However, the observed reactivity 
difference was overall less pronounced. Interestingly, an increase of the perfluoroalkylalkene 127a 
concentration turned out to be the optimal condition (entry 8). Importantly, in the absence of 
manganese(I) catalysis no reactivity was observed (entry 9). A variation of the protecting group to 
more electron-rich TMP (3,4,5-trimethoxyphenyl) provided the corresponding product 166aa with a 
slight decrease in yield (entry 10). The dimeric manganese precursor [Mn2(CO)10] showed some 
catalytic activity, albeit the product 166aa was delivered in only unsatisfactory yield (entry 11).  




Entry additive T / °C yield / %
[a]
 
1 --- 120 8
[b] 
2 NaOAc 120 44 
3 KOAc 120 15 
4 NaOAc 110 50 
5 NaOAc 105 53 










9 NaOAc 105 ---
[e] 
10 NaOAc 105 61
[d,f] 
11 NaOAc 105 32
[g] 
[a] Reaction conditions: 6a (0.50 mmol), 127a (0.75 mmol), [MnBr(CO)5] (10 mol %), additive (40 mol %), 
base (0.50 mmol), solvent (0.50 mL, 1.00 M), 20 h, isolated yield; all Z/E = 97:3, determined by 
1
H-NMR 
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spectroscopy. [b] Without K2CO3. [c] 2.00 equiv of 127a. [d] 3.00 equiv of 127a. [e] Without [Mn]. [f] With  
TMP-substituted ketimine. [g] [Mn2(CO)10] (5.0 mol %) as catalyst. 
 
3.5.3 Scope of the Allylative C–H/C–F Functionalizations  
Subsequently, an extensive study on the scope for the allylative and alkenylative manganese(I)-
catalyzed C–H/C–F functionalization on 2-pyridylindoles 105 was carried out by U. Dhawa and V. 
Müller, including various heterocycles like pyrroles, pyrazoles, tryptophan-derivatives, and 
dipeptides.
[176]
 These results highlighted the broad applicability and excellent functional group 
tolerance of the optimized catalytic system.  
Besides these significant advances, a strong focus has been directed at the generality of the catalytic 
reaction with respect to valuable ketimines 6 (Table 26). Initially, the change of methyl- to ethyl-
substituted ketimine 6b altered the yield of the desired product 166b only marginally (entries 1 and 2). 
Subsequently, different substituents in para-position to the directing group were tested (6c–h, entries 
3–8), revealing no clear trend concerning the electronic properties of the functionalized ketimine 6, 
with overall moderate to good yields. Interestingly, the sterically congested naphthalene-derived 
ketimine 6i afforded the corresponding product 166i with moderate yield, but an excellent 
diastereoselectivity (entry 9). Notably, the meta-fluorine substituted ketimine 6j delivered the 
corresponding product via C–H activation at the more acidic ortho-position next to fluorine, indicating 
a CMD-type C–H activation pathway to be likely (entry 10). This assumption is in agreement with the 
finding that there is no clear preference for electron-rich substrates (vide supra) as it would be 
indicative for a BIES-type C−H activation. In contrast, a BIES-type pathway has been previously 
shown as a potential C–H activation mechanism in manganese-catalyzed C–H functionalizations.
[14a, 
117d]
 Thereafter, a methylene-dioxy substituent of the ketimine 6k presumably acted as a secondary 
directing group to direct the manganese(I) catalyst by the Lewis basic oxygen to the sterically more 
congested position (entry 11). This site-selectivity is well-established for inter alia manganese 
catalysis.
[106, 108]
 In summary, all ketimines 6 reacted with excellent diastereoselectivities and moderate 
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Table 26. Scope of the manganese(I)-catalyzed allylative C–H/C–F functionalization of ketimines 6. 
 
  


































































166k 98:2 65 
[a] Reaction conditions: 6 (0.50 mmol), 127a (1.50 mmol), [MnBr(CO)5] (10 mol %), NaOAc (40 mol %), 





Moreover, under the optimized reaction conditions, a removable
[177]
 phenylpyrazole 18 was 
successfully converted with high yield and good diastereoselectivity (Scheme 75).    
 
 
Scheme 75. Manganese(I)-catalyzed C–H/C–F functionalization of phenylpyrazoles 18. 
 
3.5.4 Mechanistic Studies 
3.5.4.1 H/D-Exchange Experiments 
To delineate the manganese(I) catalysts mode of action, H/D-exchange experiments in either the 
presence of fully isotopically labeled CD3OD (Scheme 76a) or partly deuterated CD3OH (Scheme 
76b) were conducted. By using CD3OD, a minor deuteration in both C3-positions of the reisolated 
starting material 105a and the product 158aa was detected. This H/D-exchange presumably proceeded 
through an electrophilic activation pathway, which is less pronounced for manganese(I) catalysis than 
in the case of the more electrophilic cobalt(III) catalyst (cf. Scheme 59). Considerably stronger H/D 
exchange was observed in C2-position of the reisolated starting material 105a, indicating a reversible 
C–H bond activation step to be operative. In presence of the partly deuterated CD3OH (Scheme 76b), 
no deuterium incorporation in any position was found by means of 
1
H-NMR spectroscopy. This 
Results and Discussion  111 
 
finding supports that the H/D-exchange by using CD3OD cannot originate from a radical mechanism, 
but rather from an organometallic C–H activation by manganese catalysis.  
 
 
Scheme 76. H/D-exchange experiments with a) CD3OD and b) CD3OH. 
 
3.5.4.2 KIE Studies 
Subsequently, a KIE experiment by comparison of the initial rates of independent reactions with 
substrate 105a and its deuterated analogue [D]1-105a was conducted (Scheme 77 and Figure 27). The 
experiments revealed a KIE of kH/kD = 1.1, showing that the C–H activation event is facile and not 
turnover-limiting. 
 
Scheme 77. KIE-experiment for the manganese(I)-catalyzed C–H/C–F functionalization. 
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Figure 27. Conversion-time curves for the KIE-experiment. 
 
3.5.4.3 Experiments with Cyclometalated Complexes 
Furthermore, it was studied whether the desired product 158aa can be provided by reaction of the 
perfluoroalkylalkene 127a with the well-defined manganacycle 167 (Scheme 78). The reaction proved 
viable in an almost quantitative fashion with the same diastereoselectivity as for the catalytic 
transformation. Based on this result, a manganese(I)-catalyzed C–H activation pathway via the 
formation of manganacycle 167 can be assumed.  
Moreover, the importance of the carbonate-base for subsequent elementary steps after the C–H 
activation was studied by performing the same reaction in the absence of base. The corresponding 
reaction displayed a slight decrease in yield, but the same diastereoselectivity was observed. This 
observation possibly indicates that the C–H activation step is assisted by the carbonate base, which is 
in full agreement with the poor reactivity of the catalytic reaction by omitting the base (cf. Table 24 
entry 8). However, these findings cannot exclude a dual role of the carbonate base: On the one hand it 
could facilitate the C–H activation step, while on the other hand it could participate in a reaction to 
regenerate the active catalytic species and stabilize the fluoride anion by precipitation of potassium 
fluoride. 
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Scheme 78. Stoichiometric reaction of manganacycle 167 in a) the presence and b) absence of 
potassium carbonate. 
 
In addition, a catalytic reaction with manganacycle 167 as the catalyst afforded the desired product 
158aa in good yield, which indicates that the manganese(I) complex 167 is possibly an intermediate in 
the catalytic cycle (Scheme 79).  
 
 
Scheme 79. Catalytic reaction with manganacycle 167 as catalyst. 
 
3.5.5 Proposed Catalytic Cycle 
In conclusion, the allylative manganese(I)-catalyzed C–H/C–F functionalization of indoles 105 most 
likely proceeds via a reversible and facile BIES-type mechanistic pathway, which is supported by the 
results obtained from the H/D-exchange experiments (Scheme 76) and the KIE study (Scheme 77). 
The active catalyst 168 is proposed to be a manganese(I) carbonate complex, in which the carbonate 
assists the deprotonation step in an intramolecular manner (Scheme 80). Likewise, DFT studies by M. 
Bursch and S. Grimme support a BIES-type C–H activation mechanism to proceed and notably to be 
favored in an intramolecular fashion by carbonate as internal base.
[176]
 These studies contrast previous 
theoretical results by Maseras and Echavarran, who pointed out that the carbonate-assisted palladium-
catalyzed C–H activation proceeds favorably via an intermolecular deprotonation.
[178]
  
Thereafter, the manganacycle 169 is coordinated by the perfluoroalkylalkene 127a in a rapid and 
reversible process. Subsequently, a migratory insertion into the manganese-carbon bond forms 
intermediate 171. According to the H/D-exchange study, which disclosed no deuterium incorporation 
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in any position of the perfluoroalkylalkene side-chain, the migratory insertion is presumably an 
irreversible step (Scheme 76). Additionally, DFT-calculations by M. Bursch showed that the 
subsequent β-fluoride elimination step forms the preferred Z-configured product 158aa and regenerate 
the active catalyst by the initially formed bicarbonate.
[176]
 Future mechanistic investigations, including 
competition experiments, should reveal the C–H activation mechanism in the case of e.g. less electron-
rich substrates like ketimines 6. Interestingly, during the scope of ketimines 6 a preference for 
particularly acidic C–H bonds was found (Table 26, entry 10). These findings indicate that there might 
be rather a CMD- instead of BIES-type C–H activation operative for ketimines 6. 
 
 
Scheme 80. Proposed catalytic cycle of the allylative manganese(I)-catalyzed C–H/C–F 
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4 Summary and Outlook 
The development of highly step- and atom-economical C–H functionalizations by inexpensive and 
earth-abundant metals streamlines organic synthesis and offers new tools for inter alia pharmaceutical, 
agrochemical chemistry, and material sciences. In this thesis, several new synthetic methods have been 
devised that reveal the remarkable efficiency and synthetic diversity of ruthenium(II), cobalt(III), and 
manganese(I) complexes in C−H activation catalysis. 
In the first project, well-defined single component phosphinous acid (PA) complexes of ruthenium(II) 
have been employed as powerful catalyst for the C–H arylation of valuable and omnipresent alkene 
motifs, including challenging aryl chlorides 3 as arylating reagents (Scheme 81). For the first time, 
detailed kinetic studies, such as kinetic orders and Hammett plot analyses, revealed the mechanistic 





Scheme 81. Ruthenium(II)-PA-catalyzed C–H arylation of alkenes 9. 
 
These findings might give rise to the design of new tailor-made catalysts with enhanced efficiencies 
by adjusting the electronic features or attractive London dispersion and repulsive steric interactions on 
the easily modifiable phosphinous acid ligand. In this context, insightful studies concerning steric 
effects on the reactivity might be conducted, e.g. by comparing the buried volume of several PA 




In the next project, a cobalt(III)-catalyzed C–H/C–C functionalization of valuable heteroarenes and 
arenes by using vinylcyclopropanes 125 was achieved (Scheme 82).
[117b]
 Under very mild reaction 
conditions, the thermodynamically less stable Z-configurated diastereomer was obtained in excellent 





 catalyses, this reaction appeared to be stereo-
complementary, which bears great potential for new uniquely selective synthetic methods based on 
cobalt(III) catalysis.  
 




Scheme 82. Cobalt(III)-catalyzed C–H/C–C functionalization. 
 
In the third project, a new concept for Markovnikov/anti-Markovnikov regiocontrol in C–H 
hydroarylations was devised (Scheme 83).
[161]
 Here, the control of regioselectivity was accomplished 
by a tunable switch of the regiodetermining proto-demetalation step. Within this reaction, an expedient 
substrate scope was highlighted with excellent and fully complementary branched/linear selectivities, 
notably using unactivated alkenes. Likewise, extensive mechanistic studies, including detailed kinetic 
experiments, revealed a switch in the C–H activation manifold from a linear-selective LLHT to a 
branched-selective BIES-type pathway to be stereodiscriminating. Herein, inter alia a change from 
zeroth-order dependence on the concentration of indoles 105 for the branched- to a first order-
dependence for the linear-selective regime supported the mechanistic hypothesis. 
 
Scheme 83. Cobalt(III)-catalyzed branched/linear-selective C–H hydroarylation. 
 
Based on this mechanistic insight, an enantioselective cobalt(III)-catalyzed hydroarylation protocol 
was developed by employing monoprotected amino acids (MPAAs). However, yields and 
enantioselectivities are overall rather moderate, which gives rise to the future development of more 
reactive and selective catalytic systems e.g. by using oligopeptides as additives.  
Furthermore, cobalt(III)-catalyzed allylative and alkenylative C–H/C–F functionalizations were 
developed (Scheme 84).
[174]
 A diverse set of perfluoroalkylalkenes 127 as well as valuable 1,1-
difluoroalkenes 128 were successfully converted at 25 °C with ample scope and excellent functional 
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group tolerance. The products displayed good to excellent diastereoselectivities and the catalyst 
loading could be reduced to 0.25 mol % without loss of reactivity.  
 
 
Scheme 84. Cobalt(III)-catalyzed allylative and alkenylative C–H/C–F functionalizations. 
 
Finally, a manganese(I) complex, which obviates the use of costly Cp* ligands, was shown to be a 
competent catalyst in allylative and alkenylative C–H/C–F functionalizations, with overall excellent 
and improved diastereoselectivities as compared to the analagous cobalt(III) catalysis (Scheme 85).
[176]
 
The reaction displayed a broad applicability, including the functionalization of valuable and easily 
transformable ketimines 6. Regarding a future prospect, the development of e.g. 
manganese(I)carboxylate complexes might be of great importance for studying the selectivity control 
in this and related reactions.  
 
 
Scheme 85. Manganese(I)-catalyzed allylative and alkenylative C–H/C–F functionalizations. 
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5 Experimental Section 
5.1 General Remarks 
All reactions involving moisture- or air-sensitive reagents or products were performed under an 
atmosphere of nitrogen using pre-dried glassware and standard Schlenk techniques. If not otherwise 





The following uncorrected pressures were measured on the used vacuum pump: membrane pump 
vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from BARLOWORLD 
SCIENTIFIC. Values are uncorrected. 
 
Column and HPLC-Chromatography 
Analytical thin layer chromatography (TLC) was performed on MERCK, silica gel 60 F254 aluminum 
plates. Detection was performed under UV light at 254 nm or by treatment with a KMnO4 solution. 
Chromatographic purification of products was accomplished by flash column chromatography on 
MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 mm, 70–230 mesh ASTM). Analytical 
High-Performance-Liquid-Chromatography (HPLC) for determination of enantiomeric excess was 




 from DAICEL (both 
3.0 µm particle size; Ø = 4.6 mm and length = 250 mm) as columns.  
 
Gel permeation chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped with two 
sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 20.000; internal 
diameter = 20 mm; length = 600 mm; Flush rate = 10.0 mL/min and chloroform (HPLC-quality with 
0.6% ethanol as stabilizer) was used as the eluent.  
 
Gas Chromatography 
Gas chromatography or coupled gas chromatography-mass spectrometry was performed on a 5890 
Series II GC system with mass detector HP 5972 from HEWLETT-PACKARD, a 7890 GC system 
with/without mass detector 5975C (Triplex-Axis-Detector) or a 7890B GC system coupled with a 
5977A mass detector, both systems from AGILENT TECHNOLOGIES.  
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Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectra were recorded on VARIAN Inova 500, 600, VARIAN 
Mercury 300, VX 300, VARIAN Avance 300, VARIAN VNMRS 300 and BRUKER Avance III 300, 400 
and HD 500 spectrometers. All chemical shifts are given as δ-values in ppm relative to the residual 




C-NMR spectra were 












CDCl3 7.26 77.16 
[D]6-DMSO 2.50 39.52 
 
 
The detected resonance-multiplicities were described by the following abbreviations: s (singlet), d 
(doublet), t (triplet), q (quartet), hept (heptet), m (multiplet) or analogous representations. The 
coupling constants J are reported in Hertz (Hz). Analysis of the recorded spectra was carried out with 
MestReNova 10 software. 
 
Infrared Spectroscopy 
Infrared spectra were recorded at a BRUKER Alpha-P ATR FT-IR spectrometer. Liquid samples were 
measured as a film, solid samples neat. The analysis of the spectra was carried out using the software 
from BRUKER OPUS 6. The absorption is given in wave numbers (cm
−1
) and the spectra were recorded 
in the range of 4000–400 cm
‒1
. In situ-IR studies were performed on METTLER TOLEDO ReactIR™ 15 
with an iC IR 4.3 software. 
 
Mass Spectrometry 
Electron ionization (EI) and EI high resolution mass spectra (HR-MS) were measured on a time-of-
flight mass spectrometer AccuTOF from JOEL. Electrospray ionization (ESI) mass spectra were 
recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN, a quadrupole time-of-flight maXis 
from BRUKER DALTONIC or on a time-of-flight mass spectrometer microTOF from BRUKER 
DALTONIC. ESI-HRMS spectra were recorded on a BRUKER Apex IV or a BRUKER Daltonic 7T, 
fourier transform ion cyclotron resonance (FTICR) mass spectrometer. The ratios of mass to charge 









All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored under 
inert atmosphere (Ar or N2) according to the following standard procedures: 
1,2-Dichloroethane was dried over CaH2 for 8 h, degassed and distilled under reduced pressure.  
Dichloromethane was purified using a solvent purification system (SPS-800) from M. BRAUN. 
Diethyl ether was purified using a solvent purification system (SPS-800) from M. BRAUN. 
1,4-Dioxane was distilled from sodium benzophenone ketyl. 
1,1,1,3,3,3-Hexafluoropropan-2-ol was distilled from 3 Å molecular sieves. 
Methanol was stirred over magnesium turnings at 65 °C for 3 h prior to distillation from Mg(OMe)2. 
N-Methyl-2-pyrrolidone was stirred over CaH2 at 200 °C for 4 h and distilled under reduced 
pressure. 
Tetrahydrofuran was purified using a solvent purification system (SPS-800) from M. BRAUN. 
Toluene was purified using a solvent purification system (SPS-800) from M. BRAUN. 
2,2,2-Trifluoroethanol was stirred over CaSO4 and distilled under reduced pressure. 
Water was degassed by repeated Freeze-Pump-Thaw degassing procedure. 
 
Reagents 
Chemicals obtained from commercial sources with purity higher than 95% were used without further 













 and 2-phenylpyridines 1.
[183]
 
The following chemicals were kindly provided by the persons named below: 
Uttam Dhawa: 4-methoxy-1-(pyridin-2-yl)-1H-indole (105h) and 5-methoxy-(pyridin-2-yl)-1H-indole 
(105b). 
Weiping Liu: (E)-1-(4-methoxyphenyl)-N-(4-methoxyphenyl)ethan-1-imine (6c), (E)-1-(4-
fluorophenyl)-N-(4-methoxyphenyl)ethan-1-imine (6f), (E)-1-(4-bromophenyl)-N-(4-
methoxyphenyl)ethan-1-imine (6g) and (E)-1-(4-iodophenyl)-N-(4-methoxy-phenyl)ethan-1-imine 
(6h). 
Tjark Meyer: [RuCl2(p-cymene)(Ph2POH)] (124a), [RuCl2(p-cymene){(p-FC6H4)2POH}] (124b). 
Valentin Müller: 5-fluoro-1-(pyridin-2-yl)-1H-indole (105m) and 5-bromo-1-(pyridin-2-yl)-1H-indole 
(105c). 
Karsten Rauch: [RuCl2(p-cymene)]2 and [Ru(O2CMes)2(p-cymene)] (20). 
Svenja Warratz: [RuCl2(p-cymene)(t-BuPhPOH)] (124c) and [RuCl2(p-cymene)(o-Tol2POH)] (124g). 
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5.1.1 General Procedure A: Ruthenium(II)-PA-Catalyzed C–H Arylation  
A suspension of (E)-2-styrylpyridine 9 (0.50 mmol, 1.00 equiv), aryl bromide 2 (0.75 mmol, 
1.50 equiv), [RuCl2(p-cymene)(n-Bu2POH)] (124e) (11.7 mg, 25.0 μmol, 5.00 mol %) and K2CO3 
(138 mg, 1.00 mmol, 2.00 equiv) in PhMe (2.00 mL, 0.25 M) was stirred at 120 °C for 18 h. At 
ambient temperature, the mixture was diluted with EtOAc (5.0 mL), filtered over Celite and the 
solvents were removed in vacuo. Isolation by column chromatography on silica gel (n-hexane/EtOAc) 
yielded the corresponding products 10. 
 
5.1.2 General Procedure B: Cobalt(III)-Catalyzed C−H/C−C Functionalization 
A suspension of indole 105 (0.50 mmol, 1.00 equiv), vinylcyclopropanes 125 (0.60 mmol, 1.20 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10.0 mol %), AgSbF6 (34.4 mg, 100 µmol, 20.0 mol %) and 
NaOPiv (12.4 mg, 100 µmol, 20.0 mol %) in DCE (1.00 mL, 0.50 M) was stirred at 50 °C for 20 h. At 
ambient temperature, the solvent was removed in vacuo and the remaining residue was purified by 
column chromatography on silica gel (n-hexane/EtOAc) to yield the desired products 130. 
 
5.1.3 General Procedure C: Rhodium(III)-Catalyzed C−H/C−C Functionalization  
A suspension of indole 105 (0.25 mmol, 1.00 equiv), vinylcyclopropane 125 (0.30 mmol, 1.20 equiv), 
[Cp*Rh(CH3CN)3](SbF6)2 (19.7 mg, 25.0 µmol, 10.0 mol %) and NaOPiv (6.20 mg, 50.0 µmol, 
20.0 mol %) in DCE (1.00 mL, 0.25 M) was stirred at 50 °C for 20 h. At ambient temperature, the 
solvent was removed in vacuo and the remaining residue was purified by column chromatography on 
silica gel (n-hexane/EtOAc) to afford the desired products 130. 
 
5.1.4 General Procedure D: Cobalt(III)-Catalyzed Linear-selective C−H Alkylation  
A suspension of indole 105 (0.50 mmol, 1.00 equiv), alkene 143 (1.50 mmol, 3.00 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10.0 mol %) and AgSbF6 (34.4 mg, 100 µmol, 20.0 mol %) in 
DCE (1.00 mL, 0.50 M) was stirred at 120 °C for 20 h. At ambient temperature, the reaction mixture 
was diluted with EtOAc (5.0 mL) and the solvents were removed in vacuo. The remaining residue was 
purified by column chromatography on silica gel (n-hexane/EtOAc) to afford the desired products 144. 
 
5.1.5 General Procedure E: Cobalt(III)-Catalyzed Branched-Selective C−H Alkylation  
A suspension of indole 105 (0.50 mmol, 1.00 equiv), alkene 143 (1.50 mmol, 3.00 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10.0 mol %), AgSbF6 (34.4 mg, 100 µmol, 20.0 mol %) and 1-
AdCO2H (90.1 mg, 0.50 mmol, 1.00 equiv) in DCE (0.50 mL, 1.00 M) was stirred at 50 °C for 20 h. 
At ambient temperature, the reaction mixture was diluted with EtOAc (5.0 mL) and the solvents were 
removed in vacuo. The remaining residue was purified by column chromatography on silica gel (n-
hexane/EtOAc) to yield the desired products 145. 
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5.1.6 General Procedure F: Cobalt(III)-Catalyzed Allylative C−H/C–F 
Functionalization  
A suspension of indole 105 (0.50 mmol, 1.00 equiv), perfluoroalkylalkene 127 (0.60 mmol, 
1.20 equiv), [Cp*Co(CO)I2] (6.00 mg, 12.5 µmol, 2.5 mol %) and K2CO3 (69.1 mg, 0.50 mmol, 
1.00 equiv) in TFE (0.50 mL, 1.00 M) was stirred at 25 °C for 20 h. The mixture was diluted with 
EtOAc (5.0 mL), filtered over Celite and the solvents were removed in vacuo. Isolation by column 
chromatography on silica gel (n-hexane/EtOAc) afforded the desired products 158. 
 
5.1.7 General Procedure G: Cobalt(III)-Catalyzed Alkenylative C−H/C–F 
Functionalization  
A suspension of indole 105 (0.50 mmol, 1.00 equiv), 1,1-difluoroalkene 128 (0.75 mmol, 1.50 equiv), 
[Cp*Co(CO)I2] (6.00 mg, 12.5 µmol, 2.5 mol %) and K2CO3 (69.1 mg, 0.50 mmol, 1.00 equiv) in TFE 
(0.50 mL, 1.00 M) was stirred at 25 °C for 20 h. The mixture was diluted with EtOAc (5.0 mL), 
filtered over Celite and the solvents were removed in vacuo. Isolation by column chromatography on 
silica gel (n-hexane/EtOAc) afforded the desired products 159. 
 
5.1.8 General Procedure H: Manganese(I)-Catalyzed Allylative C−H/C−F 
Functionalization  
A suspension of ketimine 6 (0.50 mmol, 1.00 equiv), perfluoroalkylalkene 127 (1.50 mmol, 
3.00 equiv), [MnBr(CO)5] (13.7 mg, 10.0 mol %), NaOAc (16.4 mg, 40 mol %) and K2CO3 (104 mg, 
0.75 mmol, 1.50 equiv) in 1,4-dioxane (0.50 mL, 1.00 M) was stirred at 105 °C for 20 h. At ambient 
temperature, the mixture was diluted with EtOAc (5.0 mL), filtered over Celite and the solvents were 
removed in vacuo. The remaining residue was purified by column chromatography on silica gel (n-
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5.2 Ruthenium(II)-PA-Catalyzed C–H Arylation of (E)-2-Styrylpyridines  
5.2.1 Characterization Data 
 
 
(Z)-2-(2,2-Diphenylvinyl)pyridine (10aa): The general procedure A was followed using (E)-2-
styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 4-bromobenzene (2a) (118 mg, 0.75 mmol, 
1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 10aa (103 mg, 
80%) as a colorless solid.  
M.p.: 206 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.36–7.27 (m, 9H), 7.23–7.16 
(m, 2H), 7.14 (s, 1H), 6.97 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.65 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H).  
13
C-NMR (75 MHz, CDCl3): δ = 156.5 (Cq), 149.2 (CH), 145.8 (Cq), 142.6 (Cq), 139.8 (Cq), 135.3 
(CH), 130.2 (CH), 128.8 (CH), 128.7 (CH), 128.3 (CH), 128.1 (CH), 127.8 (CH), 127.7 (CH), 123.7 
(CH), 121.1 (CH). 
IR (ATR): 1583, 1560, 1506, 1488, 1219, 774, 762, 698, 552, 504 cm
–1
.  
MS (EI) m/z (relative intensity): 257 ([M]
+
, 40), 256 (100), 182 (10).  
HR-MS (ESI): m/z calcd. for [C19H16N]
+
 [M + H]
+
 258.1277, found 258.1280.  





(Z)-2-[2-(4-Methoxyphenyl)-2-phenylvinyl]pyridine (10ab): The general procedure A was followed 
using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 4-bromoanisole (2b) (140 mg, 
0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 10ab 
(138 mg, 96%) as a pale yellow solid.   
M.p.: 111 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 7.39–7.29 (m, 6H), 7.16–7.08 
(m, 3H), 7.04–6.96 (m, 1H), 6.92–6.85 (m, 2H), 6.76 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 3.83 (s, 3H).  




C-NMR (75 MHz, CDCl3): δ = 159.1 (Cq), 156.7 (Cq), 149.0 (CH), 145.6 (Cq), 142.7 (Cq), 135.3 
(CH), 131.9 (Cq), 131.3 (CH), 128.1 (CH), 128.0 (CH), 127.8 (CH), 127.8 (CH), 123.7 (CH), 121.0 
(CH), 114.0 (CH), 55.3 (CH3).  
IR (ATR): 3054, 1603, 1508, 1465, 1244, 1026, 827, 773, 762, 540 cm
–1
.  
MS (EI) m/z (relative intensity): 287 ([M]
+
, 40), 286 (100), 271 (10), 243 (20).  
HR-MS (ESI): m/z calcd. for [C20H18NO]
+
 [M + H]
+
 288.1383, found 288.1391.  






(Z)-N,N-dimethyl-4-[1-phenyl-2-(pyridin-2-yl)vinyl]aniline (10ac): The general procedure A was 
followed using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 4-bromo-N,N-
dimethylaniline (2c) (150 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 10ac (141 mg, 94%) as a yellow solid.  
M.p.: 102 °C. 
1
H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.43–7.21 (m, 6H), 7.09–7.02 
(m, 2H), 7.01 (s, 1H), 6.97 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 6.87 (ddd, J = 8.1, 8.1, 1.1 Hz, 1H), 6.72–
6.62 (m, 2H), 2.98 (s, 6H).
  
13
C-NMR (75 MHz, CDCl3): δ = 157.3 (Cq), 149.9 (Cq), 149.1 (CH), 146.1 (Cq), 143.5 (Cq), 135.2 
(CH), 131.1 (CH), 128.2 (CH), 128.1 (CH), 127.9 (CH), 127.6 (CH), 127.4 (Cq), 123.7 (CH), 120.8 
(CH), 112.2 (CH), 40.3 (CH3). 
IR (ATR): 3046, 1603, 1577, 1558, 1519, 1431, 946, 766, 512 cm
–1
.  
MS (EI) m/z (relative intensity): 300 ([M]
+
, 60), 299 (100), 283 (10), 149 (10).  
HR-MS (ESI): m/z calcd. for [C21H21N2]
+
 [M + H]
+




(Z)-2-[2-(4-Methylphenyl)-2-phenylvinyl]pyridine (10ad): The general procedure A was followed 
using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 4-bromotoluene (2d) (128 mg, 
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0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 10ad 
(126 mg, 93%) as a yellow solid.  
M.p.: 86 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.54 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.37–7.25 (m, 6H), 7.16–7.08 
(m, 5H), 6.97 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.72 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 2.39 (s, 3H).  
13
C-NMR (75 MHz, CDCl3): δ = 156.8 (Cq), 149.2 (CH), 145.8 (Cq), 142.8 (Cq), 137.5 (Cq), 132.8 
(Cq), 135.2 (CH), 130.0 (CH), 129.4 (CH), 128.4 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH), 123.4 
(CH), 121.0 (CH), 21.3 (CH3).  
IR (ATR): 3051, 1583, 1459, 775, 762, 697, 589, 521, 404 cm
–1
.  
MS (EI) m/z (relative intensity): 271 ([M]
+
, 45), 270 (100), 254 (15), 127 (10).  
HR-MS (ESI): m/z calcd. for [C20H18N]
+
 [M + H]
+
 272.1434, found 272.1436.  






(Z)-2-[2-(4-Fluorophenyl)-2-phenylvinyl]pyridine (10ae): A modified general procedure A was 
followed at 140 °C using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 1-bromo-4-
fluorobenzene (2e) (131 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 10ae (127 mg, 92%) as a pale yellow solid.  
M.p.: 95 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.42–7.28 (m, 6H), 7.21–7.12 
(m, 3H), 7.09–6.98 (m, 3H), 6.71 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H). 
 13
C-NMR (75 MHz, CDCl3): δ = 162.5 (d, 
1
JC‒F = 249 Hz, Cq), 156.5 (Cq), 149.5 (CH), 144.8 (Cq), 
142.5 (Cq), 135.8 (Cq), 135.5 (CH), 132.0 (CH, d, 
3
JC‒F = 8.0 Hz), 129.0 (CH), 128.4 (CH), 128.2 
(CH), 127.8 (CH), 123.8 (CH), 121.3 (CH), 115.8 (CH, d, 
2
JC‒F = 21.4 Hz).  
19
F-NMR (282 MHz, CDCl3): δ  = –114.0 (tt, J = 8.7, 5.5 Hz).  
IR (ATR): 1584, 1560, 1505, 1445, 1219, 1156, 760, 745, 588, 522 cm
–1
.  
MS (EI) m/z (relative intensity): 275 ([M]
+
, 40), 274 (100).  
HR-MS (ESI): m/z calcd. for [C19H15FN]
+
 [M + H]
+ 
276.1183, found 276.1187.  









(Z)-2-{2-[4-(Trifluoromethyl)phenyl]-2-phenylvinyl}pyridine (10af): A modified general procedure 
A was followed at 140 °C using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.50 equiv) and 1-
bromo-4-(trifluoromethyl)benzene (2f) (169 mg, 0.75 mmol, 1.50 equiv). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 10af (115 mg, 71%) as a pale yellow solid.  
M.p.: 75 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.60 (d, J = 7.9 Hz, 2H), 7.41–
7.27 (m, 8H), 7.20 (s, 1H), 7.03 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.72 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H). 
 13
C-NMR (75 MHz, CDCl3): δ = 158.8 (Cq), 149.4 (CH), 144.2 (Cq) 143.9 (Cq), 141.9 (Cq), 135.5 
(CH), 130.5 (CH), 129.9 (q, 
2
JC‒F = 32.8 Hz, Cq), 129.4 (CH), 128.3 (CH), 128.3 (CH), 127.7 (CH), 
125.5 (q, 
3
JC‒F = 3.7 Hz, CH), 124.1 (q, 
1
JC‒F = 274 Hz, Cq), 123.8 (CH), 121.5 (CH).  
19
F-NMR (282 MHz, CDCl3): δ  = –62.5 (m).  
IR (ATR): 3059, 1583, 1459, 1314, 1152, 1106, 1062, 1017, 742, 718 cm
–1
.  
MS (EI) m/z (relative intensity): 325 ([M]
+
, 40), 324 (100).  








Ethyl (Z)-4-[1-phenyl-2-(pyridin-2-yl)vinyl]benzoate (10ag): The general procedure A was 
followed using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and ethyl 4-bromobenzoate 
(2g) (172 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 10ag (143 mg, 87%) as a yellow solid.  
M.p.: 144 °C.  
1
H-NMR (500 MHz, CDCl3): δ = 8.50 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.04–7.96 (m, 2H), 7.32–7.25 
(m, 6H), 7.29–7.25 (m, 2H), 7.17 (s, 1H), 6.99 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.71 (ddd, J = 8.1, 1.1, 
0.9 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). 
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 13
C-NMR (125 MHz, CDCl3): δ = 166.4 (Cq), 156.0 (Cq), 149.4 (CH), 144.8 (Cq), 144.7 (Cq), 141.9 
(Cq), 135.5 (CH), 130.2 (CH), 129.9 (CH), 129.8 (Cq), 129.3 (CH), 128.3 (CH), 128.2 (CH), 127.7 
(CH), 123.8 (CH), 121.4 (CH), 61.0 (CH2), 14.3 (CH3).  
IR (ATR): 3053, 1708, 1604, 1560, 1462, 1273, 1178, 999, 776, 691 cm
–1
.  
MS (EI) m/z (relative intensity): 329 ([M]
+
, 40) 328 (100), 301 (70), 254 (30).  
HR-MS (ESI): m/z calcd. for [C22H20NO2]
+
 [M + H]
+ 




(Z)-1-{4-[1-phenyl-2-(pyridin-2-yl)vinyl]phenyl}ethan-1-one (10ah): A modified general procedure 
A was followed at 140 °C using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 1-(4-
bromophenyl)ethan-1-one (2h) (148 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography 
(n-hexane/EtOAc: 20/1) yielded 10ah (130 mg, 87%) as a pale yellow solid.  
M.p.: 97 °C. 
1
H-NMR (500 MHz, CDCl3): δ = 8.50 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.93–7.90 (m, 2H), 7.34–7.27 




C-NMR (125 MHz, CDCl3): δ = 197.7 (Cq), 156.0 (Cq), 149.4 (CH), 145.2 (Cq), 144.7 (Cq), 141.9 
(Cq), 136.3 (Cq), 135.5 (CH), 130.5 (CH), 129.4 (CH), 128.7 (CH), 128.4 (CH), 128.3 (CH), 127.7 
(CH), 123.9 (CH), 121.5 (CH), 26.6 (CH3). 
IR (ATR): 1681, 1583, 1264, 856, 747, 652, 599, 585 cm
–1
.  
MS (EI) m/z (relative intensity): 299 ([M]
+
, 40), 298 (100), 254 (200).  
HR-MS (ESI): m/z calcd. for [C21H18NO]
+
 [M + H]
+ 
300.1383, found 300.1386.  





(Z)-2-[2-(3-Methoxyphenyl)-2-phenylvinyl]pyridine (10ai): The general procedure A was followed 
using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 3-bromoanisole (2i) (140 mg, 
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0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 10ai 
(115 mg, 80%) as a pale yellow solid.  
M.p.: 108 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.41‒7.34 (m, 2H), 7.32–7.22 
(m, 5H), 7.15 (s, 1H), 6.97 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 6.89 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.79 
(ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 6.75‒6.69 (m, 1H), 3.70 (s, 3H).
  
13
C-NMR (75 MHz, CDCl3): δ = 159.9 (Cq), 156.5 (Cq), 149.2 (CH), 145.5 (Cq), 142.2 (Cq), 141.2 
(Cq), 135.3 (CH), 129.8 (CH), 128.6 (CH), 128.2 (CH), 128.0 (CH), 127.6 (CH), 123.6 (CH), 122.5 
(CH), 121.2 (CH), 115.1 (CH), 113.7 (CH), 55.2 (CH3).  
IR (ATR): 3051, 1580, 1485, 1461, 1430, 1229, 1041, 872, 742, 551 cm
–1
.  
MS (EI) m/z (relative intensity): 287 ([M]
+
, 20), 286 (100), 271 (10), 243 (20).  
HR-MS (ESI): m/z calcd. for [C20H18NO]
+
 [M + H]
+ 




(Z)-2-[2-(2-Methoxyphenyl)-2-phenylvinyl]pyridine (10aj): A modified general procedure A was 
followed at 140 °C in PhMe (0.50 mL, 1.00 M) using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 
1.00 equiv) and 2-bromoanisole (2j) (140 mg, 0.75 mmol, 1.50 equiv). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 10aj (116 mg, 81%) as a pale yellow solid.  
M.p.: 114 °C.  
1
H-NMR (500 MHz, CDCl3): δ = 8.51 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.38‒7.33 (m, 3H), 7.30‒7.23 




C-NMR (125 MHz, CDCl3): δ = 157.3 (Cq), 156.6 (Cq), 149.1 (CH), 142.1 (Cq), 141.8 (Cq), 135.3 
(CH), 131.2 (CH), 129.3 (CH), 129.3 (CH), 128.7 (Cq), 128.1 (CH), 127.6 (CH), 126.7 (CH), 122.7 
(CH), 121.1 (CH), 121.0 (CH), 111.5 (CH), 55.6 (CH3).  
IR (ATR): 3056, 1582, 1490, 1461, 1433, 1247, 1160, 1047, 756, 695 cm
–1
.  
MS (EI) m/z (relative intensity): 287 ([M]
+
, 20), 270 (10), 257 (30), 256 (100).  
HR-MS (ESI): m/z calcd. for [C20H18NO]
+
 [M + H]
+ 
288.1383, found 288.1385.  
 




(Z)-2-[2-Phenyl-2-(thiophen-3-yl)vinyl]pyridine (10al): The general procedure A was followed 
using (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) and 3-bromothiophene (9l) (122 mg, 
0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 10al 
(114 mg, 87%, Z/E = 96:4) as a pale brown solid.  
M.p.: 87 °C.  
1
H-NMR (500 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.40‒7.34 (m, 4H), 7.33‒7.27 
(m, 3H), 7.10 (s, 1H), 7.07 (dd, J = 3.0, 1.3 Hz, 1H), 7.01 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.87 (dd, 
J = 4.9, 1.3 Hz, 1H), 6.80 (dd, J = 8.1, 1.1, 0.9 Hz, 1H).  
13
C-NMR (125 MHz, CDCl3): δ = 156.6 (Cq), 149.2 (CH), 142.2 (Cq), 140.4 (Cq), 139.8 (Cq), 135.4 
(CH), 129.2 (CH), 129.1 (CH), 128.2 (CH), 128.1 (CH), 127.6 (CH), 125.7 (CH), 125.1 (CH), 123.5 
(CH), 121.3 (CH).  
IR (ATR): 3049, 1582, 1560, 1461, 1431, 863, 760, 743, 701 cm
–1
.  
MS (EI) m/z (relative intensity): 263 ([M]
+
, 40), 262 (100), 230 (25), 186 (25).  








(Z)-2-[2-(4-Methoxyphenyl)-2-(p-tolyl)vinyl]pyridine (10bb): The general procedure A was 
followed using (E)-2-(4-methylstyryl)pyridine (9b) (97.7 mg, 0.50 mmol, 1.00 equiv) and 4-
bromoanisole (2b) (140 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 10bb (136 mg, 90%) as a colorless solid.  
M.p.: 69 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.51 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.31‒7.26 (m, 1H), 7.25‒7.22 
(m, 2H), 7.14‒7.07 (m, 4H), 7.06 (s, 1H), 6.95 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.88‒6.82 (m, 2H), 6.72 
(ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 3.82 (s, 3H), 2.84 (s, 3H).  




C-NMR (75 MHz, CDCl3): δ  = 159.2 (Cq), 157.0 (Cq), 149.2 (CH), 145.4 (Cq), 140.0 (Cq), 137.9 
(Cq), 135.2 (CH), 132.2 (Cq), 131.3 (CH), 128.9 (CH), 127.7 (CH), 127.5 (CH), 123.6 (CH), 120.8 
(CH), 114.6 (CH), 55.2 (CH3), 21.1 (CH3).  
IR (ATR): 3051, 1581, 1507, 1460, 1181, 1024, 848, 824, 745, 531 cm
–1
.  
MS (EI) m/z (relative intensity): 301 ([M]
+
, 40), 300 (100), 257 (20).  
HR-MS (ESI): m/z calcd. for [C21H20NO]
+
 [M + H]
+ 




(Z)-2-{2-(p-Tolyl)-2-[4-(trifluoromethyl)phenyl]vinyl}pyridine (10bf): The general procedure A 
was followed using (E)-2-(4-methylstyryl)pyridine (9b) (97.7 mg, 0.50 mmol, 1.00 equiv) and 1-
bromo-4-(trifluoromethyl)benzene (2f) (169 mg, 0.75 mmol, 1.50 equiv). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 10bf (144 mg, 85%) as an off-white solid. 
M.p.: 89 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.50 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.61‒7.54 (m, 2H), 7.34‒7.28 
(m, 3H), 7.21‒7.16 (m, 2H), 7.15 (s, 1H), 7.14‒7.10 (m, 2H), 7.00 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.67 
(ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 2.35 (s, 3H). 
13
C-NMR (125 MHz, CDCl3): δ = 156.0 (Cq), 149.3 (CH), 144.3 (Cq), 144.0 (Cq), 139.0 (Cq), 138.4 
(Cq), 135.5 (CH), 130.6 (CH), 129.8 (q, 
2
JC–F = 32.4 Hz, Cq), 129.1 (CH), 128.6 (CH), 127.6 (CH), 
125.5 (q, 
3
JC–F = 3.8 Hz, CH), 124.0 (q, 
1
JC–F = 271 Hz, Cq), 123.7 (CH), 121.4 (CH), 21.1 (CH3).  
19
F-NMR (282 MHz, CDCl3): δ  = –62.5 (m). 
IR (ATR): 3071, 1582, 1460, 1407, 1321, 1161, 1065, 856, 837 cm
–1
.  
MS (EI) m/z (relative intensity): 339 ([M]
+
, 35), 338 (100), 268 (10).  
HR-MS (ESI): m/z calcd. for [C21H17F3N]
+
 [M + H]
+ 









(Z)-Ethyl-4-[2-(pyridin-2-yl)-1-(p-tolyl)vinyl]benzoate (10bg): The general procedure A was 
followed using (E)-2-(4-methylstyryl)pyridine (9b) (97.7 mg, 0.50 mmol, 1.00 equiv) and ethyl 4-
bromobenzoate (2g) (172 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 10bg (149 mg, 87%) as yellow solid. 
M.p.: 72 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.50 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.03‒7.96 (m, 2H), 7.30‒7.24 
(m, 3H), 7.22‒7.17 (m, 2H), 7.15 (s, 1H), 7.13‒7.08 (m, 2H), 6.97 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 6.66 
(ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 4.37 (q, J = 7.3 Hz, 2H), 2.35 (s, 3H), 1.39 (t, J = 7.3 Hz, 3H). 
13
C-NMR (125 MHz, CDCl3): δ = 166.4 (Cq), 156.2 (Cq), 149.3 (CH), 145.0 (Cq), 144.7 (Cq), 139.0 
(Cq), 138.2 (Cq), 135.4 (CH), 130.2 (CH), 129.8 (CH), 129.7 (Cq), 129.1 (CH), 128.4 (CH), 127.6 
(CH), 123.7 (CH), 121.3 (CH), 61.0 (CH2), 21.1 (CH3), 14.3 (CH3).  
IR (ATR): 2980, 1709, 1581, 1460, 1268, 1099, 813, 772, 746 cm
–1
.  
MS (EI) m/z (relative intensity): 343 ([M]
+
, 40), 342 (100), 314 (65), 268 (15).  
HR-MS (ESI): m/z calcd. for [C23H22NO2]
+
 [M + H]
+ 




2-[2,2-Bis(4-methoxyphenyl)vinyl]pyridine (10cb): The general procedure A was followed using 
(E)-2-(4-methoxystyryl)pyridine (9c) (106 mg, 0.50 mmol, 1.00 equiv) and 4-bromoanisole (2b) 
(140 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 10cb (147 mg, 93%) as a colorless solid.  
M.p.: 89 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.49 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.32‒7.22 (m, 3H), 7.12‒7.07 
(m, 2H), 7.01 (s, 1H), 6.93 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.87‒6.80 (m, 4H), 6.69 (ddd, J = 8.1, 1.1, 
0.9 Hz, 1H), 3.81 (s, 3H), 3.78 (s, 3H).  




C-NMR (125 MHz, CDCl3): δ = 159.7 (Cq), 159.3 (Cq), 157.2 (Cq), 149.2 (CH), 145.1 (Cq), 135.5 
(Cq), 135.2 (CH), 132.2 (Cq), 131.4 (CH), 129.1 (CH), 126.7 (CH), 123.5 (CH), 120.8 (CH), 114.1 
(CH), 113.6 (CH), 55.2 (CH3), 55.1 (CH3). 
IR (ATR): 2999, 1601, 1507, 1459, 1240, 1172, 1148, 826 cm
–1
.  
MS (EI) m/z (relative intensity): 317 ([M]
+
, 40), 316 (100), 273 (15).  
HR-MS (ESI): m/z calcd. for [C21H20NO2]
+
 [M + H]
+ 
318.1489, found 318.1489.  






(E)-2-{2-(4-Methoxyphenyl)-2-[4-(trifluoromethyl)phenyl]vinyl}pyridine (10cf): The general 
procedure A was followed using (E)-2-(4-methoxystyryl)pyridine (9c) (106 mg, 0.50 mmol, 
1.00 equiv) and 1-bromo-4-(trifluoromethyl)benzene (2f) (169 mg, 0.75 mmol, 1.50 equiv). Isolation 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 10cf (149 mg, 84%) as a white solid.  
M.p.: 83 °C. 
1
H-NMR (500 MHz, CDCl3): δ = 8.48 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.59–7.56 (m, 2H), 7.32–7.28 
(m, 3H), 7.25–7.21 (m, 2H), 7.11 (s, 1H), 6.96 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 6.86–6.82 (m, 2H), 6.65 
(ddd, J = 8.1, 1.0, 0.9 Hz, 1H), 3.78 (s, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 159.5 (Cq), 156.3 (Cq), 149.4 (CH), 144.1 (Cq), 143.8 (Cq), 135.4 
(CH), 134.3 (Cq), 130.6 (CH), 129.7 (q, 
2
JC‒F = 32.1 Hz, Cq), 128.9 (CH), 127.7 (CH), 125.4 (q, 
3
JC‒F = 
3.5 Hz, CH), 124.2 (q, 
1
JC‒F = 273 Hz, Cq), 123.6 (CH), 121.2 (CH), 113.8 (CH), 55.2 (CH3).  
19
F-NMR (282 MHz, CDCl3): δ = –62.3 (m).
  
IR (ATR): 2963, 1608, 1579, 1510, 1409, 1239, 1108, 993, 801, 557 cm
–1
.  
MS (EI) m/z (relative intensity): 355 ([M]
+
, 30), 354 (100), 311 (25).  
HR-MS (ESI): m/z calcd. for [C21H17F3NO]
+
 [M + H]
+ 
356.1257, found 356.1255. 
The spectral data are in accordance with those reported in the literature.
[36a] 
 




(Z)-2-[2-(4-Methoxyphenyl)-2-(4-trifluoromethyl)phenylvinyl]pyridine (10db): The general 
procedure A was followed using (E)-2-[4-(trifluoromethyl)styryl]pyridine (9d) (125 mg, 0.50 mmol, 
1.00 equiv) and 1-bromoanisole (2b) (140 mg, 0.75 mmol, 1.50 equiv). Isolation by column 




H-NMR (300 MHz, CDCl3): δ = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.56–7.54 (m, 2H), 7.47–7.44 
(m, 2H), 7.32 (ddd, J = 8.1, 7.5, 1.9 Hz, 1H),  7.11 (s, 1H), 7.10‒7.04 (m, 2H), 7.00 (ddd, J = 7.5, 4.9, 
1.1 Hz, 1H), 6.90–6.83 (m, 2H), 6.78 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 3.80 (s, 3H).  
13
C-NMR (75 MHz, CDCl3): δ = 159.5 (Cq), 156.3 (Cq), 149.4 (CH), 146.6 (Cq), 144.1 (Cq), 135.4 
(CH), 131.3 (CH), 131.1 (Cq), 130.1 (CH), 129.8 (q, 
2
JC‒F = 32.1 Hz, Cq), 128.1 (CH), 125.1 (q, 
3
JC‒F = 
3.5 Hz, CH), 124.1 (q, 
1
JC‒F = 273 Hz, Cq), 123.8 (CH), 121.5 (CH), 114.3 (CH), 55.2 (CH3).  
19
F-NMR (282 MHz, CDCl3): δ = –62.5 (m).
  
IR (ATR): 2963, 1608, 1579, 1510, 1409, 1239, 1108, 993, 801, 557 cm
–1
.  
MS (EI) m/z (relative intensity): 355 ([M]
+
, 30), 354 (100), 311 (25).  




355.1184, found 355.1187.  






2-{2,2-Bis[4-(trifluoromethyl)phenyl]vinyl}pyridine (10df): The general procedure A was followed 
using (E)-2-[4-(trifluoromethyl)styryl]pyridine (9d) (125 mg, 0.50 mmol, 1.00 equiv) and 1-bromo-4-
(trifluoromethyl)benzene (2f) (169 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography 
(n-hexane/EtOAc: 20/1) yielded 10df (151 mg, 77%) as a colorless solid.  
M.p.: 109 °C.  




H-NMR (300 MHz, CDCl3): δ = 8.52 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.67–7.59 (m, 4H), 7.47‒7.38 




C-NMR (75 MHz, CDCl3): δ = 155.3 (Cq), 149.6 (CH), 145.3 (Cq), 143.0 (Cq), 142.9 (Cq), 135.7 
(CH), 131.3 (CH), 130.5 (CH), 130.0 (q, 
2
JC‒F = 32.5 Hz, Cq), 130.0 (q, 
2
JC‒F = 32.5 Hz, Cq), 128.0 
(CH), 125.8 (q, 
3
JC‒F = 3.8 Hz, CH), 125.4 (q, 
3
JC‒F = 3.8 Hz, CH), 124.0 (CH), 123.9 (q, 
1
JC‒F = 
275 Hz, Cq), 123.8 (q, 
1
JC‒F = 275 Hz, Cq), 122.0 (CH). 
19
F-NMR (282 MHz, CDCl3): δ = –62.6 (m).  
IR (ATR): 1578, 1319, 1163, 1103, 1064, 1017, 837, 769, 739 cm
–1
.  
MS (EI) m/z (relative intensity): 393 ([M]
+
, 40), 392 (100), 322 (15), 248 (10).  
HR-MS (ESI): m/z calcd. for [C21H14F6N]
+
 [M + H]
+ 




(E)-1-{4-[2-(Pyridin-2-yl)-1-(4-(trifluoromethyl)phenyl)vinyl]phenyl}ethan-1-one (10dh): The 
general procedure A was followed using (E)-2-[4-(trifluoromethyl)styryl]pyridine (9d) (125 mg, 
0.50 mmol, 1.00 equiv) and 1-(4-bromophenyl)ethan-1-one (2h) (148 mg, 0.75 mmol, 1.50 equiv). 
Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 10dh (143 mg, 78%) as a 
colorless solid.  
M.p.: 101 °C.  
1
H-NMR (300 MHz, CDCl3): δ = 8.52 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.96‒7.90 (m, 2H), 7.57–7.54 
(m, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.34 (ddd, J = 8.1, 7.5, 1.9 Hz, 1H), 7.30‒7.25 (m, 2H), 7.21 (s, 
1H), 7.03 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.73 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 2.63 (s, 3H).  
13
C-NMR (75 MHz, CDCl3): δ = 197.6 (Cq), 155.4 (Cq), 149.5 (CH), 146.3 (Cq), 144.3 (Cq), 143.3 
(Cq), 136.6 (CH), 135.7 (Cq), 131.2 (CH), 130.4 (CH), 130.3 (q, 
2
JC‒F = 32.5 Hz, Cq), 128.8 (CH), 
128.0 (CH), 125.3 (q, 
3
JC‒F = 3.8 Hz, CH), 124.1 (q, 
1
JC‒F = 270 Hz, Cq), 124.0 (CH), 121.9 (CH), 26.6 
(CH3). 
19
F-NMR (282 MHz, CDCl3): δ = –62.6 (m).
  
IR (ATR): 1672, 1322, 1268, 1162, 1136, 1109, 1017, 834, 740, 607 cm
–1
.  
MS (EI) m/z (relative intensity): 367 ([M]
+
, 30), 366 (100), 322 (15).  
HR-MS (ESI): m/z calcd. for [C22H17F3NO]
+
 [M + H]
+ 
368.1257, found 368.1259. 
 




(Z)-2-[1-(4-Methoxyphenyl)-1-(p-tolyl)prop-1-en-2-yl]pyridine (10eb): A modified general 
procedure A was followed at 140 °C in PhMe (0.50 mL, 1.00 M) using (E)-2-[1-(4-
methylphenyl)prop-1-en-2-yl]pyridine (9e) (113 mg, 0.50 mmol, 1.00 equiv) and 4-bromoanisole (2b) 
(140 mg, 0.75 mmol, 1.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 10eb (82.0 mg, 52%, Z/E = 12:1) as a pale red solid.  
M.p.: 105 °C.  
1
H-NMR (500 MHz, CDCl3): δ = 8.55 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.30 (ddd, J = 8.1, 7.5, 1.9 Hz, 
1H), 7.15‒7.12 (m, 4H), 6.97 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 6.86 (ddd, J = 8.1, 1.1, 0.9 Hz, 1H), 
6.78‒6.72 (m, 2H), 6.59‒6.54 (m, 2H), 3.68 (s, 3H), 2.35 (s, 3H), 2.20 (s, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 162.6 (Cq), 158.0 (Cq), 148.9 (CH), 140.7 (Cq), 140.3 (Cq), 136.4 
(Cq), 135.4 (Cq), 134.8 (Cq), 131.8 (CH), 129.8 (CH), 129.7 (CH), 128.7 (CH), 125.4 (CH), 120.8 
(CH), 113.0 (CH), 55.0 (CH3), 21.5 (CH3), 21.2 (CH3).  
IR (ATR): 3050, 1580, 1505, 1460, 1289, 1239, 1175, 746, 572 cm
–1
.  
MS (EI) m/z (relative intensity): 315 ([M]
+
, 40), 314 (100), 300 (10), 206 (10).  
HR-MS (ESI): m/z calcd. for [C22H22NO]
+
 [M + H]
+
 316.1696, found 316.1697. 
 
5.2.2 Mechanistic Studies 
5.2.2.1 Experiments with Radical Scavengers  
A suspension of (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv), 4-bromoanisole (2b) 
(140 mg, 0.75 mmol, 1.50 equiv), [RuCl2(p-cymene)(n-Bu2POH)] (124e) (11.7 mg, 25.0 µmol, 
5.00 mol %), K2CO3 (138 mg, 1.00 mmol, 2.00 equiv), a radical scavenger (0.50 mmol, 1.00 equiv) 
and n-dodecane (25 µL) as the internal standard in PhMe (2.00 mL, 0.25 M) was heated at 120 °C for 
18 h. At ambient temperature, the conversion was measured by GC. 
 
5.2.2.2 KIE Studies 
Two parallel reactions of (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv) or [D]1-9a 
(91.5 mg, 0.50 mmol, 1.00 equiv), 4-bromoanisole (2b) (140 mg, 0.75 mmol), [RuCl2(p-cymene)(n-
Bu2POH)] (124e) (11.7 mg, 25.0 µmol, 5.0 mol %), K2CO3 (138 mg, 1.00 mmol) and n-dodecane 
(25 µL) in PhMe (2.0 mL) were placed in a 25 mL Schlenk tube, equipped with the sensor of a 
ReactIR™ 15 machine, and heated at 120 °C under nitrogen atmosphere. The KIE was determined by 
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following the corresponding initial reaction rates, which were obtained by integration of the 




5.2.2.3 Hammett Plot Analyses 
5.2.2.3.1 Hammett Plot with (E)-2-styrylpyridine (9a) 
A suspension of (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 1.00 equiv), p-X-C6H4Br   2 
(0.75 mmol, 1.50 equiv), [RuCl2(p-cymene)(n-Bu2POH)] (124e) (11.7 mg, 25.0 µmol, 5.00 mol %), 
K2CO3 (138 mg, 1.00 mmol, 2.00 equiv) and n-dodecane (25 µL) in PhMe (2.0 mL, 0.25 M) was 
stirred at 120 °C. Periodic aliquots (25 μL) were removed by a syringe and the conversions were 
analyzed by GC up to ca. 10–20% conversion.  
 
Table 27. Reaction rates kX and σp-values for the Hammett plot analysis with aryl bromides 2.
Entry substituent X σp kX / μmol min
−1
 log (kX / kH) 
1 NMe2 ‒0.83 0.319 ‒0.340 
2 OMe ‒0.27 0.606 ‒0.062 
3 H 0 0.699 0 
4 Cl 0.23 0.630 ‒0.045 
5 CO2Et 0.45 0.579 ‒0.082 
6 CF3 0.54 0.557 ‒0.099 
 
5.2.2.4 Kinetic Order Analysis  
5.2.2.4.1 Kinetic reaction order with respect to the concentration of (E)-2-styrylpyridine (9a) 
The kinetic order with respect to the concentration of (E)-2-styrylpyridine (9a) was examined by 
applying the initial rate method. A suspension of 9a (0.500, 0.370, 0.250, 0.125 mmol), 4-
bromoanisole (2b) (140 mg, 0.75 mmol), [RuCl2(p-cymene)(n-Bu2POH)] (124e) (11.7 mg, 
25.0 µmol), K2CO3 (138 mg, 1.00 mmol) and n-dodecane (25 µL) in PhMe (2.0 mL) was stirred at 
120 °C. Periodic aliquots (25 μL) were removed by a syringe and analyzed by GC up to ca. 10–20% 
conversion. 
 
Table 28. Kinetic reaction order with respect to the concentration of 9a.
Entry c / mol L
−1




log (c / mol L
−1





1 0.250 3.319 0.602 ‒3.479 
2 0.185 2.500 0.733 ‒3.602 
3 0.125 1.841 ‒0.903 ‒3.735 
4 0.063 0.989 ‒1.200 ‒4.004 
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5.2.2.4.2 Kinetic reaction order with respect to the concentration of 4-bromoanisole (2b) 
The kinetic order with respect to the concentration of 4-bromoanisole (2b) was examined by the initial 
rate method. A suspension of (E)-2-Styrylpyridine (9a) (90.5 mg, 0.50 mmol), 4-bromoanisole (2b) 
(4.00, 2.00, 0.600, 0.250, 0.125 mmol), [RuCl2(p-cymene)(n-Bu2POH)] (124e) (11.7 mg, 25.0 µmol), 
K2CO3 (138 mg, 1.00 mmol) and n-dodecane (25 µL) in PhMe (2.0 mL) was stirred at 120 °C. 
Periodic aliquots (25 μL) were removed by a syringe and analyzed by GC up to ca. 10–20% 
conversion. 
 
Table 29. Kinetic reaction order with respect to the concentration of 2b.  
Entry c / mol L
−1




log (c / mol L
−1





1 2.000 2.937 0.301 ‒3.532 
2 1.000 2.831 0 ‒3.548 
3 0.300 2.483 ‒0.523 ‒3.605 
4 0.125 2.023 ‒0.903 ‒3.694 
5 0.063 1.469 ‒1.201 ‒3.833 
 
5.2.2.4.3 Kinetic reaction order with respect to concentration of [RuCl2(p-cymene)(n-
Bu2POH)] (124e) 
The kinetic order with respect to the concentration of [RuCl2(p-cymene)(n-Bu2POH)] (124e) was 
examined by the initial rate method. A suspension of (E)-2-styrylpyridine (9a) (90.5 mg, 0.50 mmol, 
1.00 equiv), 4-bromoanisole (2b) (140 mg, 0.75 mmol, 1.50 equiv), [RuCl2(p-cymene)(n-Bu2POH)] 
(124e) (1.25, 2.50, 3.50, 5.00 mol %), K2CO3 (138 mg, 1.00 mmol, 1.00 equiv) and n-dodecane 
(25 µL) in PhMe (2.0 mL) was stirred at 120 °C. Periodic aliquots (25 μL) were removed by a syringe 
and analyzed by GC up to ca. 10–20% conversion. 
 
Table 30. Kinetic reaction order with respect to the concentration of 124e.
Entry c / mol L
−1




log (c / mol L
−1





1 1.25 0.697 0.097 ‒4.157 
2 2.50 1.560 0.398 ‒3.807 
3 3.50 2.565 0.544 ‒3.591 
4 5.00 3.319 0.699 ‒3.479 
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5.3 Cobalt(III)-Catalyzed C−H/C−C Functionalization  
5.3.1 Characterization Data 
 
(Z)-Dimethyl 2-{4-[1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130aa): The general 
procedure B was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded 130aa (176 mg, 93%, E/Z = 1:11) as a yellow oil. 
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.86 (ddd, J = 8.0, 7.6, 1.9 Hz, 
1H), 7.59‒7.53 (m, 1H), 7.46‒7.41 (m, 1H), 7.36–7.27 (m, 2H), 7.15–7.09 (m, 2H), 6.43 (d, J = 
0.7 Hz, 1H), 5.64 (dtt, J = 10.8, 7.2, 1.0 Hz, 1H), 5.40 (dtt, J = 10.8, 7.6, 1.0 Hz, 1H), 3.69 (s, 6H), 
3.65 (d, J = 7.2 Hz, 2H), 3.35 (t, J = 7.7 Hz, 1H), 2.62 (ddd, J = 7.7, 7.6, 1.0 Hz, 1.83H, Z), 2.54 (ddd, 
J = 7.7, 7.6, 1.0 Hz, 0.17H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 169.0 (Cq), 151.1 (Cq), 149.5 (CH), 139.2 (Cq), 138.1 (CH), 137.2 
(Cq), 128.8 (CH), 128.4 (Cq), 126.2 (CH), 121.9 (CH), 121.7 (CH), 120.8 (CH), 120.5 (CH), 119.9 
(CH), 109.9 (CH), 102.7 (CH), 52.5 (CH3), 51.5 (CH), 31.7 (CH2, E), 30.9 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z).  
IR (ATR): 1732, 1586, 1469, 1436, 1150, 745 cm
–1
.  
MS (EI) m/z (relative intensity): 378 ([M]
+
, 30), 247 (100), 219 (90), 206 (70).  




378.1574, found 378.1578.  
 
 
(Z)-Dimethyl 2-{4-[5-methoxy-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate  (130ba): 
The general procedure B was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (105b) (112 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ba (188 mg, 92%, E/Z = 
1:13) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.61 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.85 (ddd, J = 8.1, 7.5, 1.9 Hz, 
1H), 7.40 (ddd, J = 8.1, 1.0, 0.8 Hz, 1H), 7.26 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.24–7.20 (m, 1H), 7.01 
(d, J = 2.6 Hz, 1H), 6.76 (dd, J = 8.9, 2.6 Hz, 1H), 6.34 (d, J = 0.8 Hz, 1H), 5.61 (dtt, J = 10.7, 7.6, 
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1.5 Hz, 1H), 5.38 (dtt, J = 10.7, 7.7, 1.0 Hz, 1H), 3.82 (s, 3H), 3.68 (s, 6H), 3.58 (d, J = 7.6 Hz, 2H), 
3.34 (t, J = 7.7 Hz, 1H), 2.61 (ddd, J = 7.7, 7.6, 1.5 Hz, 1.86H, Z), 2.52 (ddd, J = 7.7, 7.6, 1.5 Hz, 
0.14H, E).  
13
C-NMR (125 MHz, CDCl3): δ  = 169.2 (Cq), 154.8 (Cq), 151.4 (Cq), 149.5 (CH), 139.8 (Cq), 138.2 
(CH), 132.4 (Cq), 129.1 (Cq), 129.0 (CH), 126.3 (CH), 121.7 (CH), 120.6 (CH), 111.3 (CH), 110.9 
(CH), 102.7 (CH), 102.1 (CH), 55.8 (CH3), 52.5 (CH3), 51.5 (CH), 31.7 (CH2, E), 30.6 (CH2, E), 26.7 
(CH2, Z), 25.9 (CH2, Z).  
IR (ATR): 1732, 1582, 1470, 1434, 1202, 1030, 839 cm
–1
.  
MS (EI) m/z (relative intensity): 408 ([M]
+
, 30), 277 (80), 249 (100), 236 (40).  








(Z)-Dimethyl 2-{4-[5-bromo-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130ca): The 
general procedure B was followed using 5-bromo-1-(pyridin-2-yl)-1H-indole (105c) (137 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ca (203 mg, 89%, E/Z = 1:9) 
as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.89 (ddd, J = 7.9, 7.5, 2.0 Hz, 
1H), 7.66‒7.63 (m, 1H), 7.39 (ddd, J = 7.9, 1.0, 0.8 Hz, 1H), 7.35–7.30 (m, 1H), 7.19–7.16 (m, 2H), 
6.34 (d, J = 0.8 Hz, 1H), 5.59 (dtt, J = 10.8, 7.6, 1.4 Hz, 1H), 5.39 (dtt, J = 10.8, 7.6, 1.2 Hz, 1H), 3.68 
(s, 6H), 3.60 (d, J = 7.6 Hz, 2H), 3.34 (t, J = 7.6 Hz, 1H), 2.58 (ddd, J = 7.6, 7.6, 1.4 Hz, 1.80H, Z), 
2.52 (ddd, J = 7.6, 7.6, 1.4 Hz, 0.20H, E).  
13
C-NMR (100 MHz, CDCl3): δ = 169.2 (Cq), 150.9 (Cq), 149.8 (CH), 140.7 (Cq), 138.5 (CH), 136.0 
(Cq), 130.2 (Cq), 128.5 (CH), 127.8 (CH), 124.6 (CH), 122.4 (CH), 121.0 (CH), 113.8 (Cq), 111.6 
(CH), 102.2 (CH), 95.7 (CH), 52.6 (CH3), 51.4 (CH), 31.6 (CH2, E), 30.8 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z).  
IR (ATR): 1731, 1586, 1470, 1435, 1148, 783, 734 cm
–1
.  




, 25), 325 (100), 297 (90), 286 (40), 245 (55).  






 456.0679, found 456.0689.  
 





(Z)-Dimethyl 2-{4-[5-iodo-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130da): The 
general procedure B was followed using 5-iodo-1-(pyridin-2-yl)-1H-indole (105d) (160 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130da (224 mg, 89%, E/Z = 
1:14) as a yellow oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.89 (ddd, J = 7.9, 7.5, 2.1 Hz, 
1H), 7.86 (d, J = 1.6 Hz, 1H), 7.39–7.30 (m, 3H), 7.08–7.04 (m, 1H), 6.32 (d, J = 0.8 Hz, 1H), 5.59 
(dtt, J = 10.8, 7.6, 1.4 Hz, 1H), 5.39 (dtt, J = 10.8, 7.4, 1.0 Hz, 1H), 3.68 (s, 6H), 3.58 (d, J = 7.6 Hz, 
2H), 3.33 (t, J = 7.5 Hz, 1H), 2.58 (ddd, J = 7.5, 7.4, 1.4 Hz, 1.87H, Z), 2.52 (ddd, J = 7.5, 7.4, 1.4 Hz, 
0.13H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 150.8 (Cq), 149.8 (CH), 140.3 (Cq), 138.5 (CH), 136.5 
(Cq), 130.9 (Cq), 130.0 (CH), 128.7 (CH), 128.4 (CH), 126.7 (CH), 122.4 (CH), 120.1 (CH), 112.1 
(CH), 101.9 (CH), 84.1 (Cq), 52.5 (CH3), 51.4 (CH), 31.7 (CH2, E), 30.8 (CH2, E), 26.7 (CH2, Z), 25.9 
(CH2, Z).  
IR (ATR): 1731, 1586, 1470, 1436, 1149, 784, 730 cm
–1
.  
MS (EI) m/z (relative intensity): 504 ([M]
+
, 40), 373 (100), 345 (95), 332 (30), 245 (45).  








(Z)-Dimethyl 2-{4-[5-nitro-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130ea): The 
general procedure B was followed using 5-nitro-1-(pyridin-2-yl)-1H-indole (105e) (120 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ea (187 mg, 88%, E/Z = 1:17) 
as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 8.48–8.43 (m, 1H), 8.00–7.91 
(m, 2H), 7.44–7.38 (m, 2H), 7.28–7.24 (m, 1H), 6.55 (d, J = 0.8 Hz, 1H), 5.59 (dtt, J = 10.8, 7.5, 
1.4 Hz, 1H), 5.43 (dtt, J = 10.8, 7.5, 1.0 Hz, 1H), 3.67 (s, 6H), 3.59 (d, J = 7.5 Hz, 1.89H, Z), 3.49 (d, 
J = 7.5 Hz, 0.11H, E), 3.35 (t, J = 7.7 Hz, 1H), 2.58 (ddd, J = 7.7, 7.5, 1.4 Hz, 2H).  
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13
C-NMR (125 MHz, CDCl3): δ  = 169.0 (Cq), 150.0 (Cq), 149.9 (CH), 142.8 (Cq), 142.3 (Cq), 140.1 
(Cq), 138.7 (CH), 127.7 (Cq), 127.6 (CH), 127.2 (CH), 123.1 (CH), 121.1 (CH), 117.3 (CH), 116.8 
(CH), 110.0 (CH), 104.0 (CH), 52.5 (CH3), 51.3 (CH), 31.5 (CH2, E), 30.9 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z).  
IR (ATR): 1732, 1587, 1511, 1436, 1326, 908, 727 cm
–1
.  
MS (EI) m/z (relative intensity): 423 ([M]
+
, 20), 292 (100), 264 (80), 251 (40), 205 (25).  




423.1425, found 423.1420. 
 
 
(Z)-Dimethyl 2-{4-[3-methyl-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130fa): The 
general procedure B was followed using 3-methyl-1-(pyridin-2-yl)-1H-indole (105f) (104 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (2a) (110 mg, 0.60 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 3/1) yielded 130fa (182 mg, 93%, E/Z = 1:5) as a 
yellow oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.61 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.85 (ddd, J = 8.0, 7.5, 2.0 Hz, 
1H), 7.54‒7.51 (m, 1H), 7.39 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 7.34‒7.25 (m, 2H), 7.15–7.10 (m, 2H), 
5.48 (dtt, J = 15.2, 7.6, 1.4 Hz, 0.17H, E), 5.34 (dtt, J = 10.6, 7.6, 1.4 Hz, 0.83H, Z), 5.18‒5.09 (m, 
1H), 3.70 (s, 5.02H, Z), 3.69 (d, J = 7.6 Hz, 2H), 3.63 (s, 0.98H, E), 3.25 (t, J = 7.6 Hz, 1H), 2.50 
(ddd, J = 7.6, 7.6, 1.4 Hz, 1.68H, Z), 2.42 (ddd, J = 7.6, 7.6, 1.4 Hz, 0.32H, E), 2.31 (s, 2.52H, Z), 2.27 
(s, 0.48H, E).  
13
C-NMR (125 MHz, CDCl3): δ  = 169.2 (Cq), 151.6 (Cq), 149.6 (Cq), 138.2 (CH), 136.5 (Cq), 134.7 
(CH), 129.8 (Cq), 129.3 (CH), 125.0 (CH), 121.9 (CH), 121.6 (CH), 121.0 (CH), 120.2 (CH), 118.2 
(Cq), 110.3 (CH), 109.8 (CH), 52.5 (CH3), 51.4 (CH), 31.6 (CH2, E), 28.0 (CH2, E), 26.7 (CH2, Z), 
23.5 (CH2, Z), 8.7 (CH3).  
IR (ATR): 1732, 1586, 1470, 1457, 1255, 1125, 1148, 738 cm
–1
.  
MS (EI) m/z (relative intensity): 392 ([M]
+
, 45), 261 (70), 233 (100), 220 (65).  













nate (130ga): The general procedure B was followed using methyl 2-(1-(pyridin-2-yl)-1H-indol-3-
yl)acetate (105g) (133 mg, 0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) 
(110 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ga 
(167 mg, 74%, E/Z = 1:11) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.86 (ddd, J = 8.0, 7.4, 2.0 Hz, 
1H), 7.60–7.57 (m, 1H), 7.40 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.31‒7.26 (m, 2H), 7.17‒7.11 (m, 2H), 
5.36 (dtt, J = 10.7, 7.6, 1.4 Hz, 1H), 5.16 (dtt, J = 10.7, 7.6, 1.4 Hz, 1H), 3.78 (s, 2H), 3.73 (d, J = 
7.6 Hz, 2H), 3.70 (s, 6H), 3.66 (s, 3H), 3.25 (t, J = 7.6 Hz, 1H), 2.46 (ddd, J = 7.6, 7.6, 1.4 Hz, 1.83H, 
Z), 2.40 (ddd, J = 7.6, 7.6, 1.4 Hz, 0.17H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 172.0 (Cq), 169.2 (Cq), 151.2 (Cq), 149.7 (CH), 138.3 (CH), 136.4 
(Cq), 129.2 (CH), 128.3 (CH), 125.4 (Cq), 122.2 (CH), 122.1 (Cq), 121.3 (CH), 120.7 (CH), 118.4 
(CH), 110.0 (CH), 107.5 (CH), 95.5 (Cq), 52.5 (CH3), 51.9 (CH3), 51.3 (CH), 31.5 (CH2, E), 30.3 
(CH2), 28.1 (CH2, E), 26.6 (CH2, Z), 23.6 (CH2, Z).  
IR (ATR): 1730, 1586, 1470, 1458, 1147, 731 cm
–1
.  
MS (EI) m/z (relative intensity): 450 ([M]
+
, 30) 319 (80), 291 (100), 259 (40), 245 (45), 219 (50).  








(Z)-Dimethyl 2-{4-[4-methoxy-1-(pyridin-2-yl)-1H-indol-2-yl}but-2-en-1-yl]malonate (130ha): 
The general procedure B was followed using 4-methoxy-1-(pyridin-2-yl)-1H-indole (105h) (112 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ha (157 mg, 77%, E/Z = 
1:13) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.61 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.85 (ddd, J = 8.1, 7.5, 2.0 Hz, 
1H), 7.41 (ddd, J = 8.1, 1.0, 0.8 Hz, 1H), 7.29 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.05–7.00 (m, 1H), 
6.94–6.92 (m, 1H), 6.54 (d, J = 7.9 Hz, 1H), 6.51 (d, J = 0.8 Hz, 1H), 5.61 (dtt, J = 10.8, 7.6, 1.4 Hz, 
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1H), 5.37 (dtt, J = 10.8, 7.7, 1.0 Hz, 1H), 3.93 (s, 3H), 3.68 (s, 6H), 3.61 (d, J = 7.6 Hz, 1.86H, Z), 
3.51 (d, J = 7.6 Hz, 0.14H, E), 3.34 (t, J = 7.7 Hz, 1H), 2.60 (ddd, J = 7.7, 7.7, 1.4 Hz, 1.86H, Z), 2.52 
(ddd, J = 7.7, 7.7, 1.4 Hz, 0.14H, E).  
13
C-NMR (125 MHz, CDCl3): δ  = 169.2 (Cq), 152.6 (Cq), 151.4 (Cq), 149.5 (CH), 139.6 (Cq), 138.2 
(CH), 137.7 (Cq), 128.8 (CH), 126.2 (CH), 122.5 (CH), 122.1 (CH), 121.0 (CH), 118.7 (Cq), 103.5 
(CH), 100.7 (CH), 99.8 (CH), 55.3 (CH3), 52.5 (CH3), 51.5 (CH), 31.6 (CH2, E), 30.7 (CH2, E), 26.7 
(CH2, Z), 25.9 (CH2, Z).  
IR (ATR): 1732, 1587, 1495, 1469, 1255, 1148, 765, 728 cm
–1
.  
MS (EI) m/z (relative intensity): 408 ([M]
+
, 45), 277 (60), 249 (100), 236 (30).  








(Z)-Dimethyl 2-{4-[6-(methoxycarbonyl)-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}-malonate  
(130ia): The general procedure B was followed using methyl 1-(pyridin-2-yl)-1H-indole-6-
carboxylate (105i) (126 mg, 0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) 
(110 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ia 
(183 mg, 84%, E/Z = 1:8) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 8.00–7.98 (m, 1H), 7.91 (ddd, J 
= 7.9, 7.5, 2.0 Hz, 1H), 7.80 (ddd, J = 8.2, 1.4, 0.8 Hz, 1H), 7.56–7.53 (m, 1H), 7.45 (dd, J = 7.9, 
1.0 Hz, 1H), 7.35–7.32 (m, 1H), 6.45 (d, J = 0.7 Hz, 1H), 5.61 (dtt, J = 10.8, 7.6, 1.5 Hz, 1H), 5.41 
(dtt, J = 10.8, 7.6, 1.0 Hz, 1H), 3.85 (s, 3H), 3.69 (s, 0.70H, E), 3.67 (s, 5.30H, Z), 3.64 (d, J = 7.6 Hz, 
2H), 3.34 (t, J = 7.7 Hz, 1H), 2.59 (ddd, J = 7.7, 7.6, 1.5 Hz, 1.77H, Z), 2.53 (ddd, J = 7.7, 7.6, 1.5 Hz, 
0.23H, E).  
13
C-NMR (125 MHz, CDCl3): δ  = 169.1 (Cq), 168.0 (Cq), 150.6 (Cq), 149.8 (CH), 143.0 (Cq), 138.7 
(CH), 136.7 (Cq), 132.2 (Cq), 128.2 (CH), 126.9 (CH), 123.4 (Cq), 122.6 (CH), 121.8 (CH), 121.2 
(CH), 119.5 (CH), 112.2 (CH), 102.9 (CH), 52.5 (CH3, Z), 52.4 (CH3, E), 51.8 (CH3, Z), 51.7 (CH3, 
E), 51.3 (CH, Z), 50.7 (CH, E), 31.6 (CH2, E), 30.8 (CH2, E), 26.7 (CH2, Z), 25.9 (CH2, Z).  
IR (ATR): 1731, 1710, 1587, 1470, 1434, 1233, 909, 725 cm
–1
.  
MS (EI) m/z (relative intensity): 436 ([M]
+
, 15), 305 (40), 277 (100), 265 (20).  




 436.1629, found 436.1630.  
 





(Z)-Dimethyl 2-{4-[7-ethyl-1-(pyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130ja): The 
general procedure B was followed using 7-ethyl-1-(pyridin-2-yl)-1H-indole (105j) (110 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ja (138 mg, 68%, E/Z = 1:8) 
as a yellow oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.64 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 7.84 (ddd, J = 8.0, 7.4, 2.0 Hz, 
1H), 7.42–7.38 (m, 2H), 7.33 (ddd, J = 7.7, 1.0, 0.9 Hz, 1H), 7.05 (dd, J = 7.6, 7.6 Hz, 1H), 6.94–6.91 
(m, 1H), 6.37 (d, J = 0.8 Hz, 1H), 5.61 (dtt, J = 10.8, 7.5, 1.4 Hz, 1H), 5.37 (dtt, J = 10.8, 7.5, 1.0 Hz, 
1H), 3.69 (s, 0.70H, E), 3.67 (s, 5.30H, Z), 3.33 (t, J = 7.5 Hz, 1H), 3.25 (d, J = 7.5 Hz, 2H), 2.25 
(ddd, J = 7.5, 7.5, 1.4 Hz, 2H), 2.14 (q, J = 7.7 Hz, 2H), 0.91 (t, J = 7.7 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 153.3 (Cq), 149.3 (CH), 140.0 (Cq), 137.8 (CH), 136.1 
(Cq), 129.3 (Cq), 128.7 (CH), 127.4 (Cq), 126.3 (CH), 124.1 (CH), 123.3 (CH), 122.2 (CH), 120.3 
(CH), 117.9 (CH), 102.0 (CH), 52.5 (CH3), 51.4 (CH), 31.6 (CH2, E), 30.7 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z), 24.8 (CH2), 14.5 (CH3).  
IR (ATR): 1733, 1584, 1436, 1150, 909, 729 cm
–1
.  
MS (EI) m/z (relative intensity): 406 ([M]
+
, 60), 275 (90), 247 (100), 234 (45), 219 (30). 








(Z)-Dimethyl 2-{4-[1-(5-methylpyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130ka): The 
general procedure B was followed using 1-(5-methylpyridin-2-yl)-1H-indole (105k) (104 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ka (159 mg, 81%, E/Z = 
1:14) as an orange oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.49 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.57–7.52 (m, 1H), 7.32–7.28 
(m, 1H), 7.26–7.22 (m, 1H), 7.13–7.08 (m, 3H), 6.40 (d, J = 0.7 Hz, 1H), 5.64 (dtt, J = 10.7, 7.5, 
1.4 Hz, 1H), 5.43–5.35 (m, 1H), 3.68 (s, 6H), 3.63 (d, J = 7.5 Hz, 2H), 3.35 (t, J = 7.7 Hz, 1H), 2.61 
(ddd, J = 7.7, 7.6, 1.4 Hz, 1.87H, Z), 2.54 (ddd, J = 7.7, 7.6, 1.4 Hz, 0.13H, E), 2.42 (s, 3H).  
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13
C-NMR (125 MHz, CDCl3): δ  = 169.2 (Cq), 151.3 (Cq), 149.8 (Cq), 149.2 (CH), 139.3 (Cq), 137.3 
(Cq), 129.0 (CH), 128.4 (Cq), 126.2 (CH), 123.1 (CH), 121.7 (CH), 121.6 (CH), 120.5 (CH), 119.9 
(CH), 110.0 (CH), 102.5 (CH), 52.4 (CH3), 51.4 (CH), 31.6 (CH2, E), 30.9 (CH2, E), 26.7 (CH2, Z), 
25.8 (CH2, Z), 21.0 (CH3). 
IR (ATR): 1732, 1603, 1457, 1433, 1151, 910, 729 cm
–1
.  
MS (EI) m/z (relative intensity): 392 ([M]
+
, 25), 261 (100), 233 (55), 220 (50).  








(Z)-Dimethyl 2-{4-[1-(4-methylpyridin-2-yl)-1H-indol-2-yl]but-2-en-1-yl}malonate (130la): The 
general procedure B was followed using 1-(4-methylpyridin-2-yl)-1H-indole (105l) (104 mg, 
0.50 mmol) and dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130la (180 mg, 92%, E/Z = 1:14) 
as an orange oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.46 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.55–7.52 (m, 1H), 7.33–7.30 
(m, 1H), 7.28–7.24 (m, 1H), 7.12–7.07 (m, 3H), 6.40 (d, J = 0.8 Hz, 1H), 5.63 (dtt, J = 10.7, 7.5, 
1.4 Hz, 1H), 5.43–5.35 (m, 1H), 3.68 (s, 6H), 3.63 (d, J = 7.5 Hz, 2H), 3.35 (t, J = 7.7 Hz, 1H), 2.60 
(ddd, J = 7.7, 7.7, 1.4 Hz, 1.87H, Z), 2.57 (ddd, J = 7.7, 7.7, 1.4 Hz, 0.13H, E),  2.44 (s, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 149.8 (CH), 148.8 (Cq), 139.2 (Cq), 138.8 (CH), 137.4 
(Cq), 131.8 (Cq), 128.9 (CH), 128.3 (Cq), 126.2 (CH), 121.6 (CH), 120.5 (CH), 120.4 (CH), 119.9 
(CH), 110.0 (CH), 102.2 (CH), 52.4 (CH3), 51.4 (CH), 31.7 (CH2, E), 30.9 (CH2, E), 26.7 (CH2, Z), 
25.9 (CH2, Z), 21.1 (CH3). 
IR (ATR): 1732, 1483, 1456, 1275, 1150, 1205, 785 cm
–1
.  
MS (EI) m/z (relative intensity): 392 ([M]
+
, 20), 261 (100), 233 (75), 220 (60).  














(130ab): The general procedure B was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.0 mg, 
0.50 mmol and 6,6-dimethyl-1-vinyl-5,7-dioxaspiro[2.5]octane-4,8-dione (125b) (118 mg, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ab (162 mg, 
83%, E/Z = 3.7:1) as an orange oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.85 (ddd, J = 8.0, 7.4, 2.0 Hz, 
1H), 7.57–7.52 (m, 1H), 7.40 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 7.33–7.27 (m, 2H), 7.12–7.07 (m, 2H), 
6.42 (d, J = 0.8 Hz, 1H), 5.72 (dtt, J = 15.2, 6.7, 1.2 Hz, 0.79H, E), 5.64 (dtt, J = 10.7, 7.2, 1.4 Hz, 
0.21H, Z), 5.50 (dtt, J = 10.7, 7.2, 1.6 Hz, 0.21H, Z), 5.42 (dtt, J = 15.2, 7.3, 1.2 Hz, 0.79H, E), 3.70 
(d, J = 7.2 Hz, 0.42H, Z), 3.55 (d, J = 6.7 Hz, 1.58H, E), 3.46 (t, J = 7.7 Hz, 1H), 2.74 (ddd, J = 7.7, 
7.2, 1.4 Hz, 2H), 1.71 (s, 6H).  
13
C-NMR (125 MHz, CDCl3): δ = 165.0 (Cq), 151.4 (Cq), 149.6 (CH), 139.2 (Cq), 138.3 (CH), 137.3 
(Cq), 131.5 (CH), 128.6 (Cq), 126.4 (CH), 122.2 (CH), 121.9 (CH), 121.0 (CH), 120.7 (CH), 120.1 
(CH), 110.1 (CH), 105.0 (Cq), 103.0 (CH), 46.3 (CH), 30.9 (CH2, E), 29.0 (CH2, E), 28.3 (CH3), 26.8 
(CH3), 26.5 (CH2, Z), 25.9 (CH2, Z). 
IR (ATR): 1782, 1743, 1586, 1469, 1284, 908, 727 cm
–1
.  
MS (EI) m/z (relative intensity): 390 ([M]
+
, 30), 287 (35), 259 (40), 247 (100), 219 (80), 206 (85).  









(130ab): The general procedure C was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.0 mg, 
0.50 mmol) and 6,6-dimethyl-1-vinyl-5,7-dioxaspiro[2.5]octane-4,8-dione (125b) (118 mg, 
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0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130ab (162 mg, 
83%, E/Z = 5.9:1) as an orange oil. 
1
H-NMR (500 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.85 (ddd, J = 8.0, 7.4, 2.0 Hz, 
1H), 7.57–7.52 (m, 1H), 7.40 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.33–7.27 (m, 2H), 7.12–7.07 (m, 2H), 
6.42 (d, J = 0.8 Hz, 1H), 5.72 (dtt, J = 15.2, 6.7, 1.2 Hz, 0.86H, E), 5.64 (dtt, J = 10.7, 7.2, 1.4 Hz, 
0.14H, Z), 5.50 (dtt, J = 10.7, 7.2, 1.6 Hz, 0.14H, Z), 5.42 (dtt, J = 15.2, 7.3, 1.2 Hz, 0.86H, E), 3.70 
(d, J = 7.2 Hz, 0.29H, Z), 3.55 (d, J = 6.7 Hz, 1.71H, E), 3.46 (t, J = 7.7 Hz, 1H), 2.74 (ddd, J = 7.7, 
7.2, 1.4 Hz, 2H), 1.71 (s, 6H).  
13
C-NMR (125 MHz, CDCl3): δ  = 165.0 (Cq), 151.4 (Cq), 149.6 (CH), 139.2 (Cq), 138.3 (CH), 137.3 
(Cq), 131.5 (CH), 128.6 (Cq), 126.4 (CH), 122.2 (CH), 121.9 (CH), 121.0 (CH), 120.7 (CH), 120.1 
(CH), 110.1 (CH), 105.0 (Cq), 103.0 (CH), 46.3 (CH), 30.9 (CH2, E), 29.0 (CH2, E), 28.3 (CH3), 26.8 
(CH3), 26.5 (CH2, Z), 25.9 (CH2, Z).  
IR (ATR): 1782, 1743, 1586, 1469, 1284, 908, 727 cm
–1
.  
MS (EI) m/z (relative intensity): 390 ([M]
+
, 30), 287 (35), 259 (40), 247 (100), 219 (80), 206 (85).  









dione (130mb): The general procedure B was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole 
(130m) (106 mg, 0.50 mmol) and 6,6-dimethyl-1-vinyl-5,7-dioxaspiro[2.5]octane-4,8-dione (125b) 
(118 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 130mb 
(165 mg, 81%, E/Z = 2.6:1) as an orange oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.85 (ddd, J = 8.0, 7.4, 2.0 Hz, 
1H), 7.42–7.27 (m, 2H), 7.24–7.14 (m, 2H), 6.82 (dt, J = 9.2, 2.6 Hz, 1H), 6.36 (d, J = 0.8 Hz, 1H), 
5.71 (dtt, J = 15.3, 6.9, 1.4 Hz, 0.72H, E), 5.65 (dtt, J = 10.6, 7.5, 1.4 Hz, 0.28H, Z), 5.54–5.37 (m, 
1H), 3.67 (d, J = 7.5 Hz, 0.56H, Z), 3.52 (d, J = 6.9 Hz, 1.44H, E), 3.47 (t, J = 7.7 Hz, 1H), 2.78 (ddd, 
J = 7.7, 7.6, 1.4 Hz, 0.55H, Z), 2.74 (ddd, J = 7.7, 7.6, 1.4 Hz, 1.45H, E), 1.75–1.64 (m, 6H).  
13
C-NMR (125 MHz, CDCl3): δ  = 165.0 (Cq), 158.5 (d, 
1
JC‒F = 236 Hz, Cq), 151.2 (Cq), 149.6 (CH), 
140.8 (Cq), 138.4 (CH), 133.9 (Cq), 131.2 (CH), 129.0 (d, 
3
JC‒F = 10.4 Hz, Cq), 126.7 (CH), 122.3 
(CH), 121.0 (CH), 120.7 (CH), 110.9 (d, 
3
JC‒F = 10.1 Hz, CH),  109.8 (d, 
2
JC‒F = 26.3 Hz, CH), 105.0 
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(Cq), 103.0 (d, 
4
JC‒F = 4.2 Hz, CH), 46.2 (CH), 30.9 (CH2, E), 29.0 (CH2, E), 28.3 (CH3), 26.8 (CH3), 
26.5 (CH2, Z), 25.9 (CH2, Z). 
19
F-NMR (282 MHz, CDCl3): δ = ‒124.0 (m).  
IR (ATR): 1782, 1745, 1585, 1469, 1288, 1174, 775, 729 cm
–1
.  
MS (EI) m/z (relative intensity): 408 ([M]
+
, 10) 324 (15), 305 (15), 277 (25), 265 (85), 237 (100), 224 
(80).  









indole-3-carboxylate (130nb): The general procedure B was followed using methyl 1-(pyridin-2-yl)-
1H-indole-3-carboxylate (130n) (126 mg, 0.50 mmol) and 6,6-dimethyl-1-vinyl-5,7-
dioxaspiro[2.5]octane-4,8-dione (125b) (118 mg, 0.60 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 3/1) yielded 130nb (168 mg, 75%, E/Z = 2.4:1) as an orange oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.68 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 8.17–8.12 (m, 1H), 7.91 (ddd, J 
= 8.0, 7.4, 2.0 Hz, 1H), 7.41–7.39 (m, 2H), 7.24 (ddd, J =  9.3, 6.8, 1.5 Hz, 1H), 7.18–7.10 (m, 2H), 
5.66 (dtt, J = 15.2, 7.4, 1.2 Hz, 0.71H, E), 5.50–5.42 (m, 0.58H, Z), 5.23 (dtt, J = 15.2, 7.2, 1.2 Hz, 
0.71H, E), 3.98 (s, 3H), 3.92 (d, J = 7.4 Hz, 2H), 3.72 (t, J = 7.5 Hz, 0.29H, Z), 3.44 (t, J = 7.5 Hz, 
0.71H, E), 2.64 (ddd, J = 7.5, 7.2, 1.2 Hz, 2H), 1.76‒1.60 (m, 6H).  
13
C-NMR (125 MHz, CDCl3): δ  = 166.1 (Cq), 165.2 (Cq, Z), 164.9 (Cq, E), 150.1 (CH), 150.0 (Cq), 
146.9 (Cq, Z), 146.0 (Cq, E), 138.7 (CH), 136.9 (Cq), 130.8 (CH), 126.6 (Cq), 126.3 (CH), 123.6 (CH), 
123.1 (CH), 122.6 (CH), 122.5 (CH), 121.8 (CH), 110.4 (CH), 106.0 (Cq), 104.9 (Cq), 50.6 (CH), 46.5 
(CH3, Z), 46.3 (CH3, E), 29.0 (CH2, E), 28.9 (CH2, E), 28.8 (CH3), 26.7 (CH3), 24.7 (CH2, Z), 23.8 
(CH2, Z). 
IR (ATR): 1746, 1694, 1537, 1457, 1283, 1189, 1099, 909, 727 cm
–1
.  
MS (EI) m/z (relative intensity): 448 ([M]
+
, 10), 364 (10), 305 (45), 277 (70), 264 (30), 245 (40).  













(Z)-Dimethyl 2-{4-[2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate (131aa): The general procedure 
B was followed using 2-phenylpyridine (1a) (77.6 mg, 0.50 mmol) and dimethyl 2-vinylcyclopropane-
1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 3/1) yielded 131aa (146 mg, 86%, E/Z = 1:9) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.68–8.63 (m, 1H), 7.73 (ddd, J = 8.0, 7.8, 1.9 Hz, 1H), 7.38–7.29 
(m, 3H), 7.29–7.20 (m, 3H), 5.59 (dtt, J = 15.1, 7.5, 1.4 Hz, 0.10H, E), 5.51 (dtt, J = 10.7, 7.5, 1.4 Hz, 
0.90H, Z), 5.32–5.20 (m, 1H), 3.69 (s, 5.40H, Z), 3.63 (s, 0.60H, E), 3.50 (d, J = 7.5 Hz, 1.80H, Z), 
3.50 (d, J = 7.5 Hz, 0.20H, E), 3.31 (t, J = 7.7 Hz, 1H), 2.56 (ddd, J = 7.7, 7.7, 1.4 Hz, 2H).  
13
C-NMR (100 MHz, CDCl3): δ  = 169.3 (Cq), 159.9 (Cq), 149.2 (CH), 140.3 (Cq), 138.3 (Cq), 136.2 
(CH), 131.8 (CH), 129.8 (CH), 129.6 (CH), 128.5 (CH), 126.2 (CH), 125.0 (CH), 124.2 (CH), 121.7 
(CH), 52.5 (CH3), 51.6 (CH), 31.0 (CH2), 26.7 (CH2).  
IR (ATR): 1732, 1586, 1435, 1231, 1196, 1150, 1024, 751 cm
–1
.  
MS (EI) m/z (relative intensity): 339 ([M]
+
, 15), 308 (100).  








(Z)-Dimethyl 2-{4-[5-methoxy-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate (131ba): The 
general procedure B was followed using 2-(4-methoxyphenyl)pyridine (1b) (92.5 mg, 0.50 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded 131ba (138 mg, 75%, E/Z = 1:4) as a colorless oil.  
1
H-NMR (600 MHz, CDCl3): δ = 8.68–8.63 (m, 1H), 7.69 (ddd, J = 8.0, 7.6, 1.9 Hz, 1H), 7.34–7.27 
(m, 2H), 7.18 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 6.82–6.75 (m, 2H), 5.58 (dtt, J = 15.8, 7.4, 1.2 Hz, 
0.20H, E), 5.51 (dtt, J = 10.7, 7.6, 1.2 Hz, 0.80H, Z), 5.32–5.24 (m, 1H), 3.80 (s, 3H), 3.68 (s, 4.80H, 
Z), 3.65 (s, 1.20H, E), 3.51 (d, J = 7.4 Hz, 1.59H, Z), 3.39 (d, J = 7.4 Hz, 0.41H, E), 3.31 (t, J = 
7.7 Hz, 1H), 2.57 (ddd, J = 7.7, 7.6, 1.2 Hz, 1.61H, Z), 2.53 (ddd, J = 7.7, 7.6, 1.2 Hz, 0.39H, E).  




C-NMR (125 MHz, CDCl3): δ  = 169.2 (Cq), 159.5 (Cq), 149.0 (CH), 139.8 (Cq), 139.5 (Cq), 136.2 
(CH), 132.9 (Cq), 132.4 (CH), 131.6 (CH), 125.1 (CH), 124.1 (CH), 121.3 (CH), 115.1 (CH), 111.4 
(CH), 55.2 (CH3), 52.4 (CH3), 51.5 (CH), 36.2 (CH2, E), 31.7 (CH2, E), 31.1 (CH2, Z), 26.6 (CH2, Z).  
IR (ATR): 1732, 1606, 1587, 1428, 1231, 1149, 988, 787 cm
–1
.  
MS (EI) m/z (relative intensity): 369 ([M]
+
, 10), 238 (100), 197 (40), 193 (10), 167 (75).  








(E)-Dimethyl 2-{4-[5-methoxy-2-(pyridin-2-yl)phenyl]but-2-en-1-yl}malonate (131ba'): The 
general procedure C was followed using 2-(4-methoxyphenyl)pyridine (1b) (46.3 mg, 0.25 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (55.2 mg, 0.30 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1 → 3/1 → 2/1) yielded 131ba' (41.6 mg, 45%, E/Z = 2:1) and 
131ba'' (16.6 mg, 12%, E/Z = 3:1) as yellow oils.  
1
H-NMR (500 MHz, CDCl3): δ = 8.68–8.63 (m, 1H), 7.68 (ddd, J = 8.0, 7.8, 1.9 Hz, 1H), 7.34–7.27 
(m, 2H), 7.18 (ddd, J = 7.8, 4.9, 1.2 Hz, 1H), 6.83–6.75 (m, 2H), 5.61–5.48 (m, 1H), 5.33–5.23 (m, 
1H), 3.82 (s, 3H), 3.69 (s, 1.80H, Z), 3.67 (s, 4.20H, E), 3.51 (d, J = 7.4 Hz, 0.60H, Z), 3.39 (d, 
J = 7.4 Hz, 1.40H, E), 3.34 (t, J = 7.7 Hz, 1H), 2.58 (ddd, J = 7.7, 7.6, 1.4 Hz, 0.60H, Z), 2.53 (ddd, 
J = 7.7, 7.6, 1.4 Hz, 1.40H, E).  
13
C-NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 159.9 (Cq), 149.0 (CH), 139.8 (Cq), 139.9 (Cq), 136.0 
(CH), 132.4 (Cq), 132.2 (CH), 131.1 (CH), 125.1 (CH), 124.2 (CH), 121.3 (CH), 115.3 (CH), 111.5 
(CH), 55.3 (CH3), 52.7 (CH3), 51.3 (CH), 36.3 (CH2, E), 31.8 (CH2, E), 31.2 (CH2, Z), 26.7 (CH2, Z).  
IR (ATR): 1732, 1586, 1468, 1436, 1256, 1150, 1170, 747 cm
–1
.  
MS (ESI) m/z (relative intensity): 370 ([M + H]
+
, 10), 238 (100), 197 (40).  















malonate (131ba''):  
1
H-NMR (600 MHz, CDCl3): δ = 8.70–8.62 (m, 1H), 7.72–7.65 (m, 1H), 7.23–7.12 (m, 2H), 6.66–
6.59 (m, 2H), 5.50–5.42 (m, 2H), 5.24 (dtt, J = 10.7, 7.6, 1.2 Hz, 1H, Z), 5.14 (dtt, J = 15.2, 7.7, 
1.4 Hz, 1H, E), 3.79 (s, 3H), 3.66 (s, 12H), 3.33 (t, J = 7.7 Hz, 1.51H, E), 3.26 (t, J = 7.7 Hz, 0.49H, 
Z), 3.08 (d, J = 7.6 Hz, 0.95H, Z), 2.94 (d, J = 7.6 Hz, 3.05H, E), 2.49 (ddd, J = 7.7, 7.7, 1.2 Hz, 
3.05H, E), 2.42 (ddd, J = 7.7, 7.6, 1.2 Hz, 0.95H, Z).  
13
C-NMR (125 MHz, CDCl3): δ = 169.1 (Cq), 159.1 (Cq), 158.7 (Cq), 149.3 (CH), 139.7 (Cq), 135.7 
(CH), 132.0 (Cq), 126.5 (CH), 125.0 (CH), 121.6 (CH), 121.6 (CH), 112.4 (CH), 55.2 (CH3), 52.4 
(CH3), 51.5 (CH, E), 51.5 (CH, Z), 36.8 (CH2, E), 31.8 (CH2, E), 31.6 (CH2, Z), 26.6 (CH2, Z).  
IR (ATR): 1730, 1602, 1459, 1434, 1230, 1148, 1021, 753 cm
–1
.  
MS (EI) m/z (relative intensity): 553 ([M]
+
, 10), 522 (10), 422 (100).  




553.2312, found 553.2310.  
 
 
(Z)-Dimethyl 2-{4-[2-(1H-pyrazol-1-yl)thiophen-3-yl]but-2-en-1-yl}malonate (133): The general 
procedure B was followed using 1-(thiophen-2-yl)-1H-pyrazole (131) (75.0 mg, 0.50 mmol) and 
dimethyl 2-vinylcyclopropane-1,1-dicarboxylate (125a) (110 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 3/1) yielded 133 (67.0 mg, 40%, E/Z = 12:1) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 7.70 (dd, J = 1.9, 0.5 Hz, 1H), 7.63 (dd, J = 2.5, 0.5 Hz, 1H), 7.11 
(d, J = 5.5 Hz, 1H), 6.84 (d, J = 5.5 Hz, 1H), 6.42 (dd, J = 2.5, 1.9 Hz, 1H), 5.56 (dtt, J = 10.6, 7.6, 
1.0 Hz, 1H), 5.38 (dtt, J = 10.6, 7.6, 1.0 Hz, 1H), 3.71 (s, 6H), 3.40–3.24 (m, 3H), 2.66 (ddd, J = 7.6, 
7.6, 1.0 Hz, 1.84H, Z), 2.60 (ddd, J = 7.6, 7.6, 1.0 Hz, 0.16H, E).  
13
C-NMR (75 MHz, CDCl3): δ = 169.2 (Cq), 141.2 (CH), 137.5 (Cq), 133.3 (Cq), 131.7 (CH), 130.0 
(CH), 127.7 (CH), 126.0 (CH), 121.9 (CH), 107.0 (CH), 52.6 (CH3), 51.4 (CH), 31.7 (CH2, E), 30.7 
(CH2, E), 26.9 (CH2, Z), 25.8 (CH2, Z).  
IR (ATR): 2953, 1733, 1515, 1457, 1233, 1154, 755 cm
–1
.  
MS (EI) m/z (relative intensity): 334 ([M]
+
, 10), 303 (20), 203 (100). 




 334.0987, found 334.0988. 
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5.3.2 Removal of the Directing Group 
 
 
To a solution of 130aa (189 mg, 0.50 mmol, 1.00 equiv) in CH2Cl2 (1.0 mL) was added MeOTf 
(90.3 mg, 60.0 μL, 0.55 mmol, 1.10 equiv) dropwise at 0 °C. After 30 min the mixture was allowed to 
warm up to 25 °C and stirred for 16 h. After removal of the solvent in vacuo Pd(OH)2/C (27.1 mg, 
10 wt.-%) and ammonium formate (315 mg, 5.00 mmol, 10.0 equiv) were added.  The mixture was 
diluted in MeOH (2.0 mL, 0.25 M) and heated at 60 °C for 20 h. After addition of EtOAc (10 mL) at 
ambient temperature, the mixture was filtered through a short pad of Celite and the solvents were 
removed in vacuo. The crude mixture was purified by flash column chromatography on silica gel (n-




Dimethyl 2-[4-(1H-indol-2-yl)butyl]malonate (143): 
M.p.: 75 °C   
1
H-NMR (400 MHz, CDCl3): δ = 8.08 (s, 1H), 7.56–7.52 (m, 1H), 7.32–7.26 (m, 1H), 7.15–7.05 (m, 
2H), 6.22 (d, J = 1.2 Hz, 1H), 3.74 (s, 6H), 3.44 (t, J = 7.7 Hz, 2H), 2.73 (t, J = 7.3 Hz, 1H), 2.03–1.94 
(m, 2H), 1.78–1.68 (m, 2H), 1.47–1.36 (m, 2H).  
13
C-NMR (100 MHz, CDCl3): δ = 169.8 (Cq), 139.3 (Cq), 135.8 (Cq), 128.7 (Cq), 120.8 (CH), 119.6 
(CH), 119.4 (CH), 110.3 (CH), 99.3 (CH), 52.4 (CH3), 51.4 (CH), 28.6 (CH2), 28.3 (CH2), 27.5 (CH2), 
26.6 (CH2).  
IR (ATR): 3387, 1726, 1459, 1289, 1139, 742, 640 cm
–1
. 
MS (EI) m/z (relative intensity): 303 ([M]
+
, 30), 144 (30), 130 (100).  




 303.1471, found 303.1465. 
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5.3.3 Mechanistic Studies 
5.3.3.1 H/D-Exchange Experiment 
 
 
A suspension of 105a (146 mg, 0.75 mmol, 1.50 equiv), 125a (91.7 mg, 0.50 mmol, 1.00 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %) and NaOPiv (12.4 mg, 
100 µmol, 20 mol %) in DCE (1.8 mL) and CD3OD (0.2 mL) was stirred at 50 °C for 20 h. After 
removal of the solvents, the crude mixture was purified by column chromatography on silica gel (n-
hexane/EtOAc: 10:1 → 5:1 → 3:1) to yield [D]n-130aa (140 mg, 74%, E/Z = 1:5) and [D]n-105a 
(45.2 mg, 31% reis.) as yellow oils. 
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A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv), AgSbF6 (34.4 mg, 20.0 mol %) and NaOPiv 
(12.4 mg, 100 µmol, 20 mol %) in DCE (1.8 mL) and CD3OD (0.2 mL) was stirred at 50 °C for 20 h. 
After removal of the solvents, the crude mixture was purified by column chromatography on silica gel 
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Two parallel reactions of 105a or [D]1-105a
[9]
 were performed to determine the KIE value by 
comparison of the initial reaction rates. A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv) or 
[D]1-105a (97.6 mg, 0.50 mmol, 1.00 equiv), 125a (110 mg, 0.60 mmol, 1.20 equiv), [Cp*Co(CO)I2] 
(23.8 mg, 10 mol %), AgSbF6 (34.4 mg, 20 mol %), NaOPiv (12.4 mg, 20 mol %) and n-dodecane 
(30 µL) in DCE (2.0 mL) was stirred at 50 °C. Periodic aliquots (25 μL) were removed to provide the 
following conversions as determined by GC-analysis: 
 
Table 31. Conversion-time table for the KIE measurement. 
t / min 5 10 15 20 25 
130aa / % 6.0 10.8 16.2 19.6 26.2 
[D]n-130aa / % 3.1 7.6 11.6 15.7 18.8 
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5.4 Regioselective Cobalt(III)-Catalyzed C−H Alkylations 
5.4.1 Characterization Data 
 
 
2-n-Octyl-1-(pyridin-2-yl)-1H-indole (144aa): The general procedure D was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144a (125 mg, 82%) as a 
colorless oil.  
1
H-NMR (600 MHz, CDCl3): δ = 8.65 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.87 (ddd, J = 7.8, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.42 (ddd, J = 7.8, 1.0, 0.9 Hz, 1H), 7.36–7.27 (m, 2H), 7.16–7.10 (m, 2H), 
6.46 (dt, J = 0.9, 0.9 Hz, 1H), 2.86 (t, J = 7.7 Hz, 2H), 1.58–1.50 (m, 2H), 1.31–1.17 (m, 10H), 0.85 (t, 
J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.5 (Cq), 149.5 (CH), 141.7 (Cq), 138.1 (CH), 137.2 (Cq), 128.6 
(Cq), 121.9 (CH), 121.4 (CH), 121.0 (CH), 120.4 (CH), 119.7 (CH), 109.9 (CH), 102.0 (CH), 31.9 
(CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.7 (CH2), 27.5 (CH2), 22.7 (CH2), 14.2 (CH3).  
IR (ATR): 2925, 2854, 1584, 1468, 1455, 780, 755, 733 cm
–1
.  
MS (EI) m/z (relative intensity): 306 ([M]
+
, 25), 221 (25), 207 (100), 196 (45), 168 (30).  




 306.2096, found 306.2103.  






5-Methoxy-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144ba): The general procedure D was followed 
using 5-methoxy-1-(pyridin-2-yl)-1H-indole (105b) (112 mg, 0.50 mmol) and oct-1-ene (143a) 
(168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144ba 
(125 mg, 74%) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.63 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.83 (ddd, J = 7.9, 7.5, 2.1 Hz, 
1H), 7.38 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.29–7.23 (m, 2H), 7.06–7.04 (m, 1H), 6.77 (dd, J = 8.9, 
2.5 Hz, 1H), 6.38 (dt, J = 0.8, 0.8 Hz, 1H), 3.85 (s, 3H), 2.83 (t, J = 7.6 Hz, 2H), 1.64–1.48 (m, 2H), 
1.34–1.21 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H).  




C-NMR (100 MHz, CDCl3): δ = 154.7 (Cq), 151.6 (Cq), 149.5 (CH), 142.3 (Cq), 138.1 (CH), 132.3 
(Cq), 129.1 (Cq), 121.7 (CH), 120.7 (CH), 110.9 (CH), 110.8 (CH), 102.1 (CH), 101.9 (CH), 55.8 
(CH3), 31.8 (CH2), 29.2 (CH2), 29.2 (CH2), 29.1 (CH2), 28.6 (CH2), 27.5 (CH2), 22.6 (CH2), 14.0 
(CH3).  
IR (ATR): 2924, 2853, 1582, 1470, 1450, 1173, 772 cm
–1
.  
MS (EI) m/z (relative intensity): 336 ([M]
+
, 40), 251 (20), 237 (100), 222 (15).  




 336.2202, found 336.2193. 
 
 
5-Fluoro-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144ma): The general procedure D was followed 
using 5-fluoro-1-(pyridin-2-yl)-1H-indole (105m) (106 mg, 0.50 mmol) and oct-1-ene (143a) 
(168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 144ma 
(123 mg, 76%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.8, 2.1, 1.0 Hz, 1H), 7.83 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.37 (ddd, J = 8.0, 1.3, 1.0 Hz, 1H), 7.31 (ddd, J = 7.5, 4.8, 1.3 Hz, 1H),  7.26–7.20 (m, 2H), 
7.88–7.80 (m, 1H), 6.39 (dt, J = 0.8, 0.8 Hz, 1H), 2.80 (t, J = 7.6 Hz, 2H), 1.63–1.50 (m, 2H), 1.34–
1.17 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 158.3 (d, 
1
JC‒F = 235 Hz, Cq), 151.2 (Cq), 149.5 (CH), 143.3 (Cq), 
138.2 (CH), 133.7 (Cq), 128.9 (d, 
3
JC‒F = 10.2 Hz, Cq), 122.1 (CH), 120.9 (CH), 110.7 (d, 
3
JC‒F = 
10.0 Hz, CH), 109.2 (d, 
2
JC‒F = 24.1 Hz, CH), 104.6 (d, 
2
JC‒F = 24.2 Hz, CH), 101.9 (d, 
4
JC‒F = 4.1 Hz, 
CH), 31.8 (CH2), 29.3 (CH2), 29.3 (CH2), 29.1 (CH2), 28.6 (CH2), 27.6 (CH2), 22.7 (CH2), 14.1 (CH3).  
19
F-NMR (282 MHz, CDCl3): δ  = –124.2 (m).
  
IR (ATR): 2924, 2854, 1584, 1469, 1436, 1176, 775 cm
–1
.  
MS (EI) m/z (relative intensity): 324 ([M]
+
, 30), 239 (25), 225 (100).  




 324.2002, found 324.1996. 
 
 
5-Bromo-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144ca): The general procedure D was followed 
using 5-bromo-1-(pyridin-2-yl)-1H-indole (105c) (136 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
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1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144ca (152 mg, 
79%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.85 (ddd, J = 8.0, 7.4, 2.1 Hz, 
1H), 7.67 (dd, J = 1.5, 0.9 Hz, 1H),  7.34 (ddd, J = 8.0, 0.9, 0.9 Hz, 1H), 7.32 (ddd, J = 7.4, 4.9, 
0.9 Hz, 1H), 7.18–7.16 (m, 2H), 6.37 (dt, J = 0.8, 0.8 Hz, 1H), 2.79 (t, J = 7.8 Hz, 2H), 1.58–1.48 (m, 
2H), 1.31–1.19 (m, 10H), 0.87 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 150.9 (Cq), 149.5 (CH), 143.0 (Cq), 138.6 (CH), 135.8 (Cq), 130.2 
(Cq), 124.0 (CH), 122.2 (CH), 122.2 (CH), 120.9 (CH), 113.5 (Cq), 111.5 (CH), 101.3 (CH), 31.8 
(CH2), 29.3 (CH2), 29.3 (CH2), 28.5 (CH2), 28.5 (CH2), 27.4 (CH2), 22.7 (CH2), 12.1 (CH3).  
IR (ATR): 2924, 2853, 1486, 1469, 1456, 864, 780 cm
–1
.  




, 20), 301 (15), 287 (100), 219 (20), 205 (30).  






 384.1201, found 384.1197.  
 
 
5-Iodo-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144da): The general procedure D was followed using 
5-iodo-1-(pyridin-2-yl)-1H-indole (144d) (160 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144da (167 mg, 
77%) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.90‒7.81 (m, 2H), 7.37‒7.29 
(m, 3H), 7.06 (ddd, J = 8.2, 0.9, 0.9 Hz, 1H), 6.35 (dt, J = 0.8, 0.8 Hz, 1H), 2.79 (t, J = 7.8 Hz, 2H), 
1.58–1.48 (m, 2H), 1.34–1.15 (m, 10H), 0.87 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 150.9 (Cq), 149.5 (CH), 142.6 (Cq), 138.2 (CH), 136.3 (Cq), 131.0 
(Cq), 129.6 (CH), 128.4 (CH), 122.2 (CH), 120.9 (CH), 112.0 (CH), 101.0 (CH), 84.0 (Cq), 31.8 
(CH2), 29.3 (CH2), 29.2 (CH2), 28.5 (CH2), 27.4 (CH2), 27.4 (CH2), 22.7 (CH2), 14.9 (CH3).  
IR (ATR): 2923, 2852, 1585, 1469, 1455, 867, 780 cm
–1
.  
MS (EI) m/z (relative intensity): 432 ([M]
+
, 60), 347 (20), 333 (100), 206 (40).  













5-Nitro-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144ea): The general procedure D was followed using 
5-nitro-1-(pyridin-2-yl)-1H-indole (105e) (120 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 144ea (73.7 mg, 
42%) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 8.48 (d, J = 2.1 Hz, 1H), 8.03‒
7.91 (m, 2H), 7.45‒7.37 (m, 2H), 7.25 (ddd, J = 8.5, 0.9, 0.6 Hz, 1H), 6.35 (dt, J = 0.8, 0.8 Hz, 1H), 
2.76 (t, J = 7.8 Hz, 2H), 1.61–1.51 (m, 2H), 1.30–1.15 (m, 10H), 0.84 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ  = 150.3 (Cq), 149.9 (CH), 145.2 (Cq), 142.3 (Cq), 140.1 (Cq), 138.6 
(CH), 127.7 (Cq), 123.1 (CH), 121.3 (CH), 117.2 (CH), 116.6 (CH), 110.0 (CH), 103.3 (CH), 31.8 
(CH2), 29.3 (CH2), 29.3 (CH2), 29.1 (CH2), 28.3 (CH2), 27.5 (CH2), 22.7 (CH2), 14.1 (CH3).  
IR (ATR): 2926, 2855, 1586, 1512, 1470, 1331, 784 cm
–1
.  
MS (EI) m/z (relative intensity): 351 ([M]
+
, 20), 264 (30), 252 (100), 206 (40).  




 351.1947, found 351.1945.  
 
 
3-Methyl-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144fa): The general procedure D was followed 
using 3-methyl-1-(pyridin-2-yl)-1H-indole (105f) (104 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 144fa (104 mg, 
65%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.85 (ddd, J = 7.9, 7.4, 2.0 Hz, 
1H), 7.56–7.51 (m, 1H), 7.41 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.33–7.26 (m, 2H), 7.16–7.08 (m, 2H), 
2.89 (t, J = 7.2 Hz, 2H), 2.31 (s, 3H), 1.32–1.13 (m, 12H), 0.85 (t, J = 6.7 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.9 (Cq), 149.4 (CH), 138.0 (CH), 137.2 (Cq), 136.5 (Cq), 129.4 
(Cq), 121.6 (CH), 121.5 (CH), 120.9 (CH), 120.0 (CH), 118.0 (CH), 109.7 (CH), 109.7 (Cq), 31.9 
(CH2), 29.4 (CH2), 29.2 (CH2), 29.2 (CH2), 29.2 (CH2), 24.8 (CH2), 22.7 (CH2), 14.2 (CH3), 8.9 (CH3). 
IR (ATR): 2923, 2854, 1585, 1470, 1436, 1362, 738 cm
–1
.  
MS (EI) m/z (relative intensity): 320 ([M]
+
, 50), 235 (30), 221 (100), 207 (25).  




 320.2252, found 320.2251. 




Methyl 2-n-octyl-1-(pyridin-2-yl)-1H-indole-3-carboxylate (144na): The general procedure D was 
followed using methyl 1-(pyridin-2-yl)-1H-indole-3-carboxylate (105n) (126 mg, 0.50 mmol) and oct-
1-ene (143a) (168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 5/1) 
yielded 144na (140 mg, 77%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 8.18 (ddd, J = 7.9, 7.7, 0.9 Hz, 
1H), 7.91 (ddd, J = 7.9, 0.9, 0.9 Hz, 1H), 7.45–7.38 (m, 2H), 7.28–7.21 (m, 1H), 7.18–7.08 (m, 2H), 
3.97 (s, 3H), 2.81 (t, J = 7.8 Hz, 2H), 1.60–1.47 (m, 2H), 1.27–1.10 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 165.9 (Cq), 150.2 (Cq), 149.9 (Cq), 149.8 (CH), 138.4 (CH), 136.7 
(Cq), 126.6 (Cq), 123.4 (CH), 122.6 (CH), 122.3 (CH), 122.2 (CH), 121.4 (CH), 110.1 (CH), 105.3 
(Cq), 50.8 (CH3), 31.8 (CH2), 29.5 (CH2), 29.4 (CH2), 29.1 (CH2), 29.0 (CH2), 25.9 (CH2), 22.6 (CH2), 
14.1 (CH3).  
IR (ATR): 2924, 2853, 1697, 1587, 1468, 1434, 1182, 1076 cm
–1
.  
MS (EI) m/z (relative intensity): 364 ([M]
+
, 35), 305 (20), 265 (35), 250 (30), 207 (100).  








4-Methoxy-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144ha): The general procedure D was followed 
using 4-methoxy-1-(pyridin-2-yl)-1H-indole (105h) (112 mg, 0.50 mmol) and oct-1-ene (143a) 
(168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144ha 
(132 mg, 79%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.85 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.40 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.32–7.27 (m, 2H), 7.08–6.92 (m, 1H), 6.62–6.52 (m, 2H), 
3.96 (s, 3H), 2.81 (t, J = 7.6 Hz, 2H), 1.61–1.51 (m, 2H), 1.32–1.21 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 152.4 (Cq), 151.6 (Cq), 149.4 (CH), 140.1 (Cq), 138.4 (Cq), 138.0 
(CH), 122.1 (CH), 121.9 (CH), 121.1 (CH), 118.9 (Cq), 103.6 (CH), 100.7 (CH), 99.0 (CH), 55.4 
(CH3), 31.8 (CH2), 29.3 (CH2), 29.3 (CH2), 29.1 (CH2), 28.6 (CH2), 27.4 (CH2), 22.7 (CH2), 14.1 
(CH3).  
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IR (ATR): 2923, 2854, 1585, 1470, 1435, 779, 738 cm
–1
.  
MS (EI) m/z (relative intensity): 336 ([M]
+
, 45), 251 (20), 237 (100), 221 (25).  








7-Ethyl-2-n-octyl-1-(pyridin-2-yl)-1H-indole (144ja): The general procedure D was followed using 
7-ethyl-1-(pyridin-2-yl)-1H-indole (105j) (111 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 144ja (102 mg, 
61%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.82 (ddd, J = 7.9, 7.6, 2.1 Hz, 
1H), 7.45–7.36 (m, 2H), 7.32 (ddd, J = 7.6, 1.0, 0.9 Hz, 1H),  7.06 (d, J = 7.7 Hz, 1H), 6.96–6.90 (m, 
1H), 6.40 (dt, J = 0.8, 0.8 Hz, 1H), 2.45 (t, J = 7.6 Hz, 2H), 2.15 (q, J = 7.5 Hz, 2H), 1.60–1.49 (m, 
2H), 1.32–1.19 (m, 10H), 0.94 (t, J = 7.5 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H). 
13
C-NMR (125 MHz, CDCl3): δ = 153.5 (Cq), 149.0 (CH), 142.5 (Cq), 137.5 (CH), 135.9 (Cq), 129.4 
(Cq), 127.3 (Cq), 124.0 (CH), 123.2 (CH), 121.8 (CH), 120.3 (CH), 117.7 (CH), 101.3 (CH), 31.9 
(CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.4 (CH2), 27.2 (CH2), 24.9 (CH2), 22.7 (CH2), 14.6 
(CH3), 14.1 (CH3).  
IR (ATR): 2926, 2855, 1582, 1467, 1435, 1340, 798, 741 cm
–1
.  
MS (EI) m/z (relative intensity): 334 ([M]
+
, 40), 249 (80), 235 (100), 219 (30).  




 334.2409, found 334.2413. 
 
 
2-(3-Phenylpropyl)-1-(pyridin-2-yl)-1H-indole (144ab): The general procedure D was followed 
using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and allylbenzene (143b) (177 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 30/1) yielded 144ab (133 mg, 
85%) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.65 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.85 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.43–7.35 (m, 2H), 7.32–7.25 (m, 3H), 7.22–7.12 (m, 5H), 6.51 (dt, J = 0.8, 
0.8 Hz, 1H), 2.93 (t, J = 7.7 Hz, 2H), 2.66 (t, J = 7.5 Hz, 2H), 1.93 (tt, J = 7.7, 7.5 Hz, 2H).  
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13
C-NMR (100 MHz, CDCl3): δ = 151.4 (Cq), 149.6 (CH), 141.9 (Cq), 141.0 (Cq), 138.1 (CH), 137.2 
(Cq), 128.5 (Cq), 128.3 (CH), 128.2 (CH), 125.7 (CH), 121.9 (CH), 121.6 (CH), 120.9 (CH), 120.5 
(CH), 119.8 (CH), 110.0 (CH), 102.3 (CH), 35.3 (CH2), 30.2 (CH2), 26.9 (CH2).  
IR (ATR): 3025, 2932, 1584, 1468, 1455, 735, 698 cm
–1
.  
MS (EI) m/z (relative intensity): 312 ([M]
+
, 20), 221 (100), 206 (40), 91 (20).  




 312.1626, found 312.1624.  






2-n-Pentadecyl-1-(pyridin-2-yl)-1H-indole (144ac): The general procedure D was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and pentadec-1-ene (143c) (316 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144ac (159 mg, 
79%) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.86 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.36–7.27 (m, 2H), 7.16–7.10 (m, 2H), 
6.46 (dt, J = 0.8, 0.8 Hz, 1H), 2.86 (t, J = 7.7 Hz, 2H), 1.65–1.53 (m, 2H), 1.35–1.19 (m, 24H), 0.92 (t, 
J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.5 (Cq), 149.4 (CH), 141.6 (Cq), 138.0 (CH), 137.1 (Cq), 128.6 
(Cq), 121.8 (CH), 121.4 (CH), 121.0 (CH), 120.4 (CH), 119.7 (CH), 109.9 (CH), 102.0 (CH), 31.9 
(CH2), 29.7 (CH2), 29.7 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 
(CH2), 29.4 (CH2), 29.3 (CH2), 28.6 (CH2), 27.5 (CH2), 22.7 (CH2), 14.0 (CH3).  
IR (ATR): 2921, 2851, 1485, 1469, 1456, 780, 735 cm
–1
.  
MS (EI) m/z (relative intensity): 404 ([M]
+
, 35), 221 (55), 207 (100), 195 (15).  








2-n-Decyl-1-(pyridin-2-yl)-1H-indole (144ad): The general procedure D was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and dec-1-ene (143d) (210 mg, 1.50 mmol). 
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Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144ad (125 mg, 75%) as a 
colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.86 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.36–7.27 (m, 2H), 7.16–7.10 (m, 2H), 
6.45 (dt, J = 0.8, 0.8 Hz, 1H), 2.86 (t, J = 7.7 Hz, 2H), 1.65–1.51 (m, 2H), 1.35–1.18 (m, 14H), 0.89 (t, 
J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.5 (Cq), 149.4 (CH), 141.6 (Cq), 138.0 (CH), 137.1 (Cq), 128.6 
(Cq), 121.8 (CH), 121.4 (CH), 121.0 (CH), 120.4 (CH), 119.7 (CH), 109.9 (CH), 102.0 (CH), 31.9 
(CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 28.6 (CH2), 27.5 (CH2), 22.7 
(CH2), 14.1 (CH3).  
IR (ATR): 2923, 2852, 1585, 1468, 1455, 780, 735 cm
–1
.  
MS (EI) m/z (relative intensity): 334 ([M]
+
, 45), 249 (30), 235 (100), 221 (45).  




 334.2409, found 334.2407.  






2-n-Hexyl-1-(pyridin-2-yl)-1H-indole (145ae): The general procedure D was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and hex-1-ene (143e) (126 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 144ae (90.5 mg, 65%) as a 
colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.67 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.87 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.36–7.27 (m, 2H), 7.16–7.10 (m, 2H), 
6.46 (dt, J = 0.9, 0.9 Hz, 1H), 2.85 (t, J = 7.7 Hz, 2H), 1.63–1.53 (m, 2H), 1.36–1.20 (m, 6H), 0.87 (t, 
J = 7.1 Hz, 3H).  
13
C-NMR (100 MHz, CDCl3): δ = 151.5 (Cq), 149.5 (CH), 141.7 (Cq), 138.1 (CH), 137.2 (Cq), 128.6 
(Cq), 121.9 (CH), 121.4 (CH), 121.1 (CH), 120.5 (CH), 119.8 (CH), 110.0 (CH), 102.0 (CH), 31.5 
(CH2), 28.9 (CH2), 28.5 (CH2), 27.4 (CH2), 22.5 (CH2), 14.0 (CH3).  
IR (ATR): 2926, 2856, 1584, 1468, 1455, 779, 735 cm
–1
.  
MS (EI) m/z (relative intensity): 278 ([M]
+
, 25), 221 (20), 207 (100).  




 278.1783, found 278.1788.  
The analytical data are in accordance with those reported in literature.
[186]
 




6-[1-(Pyridin-2-yl)-1H-indol-2-yl]hexyl acetate (144af): The general procedure D was followed 
using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and hex-5-en-1-yl acetate (143f) 
(213 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 144af 
(128 mg, 76%) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.85 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.60‒7.55 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.33–7.24 (m, 2H), 7.15–7.08 (m, 2H), 
6.44 (dt, J = 0.8, 0.8 Hz, 1H), 4.01 (t, J = 6.9 Hz, 2H), 2.84 (t, J = 7.4 Hz, 2H), 2.02 (s, 3H), 1.63–1.53 
(m, 4H), 1.36–1.28 (m, 4H).  
13
C-NMR (125 MHz, CDCl3): δ = 170.9 (Cq), 151.4 (Cq), 149.4 (CH), 141.3 (Cq), 138.1 (CH), 137.1 
(Cq), 128.5 (Cq), 121.9 (CH), 121.4 (CH), 121.0 (CH), 120.4 (CH), 119.7 (CH), 109.9 (CH), 102.0 
(CH), 64.4 (CH2), 28.9 (CH2), 28.4 (CH2), 28.4 (CH2), 27.3 (CH2), 25.6 (CH2), 21.0 (CH3).  
IR (ATR): 2933, 1736, 1585, 1470, 1456, 1242, 783, 748 cm
–1
. 
MS (EI) m/z (relative intensity): 336 ([M]
+
, 25), 221 (25), 207 (100).  




 336.1838, found 336.1838.  
 
 
10-[1-(Pyridin-2-yl)-1H-indol-2-yl]decan-1-ol (144ag): The general procedure D was followed using 
1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and dec-9-en-1-ol (143g) (234 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 144ag (117 mg, 
67%) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.87 (ddd, J = 8.0, 7.4, 2.1 Hz, 
1H), 7.59‒7.54 (m, 1H), 7.41 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.33–7.27 (m, 2H), 7.14–7.07 (m, 2H), 
6.43 (dt, J = 0.8, 0.8 Hz, 1H), 3.57 (t, J = 6.7 Hz, 2H), 2.82 (t, J = 7.6 Hz, 2H), 1.74 (bs, 1H), 1.60–
1.45 (m, 4H), 1.31–1.19 (m, 12H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.4 (Cq), 149.4 (CH), 141.6 (Cq), 138.1 (CH), 137.1 (Cq), 128.5 
(Cq), 121.9 (CH), 121.4 (CH), 121.1 (CH), 120.4 (CH), 119.7 (CH), 109.9 (CH), 101.9 (CH), 62.7 
(CH2), 32.7 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 29.3 (CH2), 28.6 (CH2), 27.4 
(CH2), 25.7 (CH2).  
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IR (ATR): 3375, 2925, 2852, 1699, 1585, 1469, 1455, 782, 736 cm
–1
.  
MS (EI) m/z (relative intensity): 350 ([M]
+
, 15), 221 (25), 207 (100).  




 350.2358, found 350.2354. 
 
 
2-(Oct-7-en-1-yl)-1-(pyridin-2-yl)-1H-indole (144ah): The general procedure D was followed using 
1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and octa-1,7-diene (143h) (165 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 40/1) yielded 144ah (99.8 mg, 
66%) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.86 (ddd, J = 7.8, 7.8, 2.1 Hz, 
1H), 7.63–7.57 (m, 1H), 7.43 (ddd, J = 7.8, 1.0, 0.9 Hz, 1H), 7.37–7.32 (m, 1H), 7.23 (ddd, J = 7.3, 
5.2, 0.9 Hz, 1H), 7.17–7.10 (m, 2H), 6.47 (dt, J = 0.8, 0.8 Hz, 1H), 5.81 (ddt, J = 17.0, 10.2, 6.6 Hz, 
1H), 5.00 (dd, J = 17.0, 2.0 Hz, 1H), 4.95 (dd, J = 10.2, 2.0 Hz, 1H), 2.86 (t, J = 7.8 Hz, 2H), 2.03 (tt, 
J = 7.8, 7.7 Hz, 2H), 1.62–1.52 (m, 2H), 1.40–1.22 (m, 6H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.5 (Cq), 149.5 (CH), 141.6 (Cq), 139.0 (CH), 138.1 (CH), 137.2 
(Cq), 128.6 (Cq), 121.9 (CH), 121.4 (CH), 121.1 (CH), 120.5 (CH), 119.8 (CH), 114.1 (CH2), 110.0 
(CH), 102.0 (CH), 33.7 (CH2), 29.0 (CH2), 28.7 (CH2), 28.6 (CH2), 28.4 (CH2), 27.4 (CH2).  
IR (ATR): 2926, 2855, 1585, 1469, 1436, 1346, 780, 737 cm
–1
.  
MS (EI) m/z (relative intensity): 304 ([M]
+
, 100), 221 (20), 207 (100).  








2-(Octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145aa): The general procedure E was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 145aa (122 mg, 80%, 95:5) as a 
colorless oil. After purification by HPLC pure 145aa could be isolated (110 mg, 72%, >99:1).  
1
H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.86 (ddd, J = 7.9, 7.5, 2.0 Hz, 
1H), 7.59‒7.53 (m, 1H), 7.40 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.32 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 
7.24–7.21 (m, 1H), 7.12–7.06 (m, 2H), 6.46 (dd, J = 0.8, 0.8 Hz, 1H), 3.16 (tq, J = 7.6, 7.6 Hz, 0.95H, 
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M), 2.86 (t, J = 7.7 Hz, 0.10H, AM), 1.64–1.55 (m, 1H), 1.46–1.33 (m, 1H), 1.25–1.10 (m, 11H), 0.82 
(t, J = 6.8 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.6 (Cq), 149.6 (CH), 147.4 (Cq), 138.1 (CH), 137.2 (Cq), 128.5 
(Cq), 122.1 (CH), 121.7 (CH), 121.3 (CH), 120.4 (CH), 119.8 (CH), 109.9 (CH), 99.8 (CH), 37.2 
(CH2), 31.7 (CH2), 30.8 (CH), 29.3 (CH2), 27.1 (CH2), 22.7 (CH2), 20.6 (CH3), 14.1 (CH3).  
IR (ATR): 2925, 2854, 1584, 1468, 1435, 780, 733 cm
–1
.  
MS (EI) m/z (relative intensity): 306 ([M]
+
, 20), 221 (55), 207 (100).  




 306.2096, found 306.2083.  
 
Asymmetric cobalt(III)-catalyzed C–H hydroarylation:  
  
A suspension of 2-pyridylindole (105a) (0.50 mmol, 1.00 equiv), oct-1-ene (143a) (168 mg, 
1.50 mmol), [Cp*Co(CO)I2] (23.8 mg, 50.0 µmol, 10.0 mol %), AgSbF6 (34.4 mg, 100 µmol, 
20.0 mol %) and Phth-L-Leu-OH (130 mg, 0.50 mmol, 1.00 equiv) in DCE (0.50 mL, 1.00 M) was 
stirred at 50 °C for 20 h. At ambient temperature, the reaction mixture was diluted with EtOAc 
(5.0 mL) and the solvents were removed in vacuo. The remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc) to yield the desired product 145aa (57.1 mg, 37%, 
M:AM = 93:7). The enantiomeric excess was determined by analytical HPLC (Chiralpak
®
 IF-3, n-




tR / min Area Assignment 
10.716 1946 Enantiomer 1 
12.688 1950 Enantiomer 2 










Enantiomeric excess of 25%: 
 
tR / min Area Assignment 
10.858 30207 Enantiomer 1 
13.081 50010 Enantiomer 2 
14.606 5824 AM-product 144aa 
 
 
5-Methoxy-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ba): The general procedure E was 
followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (105b) (112 mg, 0.50 mmol) and oct-1-ene 
(143a) (168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
145ba (116 mg, 69%, 94:6) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.1, 1.0 Hz, 1H), 7.85 (ddd, J = 7.9, 7.4, 2.1 Hz, 
1H), 7.38 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.29 (ddd, J = 7.4, 4.9, 0.9 Hz, 1H), 7.17 (dd, J = 8.9, 0.9 Hz, 
1H), 7.08–7.04 (m, 1H), 6.76 (dd, J = 8.9, 2.5 Hz, 1H), 6.39 (dd, J = 0.8, 0.8 Hz, 1H), 3.86 (s, 3H), 
3.18 (tq, J = 6.8, 6.8 Hz, 0.94H, M), 2.83 (t, J = 7.6 Hz, 0.12H, AM), 1.67–1.34 (m, 2H), 1.30–1.08 
(m, 11H), 0.84 (t, J = 7.1 Hz, 3H).  
13
C-NMR (100 MHz, CDCl3): δ = 154.7 (Cq), 151.3 (Cq), 149.6 (CH), 148.1 (Cq), 138.1 (CH), 132.4 
(Cq), 129.0 (Cq), 121.9 (CH), 121.4 (CH), 111.0 (CH), 110.7 (CH), 102.1 (CH), 99.6 (CH), 55.8 
(CH3), 37.1 (CH2), 31.6 (CH2), 30.8 (CH), 29.2 (CH2), 27.0 (CH2), 22.6 (CH2), 20.5 (CH3), 14.0 
(CH3).  
IR (ATR): 2926, 2855, 1582, 1470, 1435, 1172, 770 cm
–1
.  
MS (EI) m/z (relative intensity): 336 ([M]
+
, 55), 251 (85), 237 (100).  




 336.2202, found 336.2213. 
 




5-Fluoro-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ma): The general procedure E was followed 
using 5-fluoro-1-(pyridin-2-yl)-1H-indole (105m) (106 mg, 0.50 mmol) and oct-1-ene (143a) 
(168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 145ma 
(138 mg, 85%, 96:4) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): δ = 8.68 (ddd, J = 4.9, 2.1, 1.0 Hz, 1H), 7.88 (ddd, J = 7.9, 7.4, 2.1 Hz, 
1H), 7.39 (ddd, J = 7.9, 1.0, 1.0 Hz, 1H), 7.34 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 7.24 (dd, J = 9.1, 2.4 Hz, 
1H), 7.17 (dd, J = 8.9, 4.5 Hz, 1H), 6.85 (dd, J = 8.9, 2.4 Hz, 1H),  6.44 (dd, J = 0.8, 0.8 Hz, 1H), 3.16 
(tq, J = 6.8, 6.8 Hz, 0.96H, M), 2.80 (t, J = 7.6 Hz, 0.08H, AM), 1.70–1.59 (m, 1H), 1.50–1.36 (m, 
1H), 1.32–1.06 (m, 11H), 0.84 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 158.3 (d, 
1
JC‒F = 235 Hz, Cq), 151.4 (Cq), 149.7 (CH), 149.1 (Cq), 
138.3 (CH), 133.8 (Cq), 128.9 (d, 
3
JC‒F = 10.1 Hz, Cq), 122.3 (CH), 121.6 (CH), 110.6 (d, 
3
JC‒F = 
10.0 Hz, CH), 109.1 (d, 
2
JC‒F = 24.2 Hz, CH), 104.7 (d, 
2
JC‒F = 24.1 Hz, CH), 99.6 (d, 
4
JC‒F = 4.3 Hz, 
CH), 37.0 (CH2), 31.6 (CH2), 30.8 (CH), 29.1 (CH2), 27.0 (CH2), 22.5 (CH2), 20.5 (CH3), 14.0 (CH3).  
19
F-NMR (282 MHz, CDCl3): δ  = –124.2 (m). 
IR (ATR): 2926, 2855, 1584, 1469, 1435, 1177, 774 cm
–1
.  
MS (EI) m/z (relative intensity): 324 ([M]
+
, 20), 239 (55), 225 (100).  




 324.2002, found 324.2010. 
 
 
5-Bromo-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ca): The general procedure E was followed 
using 5-bromo-1-(pyridin-2-yl)-1H-indole (105c) (136 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 145ca (154 mg, 
80%, 95:5) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.87 (ddd, J = 7.9, 7.4, 2.1 Hz, 
1H), 7.70 (dd, J = 1.9, 0.9 Hz, 1H),  7.34 (ddd, J = 7.9, 0.9, 0.9 Hz, 1H), 7.32 (ddd, J = 7.4, 4.9, 
0.9 Hz, 1H), 7.20–7.08 (m, 2H), 6.38 (dd, J = 0.8, 0.8 Hz, 1H), 3.14 (tq, J = 6.9, 6.9 Hz, 0.95H, M), 
2.79 (t, J = 7.8 Hz, 0.10H, AM), 1.64–1.37 (m, 2H), 1.29–1.10 (m, 11H), 0.84 (t, J = 7.1 Hz, 3H).  




C-NMR (100 MHz, CDCl3): δ = 151.1 (Cq), 149.7 (CH), 148.8 (Cq), 138.3 (CH), 136.0 (Cq), 130.2 
(Cq), 124.0 (CH), 122.5 (CH), 122.3 (CH), 121.6 (CH), 113.5 (Cq), 111.4 (CH), 99.2 (CH), 36.9 
(CH2), 31.6 (CH2), 30.8 (CH), 29.1 (CH2), 26.9 (CH2), 22.5 (CH2), 20.4 (CH3), 14.0 (CH3).  
IR (ATR): 2925, 2855, 1585, 1470, 1437, 863, 781, 735 cm
–1
.  




, 25), 299 (45), 287 (100), 219 (75), 205 (15).  






 384.1201, found 384.1206.  
 
 
5-Iodo-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145da): The general procedure E was followed 
using 5-iodo-1-(pyridin-2-yl)-1H-indole (105d) (160 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 145da (178 mg, 
82%, 94:6) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.91‒7.84 (m, 2H), 7.38‒7.32 
(m, 3H), 6.99 (dd, J = 8.6, 0.9 Hz, 1H), 6.36 (dd, J = 0.8, 0.8 Hz, 1H), 3.12 (tq, J = 6.8, 6.8 Hz, 0.94H, 
M), 2.79 (t, J = 7.8 Hz, 0.12H, AM), 1.64–1.36 (m, 2H), 1.26–1.09 (m, 11H), 0.83 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.0 (Cq), 149.7 (CH), 148.3 (Cq), 138.3 (CH), 136.4 (Cq), 131.0 
(Cq), 129.6 (CH), 128.5 (CH), 122.4 (CH), 121.6 (CH), 112.0 (CH), 98.9 (CH), 83.9 (Cq), 37.0 (CH2), 
31.7 (CH2), 30.8 (CH), 29.2 (CH2), 27.0 (CH2), 22.6 (CH2), 20.5 (CH3), 14.2 (CH3).  
IR (ATR): 2924, 2854, 1584, 1469, 1436, 866, 781 cm
–1
.  
MS (EI) m/z (relative intensity): 432 ([M]
+
, 60), 348 (45), 333 (100), 219 (65), 206 (20).  




 432.1062, found 432.1067.  
 
3-Methyl-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145fa): The general procedure E was followed 
using methyl 3-methyl-1-(pyridin-2-yl)-1H-indole (105f) (104 mg, 0.50 mmol) and oct-1-ene (143a) 
(168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 145fa 
(97.6 mg, 61%, 21:79) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.85 (ddd, J = 7.9, 7.4, 2.0 Hz, 
1H), 7.56–7.51 (m, 1H), 7.41 (dt, J = 7.9, 0.9 Hz, 1H), 7.33–7.26 (m, 2H), 7.16–7.08 (m, 2H), 3.03–
2.93 (m, 0.2H, M), 2.89 (t, J = 7.2 Hz, 1.6H, AM), 2.38 (s, 0.6H, M), 2.31 (s, 2.4H, AM), 1.35–1.12 
(m, 12H), 0.84 (t, J = 6.7 Hz, 3H).  
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13
C-NMR (125 MHz, CDCl3): δ  = 152.1 (Cq, M), 151.9 (Cq, AM), 149.5 (CH, M), 149.4 (CH, AM), 
138.0 (CH, AM), 137.9 (CH, M), 137.2 (Cq, AM), 137.2 (Cq, M), 136.5 (Cq, AM), 136.5 (Cq, M), 
129.9 (Cq, M), 129.4 (Cq, AM), 121.5 (CH, M), 122.1 (CH, M), 121.6 (CH, AM), 121.5 (CH, AM), 
121.4 (CH, M), 121.0 (CH, AM), 120.0 (CH, AM), 119.8 (CH, M), 118.0 (CH, AM), 117.6 (CH, M), 
109.9 (CH, M), 109.7 (CH, AM), 109.7 (Cq, AM), 108.2 (Cq, M),  36.0 (CH2, M), 31.9 (CH2, AM), 
31.8 (CH2, M), 31.7 (CH, M), 29.4 (CH2, AM), 29.2 (CH2, AM), 29.2 (CH2, AM), 29.2 (CH2, AM), 
27.9 (CH2, M), 24.8 (CH2, AM), 22.7 (CH2, AM), 20.1 (CH3, M), 14.2 (CH3, AM), 14.2 (CH3, M), 9.6 
(CH3, M), 8.9 (CH3, AM).  
IR (ATR): 2924, 2854, 1586, 1470, 1436, 1362, 779, 739 cm
–1
.  
MS (EI) m/z (relative intensity): 320 ([M]
+
, 55), 235 (30), 221 (100), 207 (30).  








4-Methoxy-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ha): The general procedure E was 
followed using 4-methoxy-1-(pyridin-2-yl)-1H-indole (105h) (112 mg, 0.50 mmol) and oct-1-ene 
(143a) (168 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 
145ha (128 mg, 76%, 95:5) as a yellowish oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.1, 1.0 Hz, 1H), 7.87 (ddd, J = 7.9, 7.4, 2.1 Hz, 
1H), 7.39 (ddd, J = 7.9, 1.1, 1.0 Hz, 1H), 7.32 (ddd, J = 7.4, 4.9, 1.1 Hz, 1H), 7.01 (dd, J = 8.3, 7.8 Hz, 
1H), 6.86 (dd, J = 8.3, 0.8 Hz, 1H), 6.63–6.47 (m, 2H), 3.97 (s, 3H), 3.13 (tq, J = 6.8, 6.8 Hz, 0.95H, 
M), 2.78 (t, J = 7.6 Hz, 0.10H, AM), 1.64–1.57 (m, 1H), 1.42–1.34 (m, 1H), 1.25–1.09 (m, 11H), 0.81 
(t, J = 7.3 Hz, 3H).  
13
C-NMR (100 MHz, CDCl3): δ  = 152.6 (Cq), 151.8 (Cq), 149.6 (CH), 146.1 (Cq), 138.6 (Cq), 138.2 
(CH), 122.2 (CH), 122.1 (CH), 121.8 (CH), 118.8 (Cq), 103.6 (CH), 100.6 (CH), 96.8 (CH), 55.4 
(CH3), 37.1 (CH2), 31.7 (CH2), 30.7 (CH), 29.2 (CH2), 27.0 (CH2), 22.6 (CH2), 20.6 (CH3), 14.0 
(CH3).  
IR (ATR): 2926, 2855, 1586, 1470, 1440, 1258, 764 cm
–1
.  
MS (EI) m/z (relative intensity): 336 ([M]
+
, 55), 251 (85), 237 (100).  




 336.2202, found 336.2213. 
 





7-Ethyl-2-(octan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ja): The general procedure E was followed 
using 7-ethyl-1-(pyridin-2-yl)-1H-indole (105j) (111 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 145ja (118 mg, 
71%, 96:4) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.82 (ddd, J = 7.8, 7.6, 2.0 Hz, 
1H), 7.44 (dd, J = 7.8, 1.4 Hz, 1H), 7.40 (ddd, J = 7.6, 4.9, 0.9 Hz, 1H), 7.33 (ddd, J = 7.8, 0.9, 0.9 Hz, 
1H), 7.06 (t, J = 7.7 Hz, 1H), 6.96–6.90 (m, 1H), 6.40 (dd, J = 0.8, 0.8 Hz, 1H), 2.52 (tq, J = 6.8, 
6.8 Hz, 0.96H, M), 2.45 (t, J = 7.6 Hz, 0.08H, AM), 2.12 (q, J = 7.5 Hz, 2H), 1.72–1.59 (m, 1H), 
1.46–1.35 (m, 1H), 1.27–1.10 (m, 11H), 0.94 (t, J = 7.5 Hz, 3H), 0.84 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 153.6 (Cq), 149.0 (CH), 148.3 (Cq), 137.4 (CH), 135.7 (Cq), 129.4 
(Cq), 127.4 (Cq), 124.4 (CH), 123.3 (CH), 121.7 (CH), 120.3 (CH), 117.7 (CH), 99.2 (CH), 37.7 
(CH2), 31.7 (CH), 31.1 (CH2), 29.3 (CH2), 27.3 (CH2), 24.8 (CH2), 22.7 (CH2), 21.3 (CH3), 14.7 
(CH3), 14.1 (CH3).  
IR (ATR): 2925, 2854, 1583, 1467, 1435, 797, 740 cm
–1
.  
MS (EI) m/z (relative intensity): 334 ([M]
+
, 50) 249 (40), 235 (100), 221 (40).  










2-(1-Phenylpropan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ab): The general procedure E was 
followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and allylbenzene (143b) 
(177 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 30/1) yielded 145ab 
(127 mg, 82%, 99:1) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.84 (ddd, J = 7.9, 7.5, 2.1 Hz, 
1H), 7.66–7.55 (m, 1H), 7.33 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.28 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 
7.24–7.21 (m, 1H), 7.18–7.08 (m, 5H), 6.93–6.88 (m, 2H), 6.52 (dd, J = 0.8, 0.8 Hz, 1H), 3.59–3.46 
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(m, 0.99H, M), 3.00 (dd, J = 13.2, 5.3 Hz, 1H), 2.86 (t, J = 7.7 Hz, 0.02H, AM), 2.56 (dd, J = 13.2, 
8.7 Hz, 1H), 1.23 (d, J = 7.0 Hz, 3H).  
13
C-NMR (100 MHz, CDCl3): δ = 151.6 (Cq), 149.7 (CH), 146.5 (Cq), 140.3 (Cq), 138.3 (CH), 137.3 
(Cq), 129.0 (CH), 128.5 (Cq), 128.1 (CH), 125.9 (CH), 122.2 (CH), 121.7 (CH), 121.6 (CH), 120.5 
(CH), 120.1 (CH), 109.9 (CH), 100.4 (CH), 43.8 (CH2), 32.8 (CH), 19.3 (CH3).  
IR (ATR): 3025, 2932, 1584, 1468, 1437, 735, 698 cm
–1
.  
MS (EI) m/z (relative intensity): 312 ([M]
+
, 20), 221 (35), 207 (100).  








2-(Pentadecan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ac): The general procedure E was followed 
using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and pentadec-1-ene (143c) (316 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 145ac (154 mg, 
76%, 95:5) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.87 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.36–7.27 (m, 2H), 7.16–7.10 (m, 2H), 
6.50 (dd, J = 0.8, 0.8 Hz, 1H), 3.22 (tq, J = 6.8, 6.8 Hz, 0.95H, M), 2.86 (t, J = 7.7 Hz, 0.10H, AM), 
1.72–1.62 (m, 1H), 1.50–1.40 (m, 1H), 1.35–1.12 (m, 25H), 0.93 (t, J = 7.1 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.7 (Cq), 149.6 (CH), 147.4 (Cq), 138.2 (CH), 137.4 (Cq), 128.6 
(Cq), 122.1 (CH), 121.4 (CH), 121.0 (CH), 120.4 (CH), 119.7 (CH), 109.7 (CH), 99.7 (CH), 37.1 
(CH2), 32.0 (CH2), 30.8 (CH), 29.7 (CH2), 29.7 (CH2), 29.7 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 
(CH2), 29.5 (CH2), 29.4 (CH2), 27.1 (CH2), 22.7 (CH2), 20.6 (CH3), 14.2 (CH3).  
IR (ATR): 2923, 2852, 1585, 1468, 1456, 780, 735 cm
–1
.  
MS (EI) m/z (relative intensity): 404 ([M]
+
, 35), 221 (55), 207 (100), 195 (15).  








2-(Decan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ad): The general procedure E was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and dec-1-ene (143d) (210 mg, 1.50 mmol). 
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Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 145ad (118 mg, 71%, 94:6) as a 
colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.68 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.88 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.65‒7.58 (m, 1H), 7.43 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.35–7.26 (m, 2H), 7.19–7.11 (m, 2H), 
6.50 (dd, J = 0.8, 0.8 Hz, 1H), 3.23 (tq, J = 6.8, 6.8 Hz, 0.94H, M), 2.86 (t, J = 7.7 Hz, 0.12H, AM), 
1.72–1.62 (m, 1H), 1.50–1.40 (m, 1H), 1.34–1.11 (m, 15H), 0.91 (t, J = 7.1 Hz, 3H).  
13
C-NMR (100 MHz, CDCl3): δ = 151.7 (Cq), 149.6 (CH), 147.4 (Cq), 138.2 (CH), 137.4 (Cq), 128.6 
(Cq), 122.1 (CH), 121.4 (CH), 121.0 (CH), 120.4 (CH), 119.7 (CH), 109.7 (CH), 99.7 (CH), 37.1 
(CH2), 31.8 (CH2), 30.7 (CH), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 27.1 (CH2), 22.7 (CH2), 20.6 
(CH3), 14.1 (CH3).  
IR (ATR): 2923, 2852, 1585, 1468, 1435, 780, 735 cm
–1
.  
MS (EI) m/z (relative intensity): 334 ([M]
+
, 45), 249 (30), 235 (100), 221 (45).  








2-(Hexan-2-yl)-1-(pyridin-2-yl)-1H-indole (145ae): The general procedure E was followed using 1-
(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and hex-1-ene (143e) (126 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 145ae (94.6 mg, 68%, 96:4) as a 
colorless oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.67 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.86 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.62‒7.56 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.36–7.27 (m, 2H), 7.16–7.10 (m, 2H), 
6.46 (dd, J = 0.8, 0.8 Hz, 1H), 3.17 (tq, J = 7.6, 7.6 Hz, 0.96H, M), 2.82 (t, J = 7.7 Hz, 0.08H, AM), -
1.67–1.56 (m, 1H), 1.45–1.35 (m, 1H), 1.24–1.07 (m, 7H), 0.77 (t, J = 7.1 Hz, 3H).  
13
C-NMR (100 MHz, CDCl3): δ = 151.7 (Cq), 149.7 (CH), 147.5 (Cq), 138.2 (CH), 137.3 (Cq), 128.6 
(Cq), 122.2 (CH), 121.7 (CH), 121.4 (CH), 120.4 (CH), 119.9 (CH), 110.0 (CH), 99.8 (CH), 36.7 
(CH2), 30.7 (CH), 29.3 (CH2), 22.6 (CH2), 20.5 (CH3), 13.9 (CH3).  
IR (ATR): 2928, 2857, 1584, 1469, 1436, 781, 747, 736 cm
–1
.  
MS (EI) m/z (relative intensity): 278 ([M]
+
, 40), 221 (80), 207 (100).  




 278.1783, found 278.1781. 
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5-[1-(Pyridin-2-yl)-1H-indol-2-yl]hexyl acetate (145af): The general procedure E was followed 
using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and hex-5-en-1-yl acetate (143f) 
(213 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 145af 
(124 mg, 73%, 99:1) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.68 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.87 (ddd, J = 8.0, 7.6, 2.1 Hz, 
1H), 7.60‒7.54 (m, 1H), 7.41 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.33 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 
7.25–7.20 (m, 1H), 7.12–7.05 (m, 2H), 6.45 (dd, J = 0.8, 0.8 Hz, 1H), 3.94 (t, J = 6.7 Hz, 2H), 3.25–
3.13 (m, 0.99H, M), 2.84 (t, J = 7.4 Hz, 0.02H, AM), 1.99 (s, 3H), 1.69–1.59 (m, 1H), 1.51–1.39 (m, 
3H), 1.32–1.21 (m, 5H).  
13
C-NMR (100 MHz, CDCl3): δ = 171.1 (Cq), 151.6 (Cq), 149.7 (CH), 146.9 (Cq), 140.3 (CH), 138.3 
(CH), 137.3 (Cq), 128.5 (Cq), 122.2 (CH), 121.5 (CH), 120.5 (CH), 119.9 (CH), 109.9 (CH), 99.9 
(CH), 64.3 (CH2), 36.5 (CH2), 30.7 (CH), 28.5 (CH2), 23.4 (CH2), 21.0 (CH3), 20.6 (CH3).  
IR (ATR): 2933, 1736, 1585, 1470, 1437, 1242, 782, 748 cm
–1
.  
MS (EI) m/z (relative intensity): 336 ([M]
+
, 30), 221 (60), 207 (55), 135 (100).  




 336.1838, found 336.1829.  
 
 
9-[1-(Pyridin-2-yl)-1H-indol-2-yl]decan-1-ol (145ag): The general procedure E was followed using 
1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and dec-9-en-1-ol (143g) (234 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 145ag (109 mg, 
62%, 92:8) as a yellowish oil.  
1
H-NMR (400 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.88 (ddd, J = 8.0, 7.5, 2.1 Hz, 
1H), 7.60‒7.54 (m, 1H), 7.40 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.34–7.30 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 
7.25–7.21 (m, 1H), 7.13–7.06 (m, 2H), 6.44 (dd, J = 0.8, 0.8 Hz, 1H), 3.55 (t, J = 6.7 Hz, 2H), 3.16 
(tq, J = 6.9, 6.9 Hz, 0.92H, M), 2.82 (t, J = 7.6 Hz, 0.16H, AM), 1.70 (bs, 1H), 1.64–1.36 (m, 4H), 
1.31–1.01 (m, 13H).  
13
C-NMR (100 MHz, CDCl3): δ = 151.6 (Cq), 149.6 (CH), 147.4 (Cq), 138.1 (CH), 137.3 (Cq), 128.5 
(Cq), 122.2 (CH), 121.8 (CH), 121.4 (CH), 120.4 (CH), 119.9 (CH), 109.9 (CH), 99.8 (CH), 62.9 
(CH2), 38.6 (CH2), 37.0 (CH2), 36.4 (CH2), 32.7 (CH2), 30.7 (CH), 29.4 (CH2), 27.0 (CH2), 25.6 
(CH2), 20.5 (CH3).  
IR (ATR): 3374, 2924, 2852, 1699, 1586, 1468, 1436, 780, 736 cm
–1
.  
MS (EI) m/z (relative intensity): 350 ([M]
+
, 15), 264 (25), 252 (100), 206 (30).  
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 350.2358, found 350.2351. 
 
 
2-(Oct-7-en-2-yl)-1-(pyridin-2-yl)-1H-indole (145ah): The general procedure E was followed using 
1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and octa-1,7-diene (143h) (165 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 40/1) yielded 145ah (119 mg, 
78%, 94:6) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.88 (ddd, J = 7.8, 7.6, 2.0 Hz, 
1H), 7.64−7.58 (m, 1H), 7.43 (ddd, J = 7.9, 0.9, 0.9 Hz, 1H), 7.33 (ddd, J = 7.2, 4.9, 0.9 Hz, 1H), 
7.29−7.24 (m, 1H), 7.18−7.10 (m, 2H), 6.49 (dd, J = 0.8, 0.8 Hz, 1H), 5.76 (ddt, J = 17.2, 10.4, 
6.8 Hz, 1H), 5.08‒4.84 (m, 2H), 3.22 (tq, J = 6.9, 6.9 Hz, 0.94H, M), 2.86 (t, J = 7.6 Hz, 0.12H, AM), 
2.08–1.92 (m, 3H), 1.81–1.54 (m, 2H), 1.53–1.41 (m, 1H), 1.32–1.21 (m, 5H).  
13
C-NMR (125 MHz, CDCl3): δ = 151.6 (Cq), 149.6 (CH), 147.3 (Cq), 138.9 (CH), 138.2 (CH), 137.3 
(Cq), 128.5 (Cq), 122.1 (CH), 121.7 (CH), 121.4 (CH), 120.4 (CH), 119.9 (CH), 114.1 (CH2), 109.9 
(CH), 102.0 (CH, AM), 99.8 (CH, M), 38.6 (CH2, AM), 36.8 (CH2, M), 36.4 (CH2, AM), 33.5 (CH2, 
M), 30.6 (CH), 28.7 (CH2), 27.7 (CH2, AM), 26.5 (CH2), 20.5 (CH3).  
IR (ATR): 2926, 2854, 1584, 1469, 1455, 1435, 780, 734 cm
–1
.  
MS (EI) m/z (relative intensity): 304 ([M]
+
, 20), 263 (15), 221 (100), 207 (100).  








1-[3-(Octan-2-yl)thiophen-2-yl]-1H-pyrazole (148): A modified general procedure E was followed 
using 1-(thiophen-2-yl)-1H-pyrazole (131) (75.0 mg, 0.50 mmol) and oct-1-ene (143a) (168 mg, 
1.50 mmol) at 80 °C. Isolation by column chromatography (n-hexane/EtOAc: 15/1) yielded 148 
(109 mg, 83%, 79:21) as a yellowish oil.  
1
H-NMR (300 MHz, CDCl3): δ = 7.68 (dd, J = 1.9, 0.6 Hz, 1H), 7.59 (dd, J = 2.4, 0.6 Hz, 0.21H, 
AM), 7.57 (dd, J = 2.4, 0.6 Hz, 0.79H, M), 7.13 (dd, J = 5.7, 0.5 Hz, 0.79H, M), 7.09 (dd, J = 5.7, 
0.5 Hz, 0.21H, AM), 6.89–6.83 (m, 1H), 6.41–6.38 (m, 1H), 2.73 (tq, J = 7.1, 7.1 Hz, 0.79H, M), 2.51 
(t, J = 7.6 Hz, 0.42H, AM), 1.52–1.41 (m, 2H), 1.22–1.13 (m, 11H), 0.83 (t, J = 6.9 Hz, 3H).  
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13
C-NMR (125 MHz, CDCl3): δ = 142.1 (Cq), 140.9 (CH), 135.9 (Cq, AM), 135.4 (Cq, M), 132.0 (CH, 
M), 131.5 (CH, AM), 127.5 (CH, AM), 124.8 (CH, M), 122.5 (CH, M), 121.7 (CH, AM), 106.7 (CH, 
AM), 106.6 (CH, M), 37.7 (CH2), 32.1 (CH), 31.9 (CH2, AM), 31.7 (CH2, M), 30.2 (CH2, AM), 29.3 
(CH2, AM), 29.3 (CH2, AM), 29.2 (CH2, M), 27.6 (CH2), 22.7 (CH2), 21.8 (CH3), 14.1 (CH3, AM), 
14.1 (CH3, M).  
IR (ATR): 2957, 2924, 1455, 1389, 919, 746 cm
–1
.  
MS (EI) m/z (relative intensity): 262 ([M]
+
, 40), 191 (40), 177 (100), 163 (90), 144 (60).  




 262.1504, found 262.1515. 
 




To a solution of 144aa (153 mg, 0.50 mmol, 1.00 equiv) or 145aa (153 mg, 0.50 mmol, 1.00 equiv) in 
CH2Cl2 (1.0 mL) was added MeOTf (90.3 mg, 60.0 μL, 0.55 mmol, 1.10 equiv) dropwise at 0 °C. 
After 30 min, the mixture was allowed to warm up to 25 °C and stirred for 6 h. After removal of the 
solvent in vacuo, Pd(OH)2/C (19.3 mg, 10 wt.-%) and ammonium formate (315 mg, 5.00 mmol, 10.0 
equiv) were added.  The mixture was diluted with MeOH (2.0 mL, 0.25 M) and stirred at 60 °C for 6 h. 
After addition of EtOAc (10 mL) at ambient temperature, the mixture was filtered through a short pad 
of celite and the solvents were removed in vacuo. The crude mixture was purified by flash column 
chromatography on silica gel (n-hexane/EtOAc: 8/1) to yield 144aa' (106 mg, 93%) or 145aa' 












M.p.: 58 °C 
1
H-NMR (300 MHz, CDCl3): δ = 7.69 (bs, 1H), 7.64–7.54 (m, 1H), 7.31–7.26 (m, 1H), 7.23–7.14 (m, 
2H), 6.31 (dt, J = 0.8, 0.8 Hz, 1H), 2.74 (tt, J = 7.5, 7.5 Hz, 2H), 1.75 (tt, J = 7.5, 7.5 Hz, 2H), 1.48–
1.34 (m, 10H), 1.00 (t, J = 7.0 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ = 139.9 (Cq), 135.7 (Cq), 128.7 (Cq), 120.7 (CH), 119.6 (CH), 119.4 
(CH), 110.2 (CH), 99.3 (CH), 31.9 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.2 (CH2), 
22.7 (CH2), 14.2 (CH3).  
IR (ATR): 3407, 2925, 2854, 1458, 1288, 779, 748 cm
–1
.  
MS (EI) m/z (relative intensity): 229 ([M]
+
, 30), 144 (30), 130 (100).  








2-(Octan-2-yl)-1H-indole (145aa'):  
M.p.: 60 °C 
1
H-NMR (300 MHz, CDCl3): δ = 7.85 (bs, 1H), 7.55–7.49 (m, 1H), 7.32–7.26 (m, 1H), 7.17–7.01 (m, 
2H), 6.23 (dd, J = 0.8, 0.8 Hz, 1H), 2.88 (tq, J = 7.0, 7.0 Hz, 0.95H), 2.74 (t, J = 7.6 Hz, 0.05H), 1.75–
1.57 (m, 2H), 1.37–1.24 (m, 11H), 0.86 (t, J = 7.0 Hz, 3H).  
13
C-NMR (125 MHz, CDCl3): δ  = 144.9 (Cq), 135.5 (Cq), 128.6 (Cq), 120.8 (CH), 119.8 (CH), 119.5 
(CH), 110.2 (CH), 98.2 (CH), 37.3 (CH2), 33.4 (CH), 31.8 (CH2), 29.4 (CH2), 27.4 (CH2), 22.7 (CH2), 
20.7 (CH3), 14.2 (CH3).  
IR (ATR): 3406, 2926, 2855, 1458, 781, 749 cm
–1
.  
MS (EI) m/z (relative intensity): 229 ([M]
+
, 40), 158 (20), 144 (100), 130 (45).  
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5.4.3 Mechanistic Studies 
5.4.3.1 Kinetic Isotope Effect 




Two parallel reactions of 105a or [D]1-105a with 143a were performed respectively to determine the 
KIE value by comparison of the initial reaction rates by GC-analysis with n-dodecane as the internal 
standard. A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv) or [D]1-105a (97.6 mg, 0.50 mmol, 
1.00 equiv), 143a (168 mg, 235 μL, 1.50 mmol, 3.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %) 
and AgSbF6 (34.4 mg, 20.0 mol %) in DCE (2.00 mL) was stirred at 120 °C. Aliquots (25 μL) were 
periodically removed to provide the following conversions as determined by GC-analysis: 
 
Table 32. KIE for the linear-selective reaction. 
 t / min 10 20 30 40 50 
 144aa / % 2.5 5.8 11.6 18.8 25.2 
 [D]n-144aa / % 1.0 5.4 8.7 16.3 21.0 
 




Two parallel reactions of 105a or [D]1-105a with 143a were performed respectively to determine the 
KIE value by comparison of the initial reaction rates by GC-analysis with n-dodecane as the internal 
standard. A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv) or [D]1-105a (97.6 mg, 0.50 mmol, 
1.00 equiv), 143a (168 mg, 235 μL, 1.50 mmol, 3.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and 1-AdCO2H (90.1 mg, 0.50 mmol, 1.00 equiv) in DCE (2.00 mL) 
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was stirred at 50 °C. Aliquots (25 μL) were periodically removed to provide the following conversions 
as determined by GC-analysis: 
 
Table 33. KIE for the branched-selective reaction. 
 t / min 30 40 50 60 90 
 145aa / % 1.64 2.37 3.06 3.44 5.92 
 [D]n-145aa / % 0.76 1.36 1.67 1.98 3.38 
 
5.4.3.2 H/D-Exchange Experiments 




A suspension of 105a (146 mg, 0.75 mmol, 1.50 equiv), allylbenzene (143b) (59.1 mg, 0.50 mmol, 
1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %) and AgSbF6 (34.4 mg, 20.0 mol %) in DCE 
(0.9 mL) and CD3OD (0.1 mL) was stirred at 120 °C for 20 h. After removal of the solvents, the crude 
mixture was purified by column chromatography on silica gel (n-hexane/EtOAc: 20:1) to yield [D]n-
144ab (32.8 mg, 21%) and [D]n-105a (92.0 mg, 63% reis.) as yellow oils. 
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A suspension of 105a (146 mg, 0.75 mmol, 1.50 equiv), allylbenzene (143b) (59.1 mg, 0.50 mmol, 
1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %) and 1-AdCO2H 
(90.1 mg, 0.50 mmol, 1.00 equiv) in DCE (0.4 mL) and CD3OD (0.1 mL) was stirred at 50 °C for 
20 h. After removal of the solvents, the crude mixture was purified by column chromatography on 
silica gel (n-hexane/EtOAc: 20:1) to yield [D]n-145ab (64.0 mg, 41%) and [D]n-105a (77.1 mg, 53% 
reis.) as yellow oils. 
 
 








A suspension of 1-pentadecene (143c) (105 mg, 135 μL, 1.00 mmol, 1.00 equiv), [Cp*Co(CO)I2] 
(23.8 mg, 10.0 mol %) and AgSbF6 (34.4 mg, 20.0 mol %) in DCE (1.8 mL) and CD3OD (0.2 mL) 
was stirred at 120 °C for 20 h. After removal of the solvents, the crude mixture was purified by 
column chromatography on silica gel (n-hexane/EtOAc: 50:1) to yield [D]n-143c (103 mg, 98% reis.) 
as a colorless oil. 
 
 









A suspension of 1-pentadecene (143c) (105 mg, 135 μL, 1.00 mmol, 1.00 equiv), [Cp*Co(CO)I2] 
(23.8 mg, 10.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %) and 1-AdCO2H (90.1 mg, 0.50 mmol, 
1.00 equiv) in DCE (1.8 mL) and CD3OD (0.2 mL) was stirred at 50 °C for 20 h. After removal of the 
solvents, the crude mixture was purified by column chromatography on silica gel (n-hexane/EtOAc: 
50:1) to yield [D]n-143c (98.7 mg, 94% reisolated) as a colorless oil. 
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5.4.3.2.5 H/D-exchange with [D]1-105a 
 
A suspension of [D]1-105a (97.6 mg, 0.50 mmol, 1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), 
AgSbF6 (34.4 mg, 20.0 mol %) in DCE (1.0 mL) was stirred at 120 °C for 20 h. After removal of the 
solvents, the crude mixture was purified by column chromatography on silica gel (n-hexane/EtOAc: 
20:1) to yield [D]n-105a (90.2 mg, 93% reisolated) as a colorless oil. 





5.4.3.2.6 H/D-exchange with [D]1-105a under the reaction conditions  
 
 
As suspension of [D]1-105a (146 mg, 0.75 mmol, 1.50 equiv), 143a (56.0 mg, 0.50 mmol, 1.00 equiv), 
[Cp*Co(CO)I2] (23.8 mg, 10.0 mol %) and AgSbF6 (34.4 mg, 20.0 mol %) in DCE (1.0 mL) was 
stirred at 120 °C for 20 h. After removal of the solvents, the crude mixture was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 20:1) to yield [D]n-144aa (88.7 mg, 58%) and [D]n-
105a (97.8 mg, 67% reisolated) as yellow oils. 
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5.4.3.2.7 H/D-exchange with linear product 144ab 
 
A suspension of 144ab (156 mg, 0.50 mmol, 1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), 
AgSbF6 (34.4 mg, 20.0 mol %) in DCE (1.8 mL) and CD3OD (0.2 mL) was stirred at 120 °C for 20 h. 
After removal of the solvents, the crude mixture was purified by column chromatography on silica gel 
(n-hexane/EtOAc: 20:1) to yield [D]n-144ab (108 mg, 69% reisolated) as a colorless oil. 
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5.4.3.2.8 H/D-exchange with branched product 145ab 
 
A suspension of 145ab (156 mg, 0.50 mmol, 1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), 
AgSbF6 (34.4 mg, 20.0 mol %) in DCE (1.8 mL) and CD3OD (0.2 mL) was stirred at 120 °C for 20 h. 
After removal of the solvents, the crude mixture was purified by column chromatography on silica gel 
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A suspension of 5-methoxy-1-(pyridin-2-yl)-1H-indole (105b) (112 mg, 0.50 mmol, 1.00 equiv), 5-
fluoro-1-(pyridin-2-yl)-1H-indole (105m) (106 mg, 0.50 mmol, 1.00 equiv), n-octene (143a) (66.1 mg, 
0.50 mmol, 1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %) and 1-
AdCO2H (90.1 mg, 0.50 mmol, 1.00 equiv) in DCE (0.50 mL, 1.00 M) was stirred at 50 °C for 20 h. 
At ambient temperature, the solvent was removed in vacuo and the remaining residue was purified by 
column chromatography (n-hexane/EtOAc: 30/1) to afford the products 145ba (18.5 mg, 11%) and 
145ma (11.3 mg, 7%). 
 




A suspension of 144aa (153 mg, 0.50 mmol, 1.00 equiv, AM:M > 99:1), [Cp*Co(CO)I2] (23.8 mg, 
10.0 mol %), AgSbF6 (34.4 mg, 20.0 mol %) and 1-AdCO2H (90.1 mg, 0.50 mmol, 1.00 equiv) in 
DCE (0.5 mL, 1.0 M) was stirred at 50 °C for 20 h. At ambient temperature, the solvent was removed 
and the crude mixture was purified by flash column chromatography on silica gel (n-hexane/EtOAc: 
10/1) to yield 144aa (145 mg, 95%, AM:M > 99:1) as a yellow oil. 
 




A suspension of 145aa (153 mg, 0.50 mmol, 1.00 equiv, AM:M = 5:95), [Cp*Co(CO)I2] (23.8 mg, 
10.0 mol %) and AgSbF6 (34.4 mg, 20.0 mol %) in DCE (1.0 mL, 0.5 M) was stirred at 120 °C for 
20 h. At ambient temperature, the solvent was removed and the crude mixture was purified by flash 
column chromatography on silica gel (n-hexane/EtOAc: 10/1), yielding 145aa (144 mg, 94%, 
AM:M = 5:95) as a yellow oil. 
 
5.4.3.5 Kinetic Studies for the anti-Markovnikov-selective reaction  




The reaction order was examined using the initial rate method. A suspension of 105a (0.250, 0.400, 
0.500, 0.600 and 0.750 mmol), 143a (168 mg, 1.50 mmol), [Cp
*
Co(CO)I2] (23.8 mg, 50.0 μmol) and 
AgSbF6 (34.4 mg, 100 μmol) was stirred at 120 °C in DCE (2.0 mL). Aliquots up to ca. 10−20% 
conversion (25 μL; 5, 10, 15, 20, 25 min) were periodically removed by a syringe and directly 
analyzed by GC using n-dodecane (30 μL) as the internal standard. 
Table 34. Reaction order in [105a] for the linear-selective reaction. 
Entry c / mol L
−1




log (c / mol L
−1





1 0.125 7.224E-6 -0.9031 -5.141 
2 0.200 1.154E-5 -0.6990 -4.938 
3 0.250 1.851E-5 -0.6021 -4.733 
4 0.300 2.200E-5 -0.5229 -4.658 
5 0.375 2.643E-5 -0.4260 -4.578 
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5.4.3.5.2 Determination of the reaction order with respect to the concentration of 1-octene 
(143a) 
The reaction order was examined using the initial rate method. A suspension of 105a (97.1 mg, 
0.50 mmol), 143a (0.25, 0.38, 0.50, 0.75, 1.00, 1.50, 2.00 mmol), [Cp
*
Co(CO)I2] (23.8 mg, 50.0 μmol) 
and AgSbF6 (34.4 mg, 100 μmol) was stirred at 120 °C in DCE (2.0 mL). Aliquots up to ca. 10−20% 
conversion (25 μL; 5, 10, 15, 20, 25 min) were periodically removed by a syringe and directly 
analyzed by GC using n-dodecane (30 μL) as the internal standard. 
 
Table 35. Reaction order in [143a] for the linear-selective reaction. 
Entry c / mol L
−1




log (c / mol L
−1





1 0.125 1.107E-5 -0.9031 -4.956 
2 0.188 1.206E-5 -0.7270 -4.919 
3 0.250 1.414E-5 -0.6021 -4.850 
4 0.375 1.491E-5 -0.4260 -4.826 
5 0.500 1.721E-5 -0.3010 -4.764 
6 0.750 1.849E-5 -0.1249 -4.733 
7 1.000 2.056E-5 0 -4.687 
 




The reaction order was examined using the initial rate method. A suspension of 105a (97.1 mg, 
0.50 mmol), 143a (112 mg, 1.50 mmol), [Cp
*
Co(CO)I2] (3.50, 5.00, 7.50, 10.0, 11.5 and 12.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) was stirred at 120 °C in DCE (2.0 mL). Aliquots up to ca. 10−20% 
conversion (25 μL; 5, 10, 15, 20, 25 min) were periodically removed by a syringe and directly 
analyzed by GC using n-dodecane (30 μL) as internal standard. 
 
Table 36. Reaction order in [Cp*Co(CO)I2] for the linear-selective reaction. 









1 3.50 6.250E-6 0.544 -5.204 
2 5.00 1.100E-5 0.699 -5.018 
3 7.50 1.338E-5 0.875 -4.873 
4 10.0 1.849E-5 1.000 -4.733 
5 11.5 2.451E-5 1.061 -4.678 
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6 12.5 3.055E-5 1.097 -4.580 
 
5.4.3.6 Kinetic Studies for the Markovnikov-selective reaction  
5.4.3.6.1 Determination of the reaction order with respect to the concentration of indole 105a 
 
The reaction order was examined using initial rate method. A suspension of 105a (0.150, 0.250, 0.400, 
0.500 and 0.750 mmol), 143a (168 mg, 1.50 mmol), [Cp
*
Co(CO)I2] (23.8 mg, 50.0 μmol), AgSbF6 
(34.4 mg, 100 μmol) and 1-AdCO2H (90.1 mg, 0.50 mmol) was stirred at 50 °C in DCE (2.0 mL). 
Aliquots up to ca. 10% conversion (25 μL; 15, 30, 40, 50, 60 min) were periodically removed by a 
syringe and directly analyzed by GC using n-dodecane (30 μL) as the internal standard. 
 
Table 37. Reaction order in [105a] for the branched-selective reaction. 
Entry c / mol L
−1




log (c / mol L
−1





1 0.075 4.332E-6 -1.125 -5.338 
2 0.125 4.797E-6 -0.903 -5.319 
3 0.200 4.288E-6 -0.699 -5.368 
4 0.250 5.473E-6 -0.602 -5.262 
5 0.375 4.587E-6 -0.426 -5.363 
 
5.4.3.6.2 Determination of the reaction order with respect to the concentration of 1-octene 
(143a) 
The reaction order was examined using the initial rate method. A suspension of 105a (97.1 mg, 
0.50 mmol), 143a (0.50, 0.75, 1.00, 1.25 and 1.50 mmol), [Cp
*
Co(CO)I2] (23.8 mg, 50.0 μmol), 
AgSbF6 (34.4 mg, 100 μmol) and 1-AdCO2H (90.1 mg, 0.50 mmol) was stirred at 50 °C in DCE 
(2.0 mL). Aliquots up to ca. 10% conversion (25 μL; 15, 30, 40, 50, 60 min) were periodically 
removed by a syringe and directly analyzed by GC using n-dodecane (30 μL) as the internal standard. 
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Table 38. Reaction order in [143a] for the branched-selective reaction. 









1 0.250 1.547E-6 -0.6021 -5.810 
2 0.375 2.261E-6 -0.4260 -5.646 
3 0.500 2.834E-6 -0.3010 -5.547 
4 0.625 3.689E-6 -0.2041 -5.433 
5 0.750 5.473E-6 -0.1249 -5.262 
 




The reaction order was examined using the initial rate method. A suspension of 105a (97.1 mg, 
0.50 mmol), 143a (112 mg, 1.50 mmol), [Cp
*
Co(CO)I2] (2.50, 3.50, 5.00, 7.50, 10.0 mol %), AgSbF6 
(34.4 mg, 100 μmol) and 1-AdCO2H (90.1 mg, 0.50 mmol) was stirred at 50 °C in DCE (2.0 mL). 
Aliquots up to ca. 10% conversion (25 μL; 15, 30, 40, 50, 60 min) were periodically removed by a 
syringe and directly analyzed by GC using n-dodecane (30 μL) as the internal standard. 
Table 39. Reaction order in [Cp*Co(CO)I2] for the branched-selective reaction. 









1 2.50 1.375E-6 0.3979 -5.862 
2 3.50 2.082E-6 0.5441 -5.681 
3 5.00 2.980E-6 0.6989 -5.526 
4 7.50 4.725E-6 0.8751 -5.326 
5 10.0 5.504E-6 1.0000 -5.260 
 
5.4.3.7 Arrhenius Plot Analysis 
5.4.3.7.1 Arrhenius plot of anti-Markovnikov-selective reaction 
A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv), 143a (112 mg, 1.50 mmol, 3.00 equiv), 
[Cp
*
Co(CO)I2] (23.8 mg, 10.0 mol %) and AgSbF6 (34.4 mg, 20 mol %) was stirred at different 
temperatures (105, 110, 115, 120, 125 and 130 °C) in DCE (2.0 mL). Aliquots up to ca. 10−25% 
conversion (25 μL; 15, 20, 25, 30, 35 min for 115−120 °C; 20, 25, 30, 35, 40 min for 105 °C and 
110 °C) were periodically removed by a syringe and directly analyzed by GC using n-dodecane 
(30 μL) as internal standard. 
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Table 40. Arrhenius plot analysis for the linear-selective reaction. 




1 / T (K
−1





1 105 6.573E-6 0.002644 -11.93 
2 110 9.438E-6 0.002610 -11.57 
3 115 1.642E-5 0.002576 -11.02 
4 120 1.849E-5 0.002544 -10.90 
5 125 2.618E-5 0.002512 -10.55 
6 130 4.398E-5 0.002480 -10.03 
5.4.3.7.2 Arrhenius plot of Markovnikov-selective reaction 
A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv), 143a (112 mg, 1.50 mmol, 3.00 equiv), 
[Cp
*
Co(CO)I2] (23.8 mg, 10.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 1-AdCO2H (90.1 mg, 
0.50 mmol) was stirred at different temperatures (40, 45, 50, 55 and 60 °C) in DCE (2.0 mL). Aliquots 
up to ca. 10% conversion (25 μL; 15, 30, 40, 50, 60 min) were periodically removed by a syringe and 
directly analyzed by GC using n-dodecane (30 μL) as the internal standard. 
Table 41. Arrhenius plot analysis for the branched-selective reaction. 




1 / T (K
−1





1 40 2.078E-6 0.003193 -13.08 
2 45 3.156E-6 0.003143 -12.67 
3 50 5.473E-6 0.003095 -12.12 
4 55 5.953E-6 0.003047 -12.03 
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5.5 Cobalt(III)-Catalyzed C−H/C–F Functionalization  
5.5.1 Characterization Data 
 
 
(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-1-(pyridin-2-yl)-1H-indole (158aa): The general 
procedure F was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 158aa (301 mg, 97%, Z/E = 86:14) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.88 (ddd, J = 7.9, 7.6, 1.9 Hz, 
1H), 7.61 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.41 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.41–7.35 (m, 1H), 7.31 
(ddd, J = 7.3, 4.9, 0.9 Hz, 1H), 7.25−7.12 (m, 2H), 6.50 (d, J = 0.9 Hz, 1H), 6.16 (dt, J = 22.3, 8.1 Hz, 
0.14H, E), 5.82 (dt, J = 33.0, 7.5 Hz, 0.86H, Z), 3.90 (ddt, J = 7.5, 2.4, 1.8 Hz, 1.72H, Z), 3.84 (ddt, J 
= 8.1, 2.5, 1.8 Hz, 0.28H, E).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 150.8 (Cq), 149.6 (CH), 146.1 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 29.1 Hz, 
Cq), 138.3 (CH), 137.1 (Cq), 136.1 (Cq), 128.3 (Cq), 122.4 (CH), 122.1 (CH), 121.0 (CH), 120.5 (CH), 
120.0 (CH), 117.0 (dt, 
1
JC–F = 288 Hz,
 2
JC–F = 31.3 Hz, Cq), 113.3 (dt, 
2
JC‒F = 8.1 Hz, 
3
JC‒F = 4.2 Hz, 
CH), 112.4 (m, Cq), 110.9 (m, Cq), 110.7 (m, Cq), 110.5 (m, Cq), 108.6 (m, Cq), 108.3 (m, Cq), 110.1 
(CH), 106.7 (CH), 22.7 (d, 
3
JC‒F = 4.3 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –115.0 (m, E), –117.5 (m, Z), –122.0 (m), –122.1 (m), 
–122.8 (m), –123.0 (m), –126.3 (m), –130.8 (m).  
IR (ATR): 3061, 1589, 1472, 1455, 1439, 1197, 1107, 736 cm
–1
.  
MS (ESI) m/z (relative intensity): 643 ([M + Na]
+
, 20), 621 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C23H13F16N2]
+
 [M + H]
+ 
621.0818, found 621.0809. 
 
 
Z)-2-(1H,1H,2H-Perfluorohex-2-en-1-yl)-1-(pyridin-2-yl)-1H-indole (158ab): The general 
procedure F was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 
1H,1H,2H-perfluorohex-1-ene (127b) (148 mg, 0.60 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 158ab (197 mg, 94%, Z/E = 86:14) as a yellow oil.  
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1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.88 (ddd, J = 7.9, 7.6, 1.9 Hz, 
1H), 7.61 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.45 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.43–7.35 (m, 1H), 7.31 
(ddd, J = 7.1, 4.7, 0.9 Hz, 1H), 7.25−7.14 (m, 2H), 6.50 (d, J = 0.9 Hz, 1H), 6.16 (dt, J = 22.0, 7.9 Hz, 
0.14H, E), 5.82 (dt, J = 33.0, 7.4 Hz, 0.86H, Z), 3.90 (ddt, J = 7.4, 2.4, 1.8 Hz, 1.72H, Z), 3.84 (ddt, J 
= 7.9, 2.5, 1.8 Hz, 0.28H, E).
  
13
C-NMR (125 MHz, CDCl3): 𝛿  = 150.8 (Cq), 149.6 (CH), 145.8 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 29.1 Hz, 
Cq), 138.3 (CH), 137.0 (Cq), 136.0 (Cq), 128.2 (Cq), 122.4 (CH), 122.1 (CH), 121.0 (CH), 120.5 (CH), 
120.3 (CH), 117.5 (dt, 
1
JC–F = 288 Hz,
 2
JC–F = 31.3 Hz, Cq), 113.3 (td, 
2
JC‒F = 8.1 Hz, 
3
JC‒F = 4.2 Hz, 
CH), 110.1 (CH), 109.9 (m, Cq), 108.3 (m, Cq), 103.6 (CH), 22.7 (d, 
3
JC‒F = 4.3 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.8 (m), –115.9 (m, E), –118.4 (m, Z), –127.3 (m, Z), –127.9 (m, 
E), –131.0 (m).  
IR (ATR): 3059, 1587, 1119, 782, 737 cm
–1
.  
MS (ESI) m/z (relative intensity): 421 ([M + H]
+
, 100), 197 (20).  
HR-MS (ESI): m/z calcd. for [C19H13F8N2]
+
 [M + H]
+ 




(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-methoxy-1-(pyridin-2-yl)-1H-indole (158ba): The 
general procedure F was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (105b) (112 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 158ba (293 mg, 90%, Z/E = 86:14) as a colorless 
solid.  
M.p.: 98 °C 
1
H-NMR (500 MHz, CDCl3): 𝛿 = 8.61 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.87 (ddd, J = 7.9, 7.6, 1.9 Hz, 
1H), 7.41 (ddd, J = 7.9, 1.0, 0.9 Hz, 1H), 7.31−7.23 (m, 2H), 7.05 (d, J = 2.5 Hz, 1H), 6.81 (dd, J = 
9.0, 2.5 Hz, 1H), 6.41 (d, J = 0.9 Hz, 1H), 6.13 (dt, J = 22.5, 8.0 Hz, 0.14H, E), 5.76 (dt, J = 33.0, 




C-NMR (125 MHz, CDCl3): 𝛿 = 154.9 (Cq), 150.9 (Cq), 149.6 (CH), 145.8 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F 
= 29.1 Hz, Cq), 138.1 (CH), 136.5 (Cq), 132.1 (Cq), 128.8 (Cq), 121.9 (CH), 120.1 (CH), 116.8 (dt, 
1
JC–F = 287 Hz,
 2
JC–F = 31.0 Hz, Cq), 113.3 (dt, 
2
JC‒F  = 8.4 Hz, 
3
JC‒F  = 4.5 Hz, CH), 112.5 (m, Cq), 
112.1 (CH), 111.0 (CH), 110.5 (m, Cq), 110.2 (m, Cq), 110.0 (m, Cq), 108.6 (m, Cq), 108.2 (m, Cq), 
103.5 (CH), 102.3 (CH), 55.8 (CH3), 22.8 (d, 
3
JC‒F  =  4.3 Hz, CH2).  




F-NMR (376 MHz, CDCl3): δ = –80.9 (m), –117.5 (m), –122.0 (m), –122.8 (m), –122.9 (m), –123.4 
(m), –126.2 (m), –130.9 (m).  
IR (ATR): 1474, 1450, 1438, 1237, 1201, 1146, 907, 729, 649 cm
–1
.  
MS (ESI) m/z (relative intensity): 673 ([M + Na]
+
, 20), 651 ([M + H]
+
, 100), 381 (15).  
HR-MS (ESI): m/z calcd. for [C24H15F16N2O]
+
 [M + H]
+ 




(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-methyl-1-(pyridin-2-yl)-1H-indole (158fa): The 
general procedure F was followed using 5-methyl-1-(pyridin-2-yl)-1H-indole (105f) (104 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 158fa (244 mg, 77%, Z/E = 86:14) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 8.62 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.84 (ddd, J = 8.0, 7.6, 1.9 Hz, 
1H), 7.46 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.38 (dd, J = 1.7, 0.9 Hz, 1H), 7.31–7.29 (m, 2H), 7.00 (dd, J 
= 8.4, 1.7 Hz, 1H), 6.41 (d, J = 0.9 Hz, 1H), 6.15 (dt, J = 22.4, 8.0 Hz, 0.14H, E), 5.80 (dt, J = 32.8, 
7.6 Hz, 0.86H, Z), 3.89 (ddt, J = 7.6, 2.5, 1.7 Hz, 1.72H, Z), 3.83 (ddt, J = 8.0, 2.4, 1.7 Hz, 0.28H, E), 
2.45 (s, 3H). 
13
C-NMR (100 MHz, CDCl3): 𝛿 = 151.0 (Cq), 149.6 (CH), 146.1 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 28.3 Hz, 
Cq), 138.3 (CH), 136.2 (Cq), 135.5 (Cq), 130.4 (Cq), 128.6 (Cq), 123.9 (CH), 121.9 (CH), 120.3 (CH), 
120.2 (CH), 117.4 (dt, 
1
JC–F = 289 Hz,
 2
JC–F = 33.9 Hz, Cq), 113.4 (dt, 
2
JC‒F = 8.1 Hz, 
3
JC‒F = 4.2 Hz, 
CH), 112.9 (m, Cq), 110.9 (m, Cq), 110.6 (m, Cq), 110.2 (m, Cq), 109.8 (CH), 108.3 (m, Cq), 107.8 (m, 
Cq), 103.4 (CH), 22.8 (d, 
3
JC‒F = 4.2 Hz, CH2), 21.3 (CH3). 
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.8 (m), –114.9 (m, E), –117.5 (m, Z), –122.0 (m), –122.1 (m),  
–122.8 (m), –122.9 (m), –126.2 (m), –131.1 (m).  
IR (ATR): 2921, 1599, 1473, 1439, 1237, 1201, 1146, 908, 731 cm
–1
.  
MS (ESI) m/z (relative intensity): 635 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C24H15F16N2]
+
 [M + H]
+ 









(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-fluoro-1-(pyridin-2-yl)-1H-indole (158ma): The 
general procedure F was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (105m) (106 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 158ma (271 mg, 85%, Z/E = 86:14) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿  = 8.62 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.84 (ddd, J = 8.0, 7.5, 1.9 Hz, 
1H), 7.43 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.33 (ddd, J = 7.5, 1.9, 1.0 Hz, 1H), 7.29 (dd, J = 9.1, 4.3 Hz, 
1H), 7.26 (dd, J = 9.3, 2.5 Hz, 1H), 6.89 (dt, J = 9.1, 2.5 Hz, 1H), 6.43 (d, J = 0.9 Hz, 1H), 6.10 (dt, 
J = 22.4, 8.2 Hz, 0.14H, E), 5.77 (dt, J = 32.5, 7.0 Hz, 0.86H, Z), 3.79 (ddt, J = 7.0, 2.4, 1.5 Hz, 
1.72H, Z), 3.85 (ddt, J = 8.2, 2.5, 1.7 Hz, 0.28H, E). 
13
C-NMR (125 MHz, CDCl3): δ = 158.5 (d, 
1
JC‒F = 236 Hz, Cq), 150.7 (Cq), 149.8 (CH), 146.2 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 29.0 Hz, Cq), 138.6 (CH), 137.7 (Cq), 133.7 (Cq), 128.8 (d, 
3
JC‒F = 10.3 Hz, Cq), 
122.4 (CH), 120.4 (CH), 117.2 (dt, 
1
JC–F = 285 Hz,
 2
JC–F = 33.3 Hz, Cq), 113.7 (m, Cq), 113.0 (dt, 
2
JC‒F  
= 8.5 Hz, 
3
JC‒F  = 4.4 Hz, CH), 112.4 (m, Cq), 110.9 (d, 
2
JC‒F = 9.5 Hz, CH), 110.5 (d, 
2
JC‒F = 26.0 Hz, 
CH), 110.4 (m, Cq), 110.0 (m, Cq), 108.6 (m, Cq), 108.2 (m, Cq), 105.4 (d, 
2
JC‒F = 23.7 Hz, CH), 103.5 
(d, 
3
JC‒F = 4.3 Hz, CH), 22.7 (d, 
3
JC‒F = 4.3 Hz, CH2).  
19
F-NMR (470 MHz, CDCl3): δ = –81.0 (m), –117.6 (m), –122.1 (m), –122.9 (m), –123.0 (m) –123.4 
(m), –123.5 (m), –126.3 (m), –130.5 (m). 
IR (ATR): 1473, 1450, 1439, 1235, 1143, 776, 663 cm
–1
.  
MS (ESI) m/z (relative intensity): 661 ([M + Na]
+
, 15), 639 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C23H12F17N2]
+
 [M + H]
+ 




(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-bromo-1-(pyridin-2-yl)-1H-indole (158ca): The 
general procedure F was followed using 5-bromo-1-(pyridin-2-yl)-1H-indole (105c) (136 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 158ca (324 mg, 93%, Z/E = 84:16) as an off-white 
solid.  
M.p.: 59 °C 




H-NMR (400 MHz, CDCl3): 𝛿 = 8.63 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.90 (ddd, J = 7.9, 7.6, 1.9 Hz, 
1H), 7.70 (dd, J = 1.4, 0.4 Hz, 1H), 7.41 (ddd, J = 7.9, 1.0, 0.8 Hz, 1H), 7.34 (ddd, J = 7.6, 4.9, 1.0 Hz, 
1H), 7.25−7.15 (m, 2H), 6.41 (d, J = 0.9 Hz, 1H), 6.11 (dt, J = 22.5, 8.3 Hz, 0.16H, E), 5.75 (dt, J = 




C-NMR (125 MHz, CDCl3): 𝛿 = 150.1 (Cq), 149.9 (CH), 146.1 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 29.5 Hz, 
Cq), 138.6 (CH), 137.4 (Cq), 135.8 (Cq), 129.9 (Cq), 125.1 (CH), 122.6 (CH), 122.0 (CH), 120.5 (CH), 
117.2 (dt, 
1
JC–F = 288 Hz,
 2
JC–F = 31.3 Hz, Cq), 114.2 (Cq), 112.9 (dt, 
2
JC‒F = 8.1 Hz, 
3
JC‒F = 4.3 Hz, 
CH), 112.3 (m, Cq), 111.6 (CH), 110.6 (m, Cq), 110.4 (m, Cq), 110.1 (m, Cq), 108.5 (m, Cq), 108.3 (m, 
Cq), 102.9 (CH), 22.6 (d, 
3
JC‒F = 4.3 Hz, CH2).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –80.9 (m), –114.9 (m, E), –117.5 (m, Z), –122.0 (m), –122.0 (m),  
–122.7 (m), –122.9 (m), –126.2 (m), –130.4 (m).  
IR (ATR): 1588, 1472, 1443, 1236, 1200, 1146, 907, 731 cm
–1
.  




, 100), 275 (80).  




 [M + H]
+ 




(Z)-2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-5-iodo-1-(pyridin-2-yl)-1H-indole (158da): The general 
procedure F was followed using 5-iodo-1-(pyridin-2-yl)-1H-indole (105d) (160 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded 158da (346 mg, 93%, Z/E = 82:18) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.62 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.98−7.82 (m, 2H), 7.45−7.38 
(m, 2H), 7.33 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 7.10 (dd, J = 8.7, 0.6 Hz, 1H), 6.40 (d, J = 0.9 Hz, 
0.18H, E), 6.39 (d, J = 0.9 Hz, 0.82H, Z), 6.09 (dt, J = 22.5, 8.0 Hz, 0.18H, E), 5.76 (dt, J = 33.0, 
7.5 Hz, 0.82H, Z), 3.90 (ddt, J = 7.5, 2.4, 1.8 Hz, 1.63H, Z), 3.84 (ddt, J = 8.0, 2.5, 1.8 Hz, 0.37H, E).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 150.3 (Cq), 149.8 (CH), 146.1 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 29.1 Hz, 
Cq), 138.5 (CH), 137.0 (Cq), 136.3 (CH), 130.6 (Cq), 130.4 (Cq), 129.8 (CH), 122.5 (CH), 117.2 (dt, 
1
JC–F = 288 Hz,
 2
JC–F = 31.3 Hz, Cq), 112.1 (CH), 112.9 (dt, 
2
JC‒F = 8.1 Hz, 
3
JC‒F = 4.2 Hz, CH), 112.4 
(m, Cq), 112.1 (CH), 110.7 (m, Cq), 110.3 (m, Cq), 110.2 (m, Cq), 108.5 (m, Cq), 108.2 (m, Cq), 102.7 
(CH), 84.5 (Cq), 22.6 (d, 
3
JC‒F = 4.3 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –117.6 (m), –122.1 (m), –121.9 (m), –122.9 (m), –123.5 
(m), –126.2 (m), –130.4 (m).  
IR (ATR): 3044, 1587, 1472, 1443, 1240, 1209, 1150, 904, 725 cm
–1
.  
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MS (ESI) m/z (relative intensity): 769 ([M + Na]
+
, 20), 747 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C23H12F16IN2]
+
 [M + H]
+ 





(158pa): A modified general procedure F was followed using methyl 2-(1-(pyridin-2-yl)-1H-indol-3-
yl)propanoate (105p) (140 mg, 0.50 mmol) and 1H,1H,2H-perfluoro-1-decene (127a) (268 mg, 0.60 
mmol) at 70 °C. Isolation by column chromatography (n-hexane/EtOAc = 10:1) yielded 158pa 
(237 mg, 67%, Z/E = 80:20) as a white solid.  
M.p.: 70 °C.  
1
H-NMR (400 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.87 (ddd, J = 8.1, 7.5, 1.9 Hz, 
1H), 7.60–7.55 (m, 1H), 7.44 (ddd, J = 8.1, 1.0, 0.8 Hz, 1H), 7.34–7.27 (m, 2H), 7.20–7.12 (m, 2H),  
5.89 (dt, J = 23.2, 8.3 Hz, 0.20H, E), 5.61 (dt, J = 33.3, 7.0 Hz, 0.80H, Z), 3.94–3.90 (m, 2H), 3.65 (s, 
3H), 3.12 (t, J = 7.8 Hz, 2H), 2.69 (t, J = 7.8 Hz, 2H).  
13
C-NMR (100 MHz, CDCl3): δ = 173.4 (Cq), 150.9 (Cq), 149.7 (CH), 144.7 (dt, 
1
JC‒F = 260 Hz, 
2
JC‒F 
= 29.1 Hz, Cq), 138.5 (CH), 136.6 (Cq), 132.2 (d, 
4
JC‒F = 2.0 Hz, Cq), 127.9 (Cq), 122.8 (CH), 122.1 
(CH), 120.8 (CH), 120.7 (CH), 118.6 (CH), 116.9 (dt, 
1
JC–F = 282 Hz,
 2
JC–F = 33.0 Hz, Cq), 114.4 (Cq), 
114.0 (dt, 
2
JC‒F = 8.1 Hz, 
3
JC‒F = 4.3 Hz, CH), 113.2 (m, Cq), 110.8 (m, Cq), 110.7 (m, Cq), 110.5 (m, 
Cq), 110.1 (CH), 108.1 (Cq), 107.4 (m, Cq), 51.6 (CH3), 34.7 (CH2), 20.2 (d, 
3
JC‒F = 4.2 Hz, CH2), 19.6 
(CH2).  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –80.8 (m), –115.4 (m, E), –117.3 (m, Z), –122.0 (m), −122.1 (m), 
–122.7 (m), –122.9 (m), –126.2 (m), –131.1 (m).  
IR (ATR): 2955, 1737, 1586, 1472, 1439, 1200, 1144, 732 cm
–1
.  
MS (ESI) m/z (relative intensity): 707 ([M + H]
+
, 100), 687 (10).  








(Z)-2-[2-(1H,1H,2H-Perfluorodec-2-en-1-yl)-1H-pyrrol-1-yl]pyridine (160): The general procedure 
G was followed using 2-(1H-pyrrol-1-yl)pyridine (146) (72.1 mg, 0.50 mmol) and 1H,1H,2H-
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perfluorodec-1-ene (127a) (268 mg, 0.60 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded 160 (174 mg, 61%, Z/E = 84:16) and 160' (40 mg, 8%, Z/E = 84:16) as 
yellow oils.  
1
H-NMR (400 MHz, CDCl3): δ = 8.47 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.77 (ddd, J = 8.2, 7.5, 1.9 Hz, 
1H), 7.28 (ddd, J = 8.2, 1.0, 0.9 Hz, 1H), 7.18 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.01 (dd, J = 3.1, 1.8 Hz, 
1H), 6.24 (dd, J = 3.1, 3.0 Hz, 1H), 6.16 (dt, J = 22.7, 8.2 Hz, 0.16H, E), 6.12–6.09 (m, 1H) 5.81 (dt, J 
= 33.4, 7.5 Hz, 0.84H, Z), 3.88 (ddt, J = 7.5, 3.9, 2.0 Hz, 1.68H, Z), 3.83 (ddt, J = 7.5, 4.0, 2.0 Hz, 
0.32H, E).  
13
C-NMR (100 MHz, CDCl3): δ = 152.5 (Cq), 148.6 (CH), 145.4 (dt, 
1
JC–F = 260 Hz, 
2
JC–F = 30.1 Hz, 
Cq), 138.5 (CH), 129.1 (Cq), 121.2 (CH), 121.0 (CH), 116.9 (dt, 
1
JC–F = 285 Hz,
 2
JC–F = 33.3 Hz, Cq), 
116.6 (CH), 114.6 (dt, 
2
JC‒F = 8.3 Hz, 
3
JC‒F = 4.3 Hz, CH), 112.2 (m, Cq), 111.3 (m, Cq), 111.2 (m, Cq), 
110.9 (m, Cq), 110.7 (CH), 109.7 (CH), 108.6 (m, Cq), 107.8 (Cq), 22.9 (d, 
3
JC−F = 4.2 Hz, CH2).  
19
F-NMR (376 MHz, CDCl3): δ = –80.8 (m), –117.5 (m), –122.0 (m), –122.8 (m), –123.0 (m), –123.5 
(m), –126.2 (m), –132.3 (m).  
IR (ATR): 1523, 1504, 1325, 1182, 992, 754 cm
–1
.  
MS (ESI) m/z (relative intensity): 593 ([M + Na]
+
, 20), 571 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C19H11F16N2]
+
 [M + H]
+ 




(Z)-2-[2,5-Di-(1H,1H,2H-Perfluorodec-2-en-1-yl)-1H-pyrrol-1-yl]pyridine (160'):  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 8.59 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.84 (ddd, J = 8.0, 7.8, 1.9 Hz, 
1H), 7.34 (ddd, J = 7.8, 4.9, 1.2 Hz, 1H), 7.20 (ddd, J = 8.0, 1.2, 0.9 Hz, 1H), 6.00 (s, 2H), 5.91 (dt, J 
= 22.5, 8.3 Hz, 0.32H, E), 5.61 (dt, J = 33.0, 7.6 Hz, 1.68H, Z), 3.47 (ddt, J = 7.6, 2.4, 1.8 Hz, 3.36H, 
Z), 3.40 (ddt, J = 8.3, 2.5, 1.8 Hz, 0.64H, E).
  
13
C-NMR (100 MHz, CDCl3): δ = 150.7 (Cq), 149.8 (CH), 145.7 (dt, 
1
JC–F = 259 Hz, 
2
JC–F = 30.1 Hz, 
Cq), 138.4 (CH), 129.1 (Cq), 123.1 (CH), 121.9 (CH), 117.4 (dt, 
1
JC–F = 288 Hz,
 2
JC–F = 33.3 Hz, Cq), 
112.6 (dt, 
2
JC‒F = 8.3 Hz, 
3
JC‒F = 4.3 Hz, CH), 111.2 (m, Cq), 110.8 (m, Cq), 110.2 (m, Cq), 109.7 (m, 
Cq), 108.8 (m, Cq), 108.2 (m, Cq), 107.8 (CH), 21.3 (d, 
3
JC–F = 4.1 Hz, CH2).  
19
F-NMR (376 MHz, CDCl3): δ = –81.2 (m), –117.7 (m), –121.9 (m), –122.2 (m), −123.1 (m), – 123.1 
(m), –126.4 (m), –131.8 (m).  
IR (ATR): 2960, 2924, 1473, 1235, 1143, 1047, 735, 559 cm
–1
.  
MS (ESI) m/z (relative intensity): 997 ([M + H]
+
, 100), 573 (20), 545 (15).  
HR-MS (ESI): m/z calcd. for [C29H13F32N2]
+
 [M + H]
+ 
997.0562, found: 997.0553. 




(Z)-1-[4-(tert-Butyl)-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]-1H-pyrazole (161c): A 
modified general procedure F was followed using 1-[4-(tert-butyl)phenyl]-1H-pyrazole (18c) 
(100 mg, 0.50 mmol), 1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol), [Cp*Co(CO)I2] 
(23.7 mg, 10 mol %) and AgSbF6 (34.4 mg, 20 mol %) at 70 °C. Isolation by column chromatography 
(n-hexane/EtOAc: 20/1) yielded 161c (248 mg, 79%, Z/E = 87:13) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 7.70 (dd, J = 2.2, 1.7 Hz, 1H), 7.56 (d, J = 4.0, 2.4 Hz, 1H), 7.36 
(dd, J = 8.2, 2.2 Hz, 1H), 7.30 (dd, J = 2.4, 2.1 Hz, 1H), 7.23 (dd, J = 8.2, 1.7 Hz, 1H), 6.42 (dd, 
J = 4.0, 2.1 Hz, 1H), 5.90 (dt, J = 21.8, 7.9 Hz, 0.13H, E), 5.67 (dt, J = 33.3, 7.6 Hz, 0.87H, Z), 3.79 
(ddt, J = 7.6, 4.1, 2.5 Hz, 2H), 1.33 (s, 9H).
  
13
C-NMR (100 MHz, CDCl3): 𝛿 = 152.2 (Cq), 145.7 (dt, 
1
JC‒F = 259 Hz,
 2
JC‒F = 29.1 Hz, Cq), 140.5 
(CH), 137.1 (Cq), 132.9 (Cq), 130.3 (CH), 127.3 (CH), 125.8 (CH), 124.7 (CH), 117.0 (dt,  
1
JC‒F = 289 Hz, 
2
JC‒F = 31.3 Hz, Cq), 114.7 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.0 (m, Cq), 
112.0 (m, Cq), 110.6 (m, Cq), 110.0 (m, Cq), 108.6 (m, Cq), 108.1 (m, Cq), 106.5 (CH), 34.7 (CH), 31.2 
(CH3), 26.3 (d, 
3
JC‒F = 3.7 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –114.5 (m, E), –117.5 (m), –122.1 (m), –122.1 (m),  
–122.9 (m, Z), –123.1 (m, E), –123.5 (m), –126.2 (m), –132.3 (m).  
IR (ATR): 2968, 1522, 1238, 1201, 1146, 909, 732 cm
–1
.  
MS (EI) m/z (relative intensity): 626 ([M]
+
, 100), 611 (20), 598 (10).  
HR-MS (ESI): m/z calcd. for [C23H19F16N2]
+
 [M + H]
+ 




(Z)-1-[4-(Methoxy)-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]-1H-pyrazole (161d): A modified 
general procedure F was followed using 1-[4-(methoxy)phenyl]-1H-pyrazole (18d) (100 mg, 
0.50 mmol), 1H,1H,2H-perfluorodec-1-ene (127a) (268 mg, 0.60 mmol), [Cp*Co(CO)I2] (23.7 mg, 
10 mol %) and AgSbF6 (34.4 mg, 20 mol %) at 70 °C. Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded 161d (159 mg, 53%, Z/E = 82:18) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 7.69 (dd, J = 1.9, 0.7 Hz, 1H), 7.59 (d, J = 2.3, 0.7 Hz, 1H), 7.24–
7.21 (m, 1H), 6.84 (dd, J = 8.6, 2.9 Hz, 1H), 6.79 (d, J = 2.9, 1H), 6.41 (dd, J = 2.3, 1.9 Hz, 1H), 5.88 
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(dt, J = 21.8, 7.9 Hz, 0.18H, E), 5.62 (dt, J = 33.3, 7.6 Hz, 0.82H, Z), 3.82 (s, 3H), 3.45 (ddt, J = 7.6, 
4.1, 2.5 Hz, 2H).  
13
C-NMR (100 MHz, CDCl3): 𝛿 = 160.0 (Cq), 146.0 (dt, 
1
JC‒F = 259 Hz,
 2
JC‒F = 29.1 Hz, Cq), 140.6 
(CH), 135.3 (Cq), 132.9 (Cq), 130.7 (CH), 127.8 (CH), 117.4 (dt, 
1
JC‒F = 289 Hz, 
2
JC‒F = 31.3 Hz, Cq), 
115.4 (CH), 114.2 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.5 (m, Cq), 112.6 (CH), 110.9 (m, Cq), 
110.8 (m, Cq), 110.6 (m, Cq), 108.6 (m, Cq), 107.7 (m, Cq), 106.5 (CH), 55.5 (CH3), 26.0 (d,  
3
JC‒F = 3.7 Hz, CH2).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –80.8 (m), –114.5 (m, E), –117.4 (m), –122.0 (m), –122.0 (m),  
–122.7 (m), –122.9 (m),–126.2 (m), −131.5 (m).  
IR (ATR): 2963, 1521, 1235, 1199, 1144, 1044, 735 cm
–1
.  
MS (ESI) m/z (relative intensity): 623 ([M + Na]
+
, 10), 601 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C20H13F16N2O]
+
 [M + H]
+ 




(Z)-2-(1-Fluoro-2-phenylvinyl)-1-(pyridin-2-yl)-1H-indole (159aa): The general procedure G was 
followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 1-(2,2-difluorovinyl)-
benzene (128a) (105 mg, 0.75 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 159aa (152 mg, 97%, Z/E = 99:1) as a colorless solid.  
M.p.: 68 °C. 
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.70 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.86 (ddd, J = 8.1, 7.5, 2.0 Hz, 
1H), 7.72 (ddd, J = 8.1, 1.0, 0.9 Hz, 1H), 7.56–7.52 (m, 4H), 7.35–7.16 (m, 6H), 7.03 (d, J = 0.9 Hz, 
1H), 6.48 (d, J = 18.9 Hz, 0.03H, E), 6.04 (d, J = 38.0 Hz, 0.97H, Z).  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 151.8 (Cq), 151.1 (d, 
1
JC–F = 257 Hz, Cq), 149.3 (CH), 138.4 (Cq), 
138.2 (CH), 133.3 (d, 
4
JC–F = 3.8 Hz, Cq), 132.3 (d, 
2
JC–F = 30.1 Hz, Cq), 128.9 (d, 
4
JC–F = 7.8 Hz, CH), 
128.6 (CH), 127.7 (Cq), 127.6 (CH), 124.4 (CH), 122.4 (CH), 121.7 (CH), 121.3 (CH), 120.7 (CH), 
111.4 (CH), 110.1 (d, 
2
JC–F = 9.4 Hz, CH), 107.6 (d, 
3
JC–F = 4.5 Hz, CH).  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –91.9 (d, J = 18.9 Hz), –105.9 (d, J = 38.0 Hz).  
IR (ATR): 3054, 3024, 1586, 1467, 1436, 1382, 1349, 1147, 783, 739 cm
–1
.  
MS (ESI) m/z (relative intensity): 337 ([M + Na]
+
, 100), 315 ([M + H]
+
, 20).  
HR-MS (ESI): m/z calcd. for [C21H16FN2]
+
 [M + H]
+ 
315.1292, found 315.1300. 
 




(Z)-2-(1-Fluoro-2-phenylvinyl)-5-methoxy-1-(pyridin-2-yl)-1H-indole (159ba): The general 
procedure G was followed using 5-methoxy-1-(pyridin-2-yl)-1H-indole (105b) (112 mg, 0.50 mmol) 
and 1-(2,2-difluorovinyl)-benzene (128a) (105 mg, 0.75 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 10/1) yielded 159ba (150 mg, 87%, Z/E > 99:1) as a colorless oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.82 (ddd, J = 8.0, 7.6, 2.0 Hz, 
1H), 7.51–7.46 (m, 3H), 7.58 (ddd, J = 8.0, 1.0, 0.9 Hz, 1H), 7.35–7.27 (m, 3H), 7.26–7.19 (m, 1H), 
7.09 (d, J = 2.5 Hz, 1H), 6.94 (d, J = 0.9 Hz, 1H), 6.92 (dd, J =  9.0, 2.5 Hz, 1H), 6.02 (d, J = 37.9 Hz, 
1H, Z), 3.86 (s, 3H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 155.2 (Cq), 151.6 (Cq), 150.8 (d, 
1
JC‒F = 258 Hz, Cq), 149.2 (CH), 
138.2 (CH), 133.7 (Cq), 133.2 (d, 
4
JC‒F = 3.9 Hz, Cq), 132.3 (d, 
2
JC‒F = 30.1 Hz, Cq), 128.7 (d, 
4
JC‒F = 
7.6 Hz, CH), 128.4 (CH), 128.2 (Cq), 127.4 (CH), 122.0 (CH), 120.3 (CH), 114.5 (CH), 112.2 (CH), 
109.8 (d, 
2
JC‒F = 9.7 Hz, CH), 107.2 (d, 
3
JC‒F = 3.9 Hz, CH), 102.3 (CH), 55.7 (CH3). 
19
F-NMR (282 MHz, CDCl3): 𝛿 = –106.0 (d, J = 37.9 Hz).  
IR (ATR): 3056, 2949, 1586, 1467, 1435, 1216, 1201, 1031, 839 cm
–1
.  
MS (ESI) m/z (relative intensity): 345 ([M + H]
+
, 100), 325 (20).  
HR-MS (ESI): m/z calcd. for [C22H18FN2O]
+
 [M + H]
+ 




(Z)-2-(1-Fluoro-2-phenylvinyl)-5-fluoro-1-(pyridin-2-yl)-1H-indole (159ma): The general 
procedure G was followed using 5-fluoro-1-(pyridin-2-yl)-1H-indole (105m) (106 mg, 0.50 mmol) 
and 1-(2,2-difluorovinyl)-benzene (128a) (105 mg, 0.75 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 10/1) yielded 159ma (153 mg, 92%, Z/E > 99:1) as a colorless oil. 
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.66 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.85 (ddd, J = 8.0, 7.6, 2.0 Hz, 
1H), 7.52–7.45 (m, 3H), 7.41 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 7.36–7.30 (m, 3H), 7.29–7.21 (m, 2H), 
7.01 (ddd, J = 9.0, 2.5, 0.7 Hz, 1H), 6.96 (dd, J = 0.9, 0.9 Hz, 1H), 6.04 (d, J = 37.8 Hz, 1H, Z).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 158.6 (d, 
1
JC‒F = 238 Hz, Cq), 151.4 (Cq), 150.4 (d, 
1
JC‒F = 256 Hz, 
Cq), 149.3 (CH), 138.4 (CH), 135.0 (Cq), 133.5 (d, 
2
JC‒F = 30.3 Hz, Cq), 133.0 (d, 
4
JC−F = 4.0 Hz, Cq), 
128.8 (d, 
4
JC‒F = 8.2 Hz, CH), 128.5 (CH), 128.1 (d, 
3
JC‒F = 10.2 Hz, Cq), 127.6 (CH), 122.4 (CH), 
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120.4 (CH), 112.6 (d, 
2
JC‒F = 26.0 Hz, CH), 112.2 (d, 
3
JC‒F = 9.9 Hz, CH), 110.4 (d, 
2
JC‒F = 8.8 Hz, 
CH), 107.0 (d, 
3
JC‒F = 4.6 Hz, CH), 105.9 (d, 
2
JC‒F = 23.9 Hz, CH).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –106.4 (d, J = 37.8 Hz), –122.2 (m).  
IR (ATR): 3057, 1585, 1465, 1436, 1382, 1185, 782, 744, 662 cm
–1
.  
MS (EI) m/z (relative intensity): 332 ([M]
+
, 100), 311 (80), 255 (35).  








(Z)-2-(1-Fluoro-2-phenylvinyl)-5-iodo-1-(pyridin-2-yl)-1H-indole (159da): A modified procedure 
G was followed using 5-iodo-1-(pyridin-2-yl)-1H-indole (105d) (160 mg, 0.50 mmol) and 1-(2,2-
difluorovinyl)-benzene (128a) (105 mg, 0.75 mmol) at 50 °C. Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded 159da (183 mg, 83%, Z/E = 98:2) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.98 (dd, J = 1.7, 0.5 Hz, 1H), 
7.84 (ddd, J = 8.0, 7.6, 2.0 Hz, 1H), 7.50 (ddd, J = 4.9, 1.0, 0.8 Hz, 1H), 7.47–7.40 (m, 2H), 7.38 (ddd, 
J = 8.0, 1.7, 0.8 Hz, 1H), 7.36–7.30 (m, 3H), 7.30–7.21 (m, 2H), 6.90 (d, J = 0.9 Hz, 1H), 6.47 (d, J = 
18.7 Hz, 0.02H, E), 6.03 (d, J = 37.9 Hz, 0.98H, Z).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 151.1 (Cq), 150.1 (d, 
1
JC‒F = 258 Hz, Cq), 149.4 (CH), 138.4 (CH), 
137.6 (Cq), 132.9 (d, 
4
JC‒F = 4.6 Hz, Cq), 132.8 (d, 
2
JC‒F = 30.3 Hz, Cq), 132.4 (CH), 130.0 (Cq), 129.8 
(CH), 128.8 (d, 
4
JC‒F = 7.7 Hz, CH), 128.4 (CH), 127.6 (CH), 122.5 (CH), 120.4 (CH), 113.2 (CH), 
110.6 (d, 
2
JC‒F = 8.8 Hz, CH), 106.1 (d, 
3
JC‒F = 4.3 Hz, CH), 84.4 (Cq).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –93.1 (d, J = 18.7 Hz, E), –106.7 (d, J = 37.9 Hz, Z).  
IR (ATR): 3056, 1587, 1470, 1469, 1379, 1239, 1207, 732, 693 cm
–1
.  
MS (ESI) m/z (relative intensity): 441 ([M + H]
+
, 100), 436 (15).  
HR-MS (ESI): m/z calcd. for [C21H15FN2I]
+
 [M + H]
+ 




(Z)-2-[1-Fluoro-2-(thiophen-2-yl)vinyl]-1-(pyridin-2-yl)-1H-indole (159ab): The general procedure 
G was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 2-(2,2-
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difluorovinyl)thiophene (128b) (110 mg, 0.75 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded 159ab (154 mg, 96%, Z/E = 96:4) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.84 (ddd, J = 8.0, 7.6, 2.0 Hz, 
1H), 7.67 (ddd, J = 7.7, 1.2, 0.9 Hz, 1H), 7.56–7.51 (m, 1H), 7.42 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 
7.37–7.35 (m, 1H), 7.32 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.29–7.23 (m, 3H), 7.20 (dd, J = 7.1, 1.2 Hz, 
1H), 6.99 (d, J = 0.9 Hz, 1H), 6.51 (d, J = 17.9 Hz, 0.04H, E), 6.11 (d, J = 37.7 Hz, 0.96H, Z).
  
13
C-NMR (75 MHz, CDCl3): 𝛿 = 151.8 (Cq), 150.2 (d, 
1
JC‒F = 260 Hz, Cq), 149.4 (CH), 138.6 (Cq), 
138.3 (CH), 133.9 (d, 
4
JC‒F = 3.3 Hz, Cq), 131.8 (d, 
2
JC‒F = 29.7 Hz, Cq), 128.2 (d, 
4
JC‒F = 5.8 Hz, CH), 
127.8 (Cq), 125.3 (CH), 124.1 (CH), 124.0 (CH), 122.3 (CH), 121.6 (CH), 121.2 (CH), 120.6 (CH), 
111.2 (CH), 107.1 (d, 
3
JC‒F = 4.4 Hz, CH), 104.7 (d, 
2
JC‒F = 13.5 Hz, CH).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –93.5 (d, J = 17.9 Hz, E), –106.0 (d, J = 37.7 Hz, Z).  
IR (ATR): 3053, 1585, 1467, 1435, 1347, 1294, 1072, 773, 728 cm
–1
.  
MS (EI) m/z (relative intensity): 320 ([M]
+
, 100), 299 (90), 241 (15).  








(Z)-2-[1-Fluoro-2-(thiophen-3-yl)vinyl]-1-(pyridin-2-yl)-1H-indole (159ac): The general procedure 
G was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 3-(2,2-
difluorovinyl)thiophene (128c) (110 mg, 0.75 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded 159ac (159 mg, 99%, Z/E = 90:10) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 8.64 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.87 (ddd, J = 8.0, 7.6, 2.0 Hz, 
1H), 7.65 (ddd, J = 7.9, 1.3, 0.9 Hz, 1H), 7.56–7.54 (m, 1H), 7.41 (ddd, J = 8.0, 1.0, 0.8 Hz, 1H), 7.34 
(ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.27 (dd, J = 5.1, 1.0 Hz, 1H), 7.22–7.16 (m, 2H), 7.03 (dd, J = 3.6, 
1.0 Hz, 1H), 6.99 (d, J = 0.9 Hz, 1H), 6.98 (dd, J = 5.1, 3.6 Hz, 1H), 6.67 (d, J = 17.9 Hz, 0.10H, E), 
6.27 (d, J = 37.7 Hz, 0.90H, Z).
  
13
C-NMR (75 MHz, CDCl3): 𝛿 = 151.6 (Cq), 149.4 (d, 
1
JC‒F = 260 Hz, Cq), 148.4 (CH), 138.5 (Cq), 
138.3 (CH), 135.5 (d, 
4
JC‒F = 3.3 Hz, Cq), 131.4 (d, 
2
JC‒F = 29.7 Hz, Cq), 127.8 (Cq), 127.3 (CH), 126.9 
(CH), 126.3 (d, 
4
JC‒F = 9.5 Hz, CH), 124.3 (CH), 122.5 (CH), 121.6 (CH), 121.2 (CH), 120.6 (CH), 
111.2 (CH), 107.3 (d, 
3
JC‒F = 4.4 Hz, CH), 104.2 (d, 
2
JC‒F = 13.5 Hz, CH).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –92.1 (d, J = 17.9 Hz, E), –104.6 (d, J = 37.7 Hz, Z). 
IR (ATR): 3058, 1586, 1469, 1450, 1437, 1382, 1214, 780 cm
–1
.  
MS (EI) m/z (relative intensity): 320 ([M]
+
, 80), 299 (100).  




320.0783, found 320.0775.  
 





(Z)-2-[1-Fluoro-2-(naphthalen-1-yl)vinyl]-1-(pyridin-2-yl)-1H-indole (159ad): A modified general 
procedure G was followed using 1-(pyridin-2-yl)-1H-indole (105a) (97.1 mg, 0.50 mmol) and 1-(2,2-
difluorovinyl)naphthalene (128d) (143 mg, 0.75 mmol) at 70 °C. Isolation by column chromatography 
(n-hexane/EtOAc: 30/1 → 20/1) yielded 159ad (93.1 mg, 51%, Z/E = 92:8) as a white solid.  
M.p. = 75 °C.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 8.72 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H), 7.90 (ddd, J = 8.1, 7.6, 1.9 Hz, 
1H), 7.86−7.77 (m, 4H), 7.72 (d, J = 7.4 Hz, 1H), 7.54 (ddd, J = 8.1, 1.0, 0.8 Hz, 1H), 7.51−7.44 (m, 
4H), 7.34 (ddd, J = 7.6, 4.9, 1.3 Hz, 1H), 7.29 (ddd, J = 7.2, 7.1, 1.3 Hz, 1H), 7.26–7.24 (m, 1H), 7.15 
(d, J = 0.9 Hz, 1H), 6.92 (d, J = 17.9 Hz, 0.08H, E), 6.64 (d, J = 36.0 Hz, 0.92H, Z). 
13
C-NMR (125 MHz, CDCl3): 𝛿 = 151.9 (Cq), 151.6 (d, 
1
JC‒F = 255 Hz, Cq), 149.7 (CH), 138.9 (Cq), 
138.6 (CH), 133.7 (Cq), 132.3 (d, 
2
JC‒F = 32.3 Hz, Cq), 131.3 (Cq), 129.2 (d, 
4
JC‒F = 3.3 Hz, Cq), 128.7 
(d, 
4
JC‒F = 8.2 Hz, CH), 128.1 (CH), 127.8 (Cq), 127.4 (CH), 127.3 (CH), 126.1 (CH), 125.7 (CH), 
125.6 (CH), 124.4 (CH), 123.8 (CH), 121.7 (CH), 121.4 (CH), 121.1 (CH), 111.3 (CH), 107.6 (d, 
3
JC‒F 
= 4.2 Hz, CH), 106.3 (d, 
2
JC‒F = 10.5 Hz, CH).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –94.2 (d, J = 17.9 Hz, E), –107.3 (d, J = 36.0 Hz, Z). 
IR (ATR): 3056, 1586, 1467, 1437, 1213, 1143, 908, 732 cm
–1
.  
MS (EI) m/z (relative intensity): 364 ([M]
+
, 80), 343 (100), 266 (20).  




 364.1376, found 364.1378.  
 
5.5.2 Mechanistic Studies for the Allylative Cobalt(III)-Catalyzed C−H/C–F Activation  
5.5.2.1 H/D-Exchange Experiments 
 
A suspension of [D]1-105a (117 mg, 0.60 mmol, 1.20 equiv), 127a (223 mg, 0.50 mmol, 1.00 equiv), 
[Cp*Co(CO)I2] (6.0 mg, 2.5 mol %) and K2CO3 (69.0 mg, 0.50 mmol, 1.00 equiv) in TFE (0.5 mL) 
was stirred at 25 °C for 20 h. After removal of the solvents, the crude mixture was purified by column 
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chromatography on silica gel (n-hexane/EtOAc: 30:1 → 20:1) to yield [D]n-158aa (214 mg, 70%) and 
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Two parallel reactions of 105a and [D]1-105a with 127a were performed respectively to determine the 
KIE value by comparison of the initial reaction rates. A suspension of 105a (97.1 mg, 0.50 mmol, 
1.00 equiv) or [D]1-105a (97.5 mg, 0.50 mmol, 1.00 equiv), 127a (268 mg, 0.75 mmol, 1.50 equiv), 
[Cp*Co(CO)I2] (6.00 mg, 2.5 mol %), K2CO3 (69.1 mg, 1.00 equiv) and n-dodecane (30 μL) as the 
internal standard in TFE (2.00 mL) was stirred at 25 °C. Aliquots (25 μL) were periodically removed 
to provide the following conversions as determined by GC-analysis: 
 
Table 42. Conversion-time table for determination of the KIE. 
 t / min 10 20 30 40 50 60 
 158aa / % 4.8 5.7 8.7 11.8 13.9 16.8 
 [D]n-158aa / % 3.5 5.9 6.9 9.0 10.3 12.1 
 




A suspension of 1-(p-tolyl)-1H-pyrazole (18a) (79.0 mg, 0.50 mmol, 1.00 equiv), 1-(4-
(trifluoromethyl)phenyl)-1H-pyrazole (18b) (106 mg, 0.50 mmol, 1.00 equiv), 127a (223 mg, 
0.50 mmol, 1.00 equiv), [Cp*Co(CO)I2] (23.8 mg, 10.0 mol %), AgSbF6 (34.0 mg, 20 mol %) and 
K2CO3 (69.0 mg, 0.50 mmol, 1.00 equiv) in TFE (0.5 mL) was stirred at 70 °C for 20 h. After 
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filtration over Celite and removal of the solvents, the crude mixture was analyzed by means of 
1
H-
NMR spectroscopy with 1,3,5-trimethoxybenzene (16.8 mg, 0.10 mmol) as the internal standard to 
furnish the following conversions: 161a: 72% (Z/E = 87:13) and 161b: 19% (Z/E = 86:14). 
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5.6 Manganese(I)-Catalyzed Allylative C−H/C–F Functionalization  
5.6.1 Characterization Data 
 
 
(Z)-1-[2-(1H,1H,2H-Perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166a): The general procedure H 
was followed using N-(4-methoxyphenyl)-1-phenylethan-1-imine (6a) (113 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 25/1) yielded 166a (197 mg, 72%, Z/E = 97:3) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 7.77 (dd, J = 7.4, 1.4 Hz, 1H), 7.44 (ddd, J = 7.6, 7.4, 1.4 Hz, 1H), 
7.34 (ddd, J = 7.6, 7.5, 1.4 Hz, 1H), 7.27 (dd, J = 7.5, 1.4 Hz, 1H), 6.14 (dt, J = 23.5, 9.5 Hz, 0.03H, 
E), 5.91 (dt, J = 33.5, 8.0 Hz, 0.97H), 3.81 (ddt, J = 8.0, 4.1, 2.1 Hz, 2H), 2.59 (s, 3H).
  
13
C-NMR (100 MHz, CDCl3): 𝛿 = 201.0 (Cq), 145.9 (dt, 
1
JC‒F = 257 Hz, 
2
JC‒F = 29.1 Hz, Cq), 137.9 
(Cq), 136.8 (Cq), 132.4 (CH), 131.5 (CH), 130.1 (CH), 127.1 (CH), 117.4 (dt, 
1
JC‒F = 288 Hz, 
2
JC‒F = 
34.0 Hz, Cq), 115.3 (dt, 
2
JC‒F = 7.8 Hz, 
3
JC‒F = 4.1 Hz, CH), 113.5 (m, Cq), 113.1 (m, Cq), 111.3 (m, 
Cq), 110.9 (m, Cq), 110.2 (m, Cq), 108.3 (m, Cq), 29.1 (CH3), 28.7 (d, 
3
JC‒F = 3.5 Hz, CH2).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –81.0 (m), –117.5 (m), –122.1 (m), –122.1 (m), –122.9 (m), –123.1 
(m), –126.3 (m), –132.5 (m).  
IR (ATR): 1686, 1358, 1236, 1199, 1144, 1106, 759, 732 cm
–1
.  
MS (ESI) m/z (relative intensity): 569 ([M + Na]
+
, 100), 547 ([M + H]
+
, 45), 373 (15).  
HR-MS (ESI): m/z calcd. for [C18H11F16O]
+
 [M + H]
+ 




(Z)-1-[2-(1H,1H,2H-Perfluorodec-2-en-1-yl)phenyl]propan-1-one (166b): The general procedure H 
was followed using N-(4-methoxyphenyl)-1-phenylpropan-1-imine (6b) (120 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 30/1) yielded 166b (181 mg, 65%, Z/E = 97:3) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 7.71 (dd, J = 8.0, 1.4 Hz, 1H), 7.43 (ddd, J = 7.7, 7.5, 1.4 Hz, 1H), 
7.33 (ddd, J = 8.0, 7.5, 1.3 Hz, 1H), 7.27 (dd, J = 7.7, 1.3 Hz, 1H) 6.13 (dt, J = 22.3, 8.8 Hz, 0.03H, 
E), 5.92 (dt, J = 33.8, 7.7 Hz, 0.97H, Z), 3.76 (ddt, J = 7.7, 4.1, 2.1 Hz, 2H), 2.94 (q, J = 7.3 Hz, 2H), 
1.18 (t, J = 7.3 Hz, 3H).
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13
C-NMR (100 MHz, CDCl3): 𝛿 = 204.2 (Cq), 145.2 (dt, 
1
JC‒F = 259 Hz, 
2
JC‒F = 28.0 Hz, Cq), 137.6 
(Cq), 137.1 (Cq), 131.9 (CH), 131.4 (CH), 129.1 (CH), 127.0 (CH), 117.4 (dt, 
1
JC‒F = 288 Hz, 
2
JC‒F = 
34.9 Hz, Cq), 115.5 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.2 (m, Cq), 110.9 (m, Cq), 110.7 (m, 
Cq), 110.2 (m, Cq), 108.5 (m, Cq), 107.5 (m, Cq), 34.3 (CH2), 28.6 (d, 
3
JC‒F = 3.6 Hz, CH2), 8.20 (CH3).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –80.9 (m), –117.5 (m), –122.0 (m), –122.1 (m), –122.8 (m), –123.0 
(m), –126.2 (m), –132.5 (m).  
IR (ATR): 1687, 1238, 1203, 1148, 907, 729 cm
–1
.  
MS (ESI) m/z (relative intensity): 583 ([M + Na]
+
, 100), 561 ([M + H]
+
, 60), 381 (15).  
HR-MS (ESI): m/z calcd. for [C19H13F16O]
+
 [M + H]
+ 




(Z)-1-[4-Methoxy-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166c): The general 
procedure H was followed using N-bis(4-methoxyphenyl)ethan-1-imine (6c) (128 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 30/1) yielded 166c (181 mg, 63%, Z/E = 97:3) as a yellow oil. 
1
H-NMR (500 MHz, CDCl3): 𝛿 = 7.81 (d, J = 8.8 Hz, 1H), 7.82 (dd, J = 8.8, 2.6 Hz, 1H), 7.75 (d, J = 
2.6 Hz, 1H), 6.15 (dt, J = 23.8, 8.6 Hz, 0.03H, E), 5.92 (dt, J = 33.9, 7.7 Hz, 0.97H, Z), 3.86 (ddt, J = 
7.7, 4.1, 1.7 Hz, 2H), 3.84 (s, 3H), 2.55 (s, 3H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 198.9 (Cq), 162.4 (Cq), 145.9 (dt, 
1
JC‒F = 258 Hz, 
2
JC‒F = 29.0 Hz, 
Cq), 141.1 (Cq), 133.1 (CH), 128.8 (Cq), 116.9 (CH), 116.5 (dt, 
1
JC‒F = 287 Hz, 
2
JC‒F = 31.3 Hz, Cq), 
115.1 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 112.8 (m, Cq), 111.5 (CH), 110.5 (m, Cq), 110.3 (m, Cq), 
110.0 (m, Cq), 108.2 (m, Cq), 107.9 (m, Cq), 55.2 (CH3), 29.2 (d, 
3
JC‒F = 3.7 Hz, CH2), 28.7 (CH3).
  
19
F-NMR (470 MHz, CDCl3): 𝛿 = –81.0 (m), –117.5 (m), –122.1 (m), –122.2 (m), –122.9 (m), –123.1 
(m), –126.3 (m), –132.6 (m).  
IR (ATR): 1676, 1604, 1585, 1235, 1199, 1144, 1106, 733, 706 cm
–1
.  
MS (ESI) m/z (relative intensity): 599 ([M + Na]
+
, 90), 577 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C19H13F16O2]
+
 [M + H]
+ 









(Z)-1-[4-Trifluoromethyl-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166d): The 
general procedure H was followed using 1-(4-trifluoromethylphenyl)-N-(4-methoxyphenyl)ethan-1-
imine (6d) (147 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 30/1) yielded 166d (157 mg, 51%, Z/E = 
97:3) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 7.83 (d, J = 8.0 Hz, 1H), 7.61 (dd, J = 8.0, 1.4 Hz, 1H), 7.51 (d, J = 
1.4 Hz, 1H), 6.10 (dt, J = 22.6, 8.5 Hz, 0.03H, E), 5.87 (dt, J = 33.4, 7.8 Hz, 0.97H, Z), 3.83 (ddt, J = 
7.8, 4.0, 2.0 Hz, 2H), 2.62 (s, 3H).
  
13
C-NMR (100 MHz, CDCl3): 𝛿 = 200.3 (Cq), 146.5 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 29.5 Hz, Cq), 139.9 
(Cq), 138.5 (Cq), 133.7 (q, 
2
JC‒F = 33.0 Hz, Cq), 130.0 (CH), 128.0 (q, 
3
JC‒F = 3.8 Hz, CH), 124.1 (q, 
3
JC‒F = 3.7 Hz, CH), 123.4 (d, 
1
JC‒F = 273 Hz, Cq), 117.0 (dt, 
1
JC‒F = 286 Hz, 
2
JC‒F = 22.3 Hz, Cq), 
114.2 (dt, 
2
JC‒F = 7.8 Hz, 
3
JC‒F = 3.7 Hz, CH), 113.2 (m, Cq), 111.1 (m, Cq), 110.7 (m, Cq), 110.2 (m, 
Cq), 108.6 (m, Cq), 107.7 (m, Cq), 29.3 (CH3), 28.3 (d, 
3
JC‒F = 3.7 Hz, CH2).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –63.5 (m), –80.9 (m), –117.6 (m), –122.1 (m), –122.1 (m), –122.8 
(m), –123.1 (m), –126.3 (m), –130.6 (m).   
IR (ATR): 1695, 1334, 1238, 1201, 1172, 1130, 1093, 833, 720 cm
–1
.  
MS (EI) m/z (relative intensity): 614 ([M]
+
, 100), 599 (85), 579 (20).  
HR-MS (ESI): m/z calcd. for [C19H9F19O + Na]
+




(Z)-4-Acetyl-3-(1H,1H,2H-perfluorodec-2-en-1-yl)benzonitrile (166e): The general procedure H 
was followed using 4-{1-[(4-methoxyphenyl)imino]ethyl}benzonitrile (6e) (125 mg, 0.50 mmol) and 
1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 20/1) yielded 166e (134 mg, 47%, Z/E = 97:3) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 7.81 (d, J = 7.7 Hz, 1H), 7.66 (dd, J = 7.7, 1.9 Hz, 1H), 7.56 (d, J = 
1.9 Hz, 1H), 6.07 (dt, J = 23.8, 8.6 Hz, 0.03H, E), 5.86 (dt, J = 33.0, 7.7 Hz, 0.97H, Z), 3.79 (ddt, J = 
7.7, 4.2, 2.1 Hz, 2H), 2.61 (s, 3H).
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13
C-NMR (100 MHz, CDCl3): 𝛿 = 199.9 (Cq), 146.6 (dt, 
1
JC‒F = 261 Hz, 
2
JC‒F = 28.7 Hz, Cq), 140.5 
(Cq), 138.8 (Cq), 134.7 (CH), 130.9 (CH), 130.0 (CH), 117.4 (Cq), 116.8 (dt, 
1
JC‒F = 289 Hz, 
2
JC‒F = 
33.8 Hz, Cq), 115.8 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.9 (m, Cq), 113.0 (m, Cq), 111.2 (m, 
Cq), 110.7 (m, Cq), 110.3 (m, Cq), 108.3 (m, Cq), 107.6 (m, Cq), 29.4 (CH3), 28.2 (d, 
3




F-NMR (376 MHz, CDCl3): 𝛿 = –80.8 (m), –117.5 (m), –122.0 (m), –122.0 (m), –122.8 (m), –122.9 
(m), –126.1 (m), –130.0 (m).  
IR (ATR): 3051, 2920, 1585, 1467, 1435, 1380, 1348 cm
–1
.  
MS (ESI) m/z (relative intensity): 594 ([M + Na]
+
, 20), 572 ([M + H]
 +
, 100).  
HR-MS (ESI): m/z calcd. for [C19H10F16NO]
+
 [M + H]
+ 




(Z)-1-[4-Fluoro-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166f): The general 
procedure H was followed using 1-(4-fluorophenyl)-N-(4-methoxyphenyl)ethan-1-imine (6f) (122 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 30/1) yielded 166f (195 mg, 69%, Z/E = 97:3) as a colorless oil.  
1
H-NMR (500 MHz, CDCl3): 𝛿 = 7.82 (dd, J = 8.4, 5.7 Hz, 1H), 7.02 (ddd, J = 10.1, 8.4, 2.4 Hz, 1H), 
6.96 (dd, J = 9.4, 2.4 Hz, 1H), 6.11 (dt, J = 23.5, 8.5 Hz, 0.03H, E), 5.89 (dt, J = 33.6, 7.6 Hz, 0.97H, 
Z), 3.83 (ddt, J = 7.6, 4.1, 1.7 Hz, 2H), 2.58 (s, 3H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 200.3 (Cq), 161.6 (d, 
1
JC‒F = 254 Hz, Cq), 145.7 (dt, 
1
JC‒F = 260 Hz, 
2
JC‒F = 29.5 Hz, Cq), 139.3 (d, 
3
JC‒F = 3.2 Hz, Cq), 128.3 (d, 
3
JC‒F = 8.6 Hz, CH), 125.2 (d, 
4
JC‒F = 
3.8 Hz, CH), 124.6 (d, 
2
JC‒F = 16.8 Hz, CH), 118.9 (d, 
2
JC‒F = 23.7 Hz, CH), 116.8 (dt, 
1
JC‒F = 287 Hz, 
2
JC‒F = 32.8 Hz, Cq), 113.9 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.2 (m, Cq), 111.3 (m, Cq), 110.8 
(m, Cq), 110.2 (m, Cq), 108.3 (m, Cq), 107.5 (m, Cq), 29.4 (CH3), 20.3 (dd, 
3
JC‒F = 5.8, 4.4 Hz, CH2).
  
19
F-NMR (470 MHz, CDCl3): 𝛿 = –80.8 (m), –105.8 (m), –117.4 (m), –122.0 (m), –122.0 (m), –122.8 
(m), –123.0 (m), –126.2 (m), –131.4 (m).   
IR (ATR): 1692, 1456, 1237, 1199, 1144, 791, 730  cm–1.  
MS (ESI) m/z (relative intensity): 587 ([M + Na]
+
, 100), 565 ([M + H]
+
, 15).  
HR-MS (ESI): m/z calcd. for [C18H10F17O]
+
 [M + H]
+ 
565.0455, found 565.0457.  
 
 





(Z)-1-[4-Bromo-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166g): The general 
procedure H was followed using 1-(4-bromophenyl)-N-(4-methoxyphenyl)ethan-1-imine (6g) 
(152 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 30/1) yielded 166g (218 mg, 71%, Z/E = 97:3) as a yellow 
oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 7.64 (d, J = 8.5 Hz, 1H), 7.49 (dd, J = 8.5, 2.0 Hz, 1H), 7.42 (d, J = 
2.0 Hz, 1H), 6.11 (dt, J = 22.3, 8.8 Hz, 0.03H, E), 5.86 (dt, J = 33.3, 7.8 Hz, 0.97H, Z), 3.79 (ddt, J = 
7.8, 4.1, 2.0 Hz, 2H), 2.57 (s, 3H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 199.7 (Cq), 145.8 (dt, 
1
JC‒F = 259 Hz, 
2
JC‒F = 28.4 Hz, Cq), 140.0 
(Cq), 135.3 (Cq), 134.4 (CH), 131.4 (CH), 130.2 (CH), 126.9 (Cq), 117.0 (dt, 
1
JC‒F = 288 Hz, 
2
JC‒F = 
32.3 Hz, Cq), 114.4 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 112.5 (m, Cq), 110.8 (m, Cq), 110.7 (m, 
Cq), 110.3 (m, Cq), 108.7 (m, Cq), 107.4 (m, Cq), 29.1 (CH3), 28.6 (d, 
3
JC‒F = 3.5 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –117.5 (m), –122.0 (m), –122.1 (m), –122.8 (m), –123.1 
(m), –126.3 (m), –131.3 (m).  
IR (ATR): 1686, 1238, 1203, 1148, 906, 729 cm
–1
.  








, 100), 450 (50).  




 [M + H]
+ 




(Z)-1-[4-Iodo-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166h): The general 
procedure H was followed using 1-(4-iodophenyl)-N-(4-methoxyphenyl)ethan-1-imine (6h) (176 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 30/1) yielded 166h (248 mg, 74%, Z/E = 97:3) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 7.74 (dd, J = 8.2, 1.7 Hz, 1H), 7.66 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 
8.2 Hz, 1H), 6.10 (dt, J = 22.3, 8.8 Hz, 0.03H, E), 5.88 (dt, J = 33.3, 7.7 Hz, 0.97H, Z), 3.78 (ddt, J = 
7.7, 4.1, 2.1 Hz, 2H), 2.62 (s, 0.09H, E), 2.58 (s, 2.91H, Z).
  
13
C-NMR (75 MHz, CDCl3): 𝛿 = 199.9 (Cq), 145.9 (dt, 
1
JC‒F = 260 Hz, 
2
JC‒F = 28.9 Hz, Cq), 140.4 
(CH), 139.6 (Cq), 136.3 (CH), 135.9 (Cq), 131.2 (CH), 117.0 (dt, 
1
JC‒F = 288 Hz, 
2
JC‒F = 32.3 Hz, Cq), 




JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.0 (m, Cq), 111.1 (m, Cq), 110.6 (m, Cq), 110.3 (m, 
Cq), 108.7 (m, Cq), 107.4 (m, Cq), 99.6 (Cq), 29.1 (CH3), 28.4 (d, 
3
JC−F = 3.5 Hz, CH2).  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –80.7 (m), –117.4 (m), –122.0 (m), –122.0 (m), –122.9 (m), –123.0 
(m), –126.1 (m), –131.0 (m).  
IR (ATR): 1687, 1581, 1551, 1235, 1198, 1143, 720, 707 cm
–1
.  
MS (ESI) m/z (relative intensity): 695 ([M + Na]
+
, 100), 673 ([M + H]
+
, 20).  
HR-MS (ESI): m/z calcd. for [C18H10F16IO]
+
 [M + H]
+ 




(Z)-1-[3-(1H,1H,2H-Perfluorodec-2-en-1-yl)naphthalen-2-yl]ethan-1-one (166i): The general 
procedure H was followed using N-(4-methoxyphenyl)-1-(naphthalen-2-yl)ethan-1-imine (6i) 
(138 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 30/1) yielded 166i (179 mg, 60%, Z/E = 98:2) as a red oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 8.32 (s, 1H), 7.89 (dd, J = 8.0, 1.3 Hz, 1H), 7.79 (dd, J = 7.9, 
1.4 Hz, 1H), 7.67 (s, 1H), 7.59 (ddd, J = 8.0, 6.9, 1.4 Hz, 1H), 7.52 (ddd, J = 7.9, 6.9, 1.3 Hz, 1H), 
6.24 (dt, J = 33.2, 8.2 Hz, 0.02H, E), 5.99 (dt, J = 33.5, 7.6 Hz, 0.98H, Z), 3.99 (ddt, J = 7.6, 4.1, 
2.1 Hz, 2H), 2.73 (s, 3H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 200.5 (Cq), 145.5 (dt, 
1
JC‒F = 258 Hz, 
2
JC‒F = 28.3 Hz, Cq), 134.8 
(Cq), 134.7 (Cq), 134.0 (Cq), 131.8 (CH), 131.4 (Cq), 130.1 (CH), 128.7 (CH), 128.6 (CH), 127.2 (CH), 
126.7 (CH), 117.1 (dt, 
1
JC‒F = 287 Hz, 
2
JC‒F = 32.8 Hz, Cq), 115.5 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, 
CH), 113.2 (m, Cq), 110.9 (m, Cq), 110.8 (m, Cq), 109.9 (m, Cq), 108.7 (m, Cq), 108.2 (m, Cq), 29.0 
(CH3), 28.9 (d, 
3
JC‒F = 3.1 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –117.4 (m), –122.0 (m), –122.1 (m), –122.8 (m), –123.0 
(m), –126.2 (m), –132.3 (m).  
IR (ATR): 1681, 1238, 1201, 1149, 906, 728 cm
–1
.  
MS (ESI) m/z (relative intensity): 619 ([M + Na]
+
, 100), 597 ([M + H]
+
, 40).  
HR-MS (ESI): m/z calcd. for [C22H13F16O]
+
 [M + H]
+ 










(Z)-1-[3-Fluoro-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]ethan-1-one (166j): The general 
procedure H was followed using 1-(3-fluorophenyl)-N-(4-methoxyphenyl)ethan-1-imine (6j) (122 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 30/1) yielded 166j (149 mg, 53%, Z/E = 97:3) as a yellow oil.  
1
H-NMR (400 MHz, CDCl3): 𝛿 = 7.53 (dd, J = 7.8, 0.9 Hz, 1H), 7.33 (ddd, J = 7.8, 7.8, 5.3 Hz, 1H), 
7.21 (ddd, J = 8.4, 7.8, 0.9 Hz, 1H), 5.98 (dt, J = 23.5, 8.1 Hz, 0.03H, E), 5.79 (dt, J = 33.0, 7.3 Hz, 
0.97H, Z), 3.81 (ddt, J = 7.3, 4.1, 2.0 Hz, 2H), 2.59 (s, 3H).
  
13
C-NMR (100 MHz, CDCl3): 𝛿 = 200.3 (Cq), 161.6 (d, 
1
JC‒F = 254 Hz, Cq), 145.7 (dt, 
1
JC‒F = 260 Hz, 
2
JC‒F = 29.5 Hz, Cq), 139.3 (d, 
3
JC‒F = 3.2 Hz, Cq), 128.3 (d, 
3
JC‒F = 8.6 Hz, CH), 125.2 (d, 
4
JC‒F = 
3.8 Hz, CH), 124.6 (d, 
2
JC‒F = 16.8 Hz, Cq), 118.9 (d, 
2
JC‒F = 23.7 Hz, CH), 116.8 (dt, 
1
JC‒F = 287 Hz, 
2
JC‒F = 32.8 Hz, Cq), 113.9 (dt, 
2
JC‒F = 8.9 Hz, 
4
JC‒F = 3.6 Hz, CH), 113.2 (m, Cq), 111.3 (m, Cq), 110.8 
(m, Cq), 110.2 (m, Cq), 108.3 (m, Cq), 107.5 (m, Cq), 29.4 (CH3), 20.3 (dd, 
3
JC‒F = 5.8, 4.4 Hz, CH2).
  
19
F-NMR (376 MHz, CDCl3): 𝛿 = –80.8 (m), –115.1 (m), –117.5 (m), –122.0 (m), –122.1 (m), –122.8 
(m), –123.0 (m), –126.2 (m), –131.0 (m).  
IR (ATR): 1692, 1456, 1237, 1199, 1144, 791, 730 cm
–1
.  
MS (ESI) m/z (relative intensity): 587 ([M + Na]
+
, 40), 441 (100), 419 (30).  
HR-MS (ESI): m/z calcd. for [C18H10F17O]
+
 [M + H]
+ 




(Z)-1-[4-(1H,1H,2H-Perfluorodec-2-en-1-yl)benzo[d][1,3]dioxol-5-yl]ethan-1-one (166k): The 
general procedure H was followed using 1-(benzo[d][1,3]dioxol-5-yl)-N-(4-methoxyphenyl)ethan-1-
imine (6k) (135 mg, 0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (669 mg, 1.50 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 166k (193 mg, 65%, Z/E = 
98:2) as a yellow oil.  
1
H-NMR (300 MHz, CDCl3): 𝛿 = 7.43 (d, J = 8.2 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 6.02 (s, 2H), 5.85 
(dt, J = 33.5, 7.4 Hz, 1H), 3.85 (ddt, J = 7.4, 4.1, 2.1 Hz, 2H), 2.53 (s, 3H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 198.6 (Cq), 150.2 (Cq), 147.8 (Cq), 145.3 (dt, 
1
JC‒F = 260 Hz, 
2
JC‒F = 
29.5 Hz, Cq), 130.8 (Cq), 126.5 (CH), 119.6 (Cq), 116.8 (dt, 
1
JC‒F = 287 Hz, 
2
JC‒F = 32.8 Hz, Cq), 114.1 




JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.2 (m, Cq), 110.9 (m, Cq), 110.8 (m, Cq), 109.9 (m, Cq), 
108.7 (m, Cq), 108.2 (m, Cq), 106.2 (CH), 101.8 (CH2), 28.8 (CH3), 21.8 (d, 
3
JC‒F = 4.0 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –117.5 (m), –122.0 (m), –122.1 (m), –122.8 (m), –123.1 
(m), –126.2 (m), –131.7 (m).  
IR (ATR): 1675, 1453, 1237, 1200, 1146, 1058, 939, 731 cm
–1
.  
MS (ESI) m/z (relative intensity): 613 ([M + Na]
+
, 80), 591 ([M + H]
+
, 100).  
HR-MS (ESI): m/z calcd. for [C19H11F16O3]
+
 [M + H]
+ 




(Z)-1-[4-(tert-Butyl)-2-(1H,1H,2H-perfluorodec-2-en-1-yl)phenyl]-1H-pyrazole (161c): The 
general procedure H was followed using 1-[4-(tert-butyl)phenyl]-1H-pyrazole (18c) (100 mg, 
0.50 mmol) and 1H,1H,2H-perfluorodec-1-ene (127a) (315 mg, 0.75 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 20/1) yielded 161c (241 mg, 77%, Z/E = 87:13) as a colorless 
solid.  
M.p.: 80 °C. 
1
H-NMR (300 MHz, CDCl3): 𝛿 = 7.70 (dd, J = 2.2, 1.7 Hz, 1H), 7.56 (dd, J = 4.0, 2.4 Hz, 1H), 7.36 
(dd, J = 8.2, 2.2 Hz, 1H), 7.30 (dd, J = 2.4, 2.1 Hz, 1H), 7.23 (dd, J = 8.2, 1.7 Hz, 1H), 6.42 (dd, J = 
4.0, 2.1 Hz, 1H), 5.90 (dt, J = 21.8, 7.9 Hz, 0.13H, E), 5.67 (dd, J = 33.3, 7.6 Hz, 0.87H, Z), 3.79 (ddt, 
J = 7.6, 4.1, 2.5 Hz, 2H), 1.33 (s, 9H).
  
13
C-NMR (125 MHz, CDCl3): 𝛿 = 152.2 (Cq), 145.7 (dt, 
1
JC‒F = 259 Hz,
 2
JC‒F = 29.1 Hz, Cq), 140.5 





JC‒F = 31.3 Hz, Cq), 114.7 (dt, 
2
JC‒F = 8.9 Hz, 
3
JC‒F = 3.6 Hz, CH), 113.0 (m, Cq), 112.0 (m, 
Cq), 110.6 (m, Cq), 110.0 (m, Cq), 108.6 (m, Cq), 108.1 (m, Cq), 106.5 (CH), 34.7 (CH), 31.2 (CH3), 
26.3 (d, 
3
JC‒F = 3.7 Hz, CH2).
  
19
F-NMR (282 MHz, CDCl3): 𝛿 = –80.9 (m), –114.5 (m, E), –117.5 (m, Z), –122.1 (m), –122.1 (m), –
122.9 (m, Z), –123.1 (m, E), –123.5 (m), –126.2 (m), –132.3 (m).  
IR (ATR): 2968, 1522, 1238, 1201, 1146, 909, 732 cm
–1
. 
MS (EI) m/z (relative intensity): 626 ([M]
+
, 100), 611 (20), 598 (10).  
HR-MS (ESI): m/z calcd. for [C23H19F16N2]
+
 [M + H]
+  
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5.6.2 Mechanistic Studies 
5.6.2.1 H/D-Exchange Experiments 




A suspension of 105a (116 mg, 0.60 mmol, 1.20 equiv), 127a (224 mg, 0.50 mmol, 1.00 equiv), 
[MnBr(CO)5] (13.7 mg, 10.0 mol %) and K2CO3 (69.0 mg, 0.50  mmol, 1.00 equiv) in 1,4-dioxane 
(0.9 mL) and CD3OD (0.1 mL) was stirred at 80 °C for 20 h. After removal of the solvents, the crude 
mixture was purified by column chromatography on silica gel (n-hexane/EtOAc: 30:1 → 20:1) to yield 
[D]n-158aa (167 mg, 54%, Z/E = 90:10) and [D]n-105a (40.7 mg, 35% reisolated) as yellow oils. 
 
 








A suspension of 105a (97.0 mg, 0.50 mmol, 1.00 equiv), 127a (268 mg, 0.60 mmol, 1.20 equiv), 
[MnBr(CO)5] (13.7 mg, 10.0 mol %) and K2CO3 (69.0 mg, 0.50 mmol, 1.00 equiv) in 1,4-dioxane 
(0.9 mL) and CD3OH (0.1 mL) was stirred at 80 °C for 20 h. After removal of the solvents, the crude 
mixture was purified by column chromatography on silica gel (n-hexane/EtOAc: 30:1→20:1) to yield 
158aa (171 mg, 56%, Z/E = 90:10) and 105a (43.0 mg, 37% reisolated) as yellow oils. 
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5.6.2.2 KIE Studies 
 
 
Two parallel reactions of 105a or [D]1-105a with 127a were performed respectively to determine the 
KIE value by comparison of the initial reaction rates by GC-analysis with n-dodecane as the internal 
standard. A suspension of 105a (97.1 mg, 0.50 mmol, 1.00 equiv) or [D]1-105a (97.6 mg, 0.50 mmol, 
1.00 equiv), 127a (268 mg, 0.60 mmol, 1.20 equiv), [MnBr(CO)5] (13.7 mg, 10 mol %), K2CO3 
(69.1 mg, 1.00 equiv) and n-dodecane (30 µL) in 1,4-dioxane (2.00 mL) was stirred at 80 °C. Aliquots 
(30 μL) were periodically removed to provide the following conversions as determined by GC-
analysis: 
Table 43. Conversion-time table for determination of the KIE. 
 t / min 40 60 80 100 120 
 158aa / % 5.19 8.00 13.2 17.9 20.9 
 [D]n-158aa / % 3.25 5.69 9.98 14.4 17.7 
 
5.6.2.3 Experiments with Cyclometalated Complex 167 




A suspension of indole 105a (97.1 mg, 0.50 mmol, 1.00 equiv), 1H,1H,2H-perfluorodecene (127a) 
(268 mg, 0.60 mmol, 1.20 equiv), 167 (18.0 mg, 10.0 mol %) and K2CO3 (69.1 mg, 0.50 mmol, 
1.00 equiv) in 1,4-dioxane (0.50 mL, 1.00 M) was stirred at 80 °C for 20 h. At ambient temperature, 
the solvent was removed in vacuo and the remaining residue was purified by column chromatography 
on silica gel to afford the desired product 158aa (240 mg, 77%, Z/E = 90:10). 
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A suspension of complex 167 (72.0 mg, 0.20 mmol, 1.00 equiv), 1H,1H,2H-perfluorodecene (127a) 
(107 mg, 0.24 mmol, 1.20 equiv), K2CO3 (27.6 mg, 0.20 mmol, 1.00 equiv) in 1,4-dioxane (0.20 mL, 
1.00 M) was stirred at 80 °C for 20 h. At ambient temperature, the reaction mixture was diluted with 
water (5.0 mL) and extracted with EtOAc (3 x 10 mL). After removal of the solvents in vacuo, the 
remaining residue was purified by column chromatography on silica gel to afford the desired product 
158aa (115 mg, 93%, Z/E = 90:10). 
5.6.2.3.3 Stoichiometric Reaction with Complex 167 in the absence of K2CO3 
 
 
A suspension of complex 167 (72.0 mg, 0.20 mmol, 1.00 equiv), 1H,1H,2H-perfluorodecene (127a) 
(107 mg, 0.24 mmol, 1.20 equiv) in 1,4-dioxane (0.20 mL, 1.00 M) was stirred at 80 °C for 20 h. At 
ambient temperature, the reaction mixture was diluted with water (5.0 mL) and extracted with EtOAc 
(3 x 10 mL). The solvents were removed in vacuo and the remaining residue was purified by column 
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